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Abstract 
 
Streptococcus pyogenes is adapted for persistence in humans. It typically colonizes the 
tonsils and skin, and humans are the only known reservoir.  S. pyogenes can cause a wide 
range of mild to serious infections. Most streptococci-related deaths are due to 
complications of rheumatic fever and invasive infections.  S. pyogenes produces virulence 
factors that contribute to the pathogen’s ability to colonize and cause disease, including 
streptococcal superantigens (SAgs), also known as streptococcal pyrogenic exotoxins 
(Spes).  SAgs function by cross-linking T cells and antigen presenting cells (APC) which 
may cause a massive inflammatory response, and as such have been found to contribute 
to streptococcal toxic shock syndrome (STSS).  The role of SAgs in adaptation of S. 
pyogenes to its target niche has not been investigated.  S. pyogenes experimentally 
colonizes mouse complete nasal turbinates (cNT).  Murine models of streptococcal 
infection are imperfect systems due to inherent host-specific tropism.  In this thesis, the 
colonization potential of S. pyogenes MGAS8232, associated with rheumatic heart 
disease, and S. pyogenes MGAS5005, associated with invasive infections, were assessed 
to explore the contribution of SAgs to nasal colonization in a mouse model. Colonization 
was tested in multiple mouse strains expressing human or mouse major histocompatibility 
complex (MHC) class II.  C57BL/6 (B6) mice expressing human leukocyte antigen 
(HLA) transgenes showed enhanced colonization, up to ~100,000-fold at 48 hours post-
inoculation. Individual and combined SAg deletions were assessed for nasal colonization.  
S. pyogenes MGAS8232 deletion colonization in mice expressing HLA-DR4 and HLA-
DQ8 (DR4/DQ8) determined that SpeA was the major contributing SAg to the 
establishment of colonization, with minor contributions from SpeL and streptococcal 
mitogenic exotoxin Z (SmeZ).  Colonization of S. pyogenes MGAS5005 was assessed in 
FVB mice, which express murine MHC class II q (H-2
q
), and SpeJ and SmeZ were the 
main contributing SAgs to the establishment of nasal colonization. SAgs contribute to 48-
hour streptococcal recovery, but do not change the kinetics of bacterial clearance from 
cNT.  These findings support the hypothesis that SAgs play an important role in niche 
adaptation and the establishment of colonization in mild or asymptomatic streptococcal 
infections in a murine model of nasal infection. 
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1.1. Group A Streptococcus 
Streptococcus pyogenes are Gram-positive, -haemolytic cocci that are 
aerotolerant anaerobes [1-2], and obligate human pathogens [3].  Although S. pyogenes is 
known to cause a wide range of active infections, they may also persist asymptomatically 
in the human population by colonizing the human oropharynx, specifically in the tonsils 
[4].   
Streptococcal infections are contracted from direct, indirect or droplet contact 
with oral or wound secretions from an infected individual [5-7], and can be transmitted 
orally to cause streptococcal disease in atypical sites [8-9].  Casual contact rarely leads to 
disease [6].  The incubation period for streptococcal disease is one to three days post-
exposure and the infection is communicable until seven days after the start of antibiotic 
treatment [6].   
S. pyogenes produces infections of varying clinical severities which may be 
generally separated into diseases of two categories, namely severe streptococcal 
infections and mild or moderate infections. S. pyogenes is associated with significant 
morbidity and mortality globally and was ranked ninth among individual pathogens 
causing highest estimated deaths as reported by the World Health Organization in 2002 
[10].  In high-income countries, the S. pyogenes diseases that are of the greatest 
significance are pharyngitis and invasive diseases, whereas in low-income countries 
rheumatic fever, rheumatic heart disease and glomerulonephritis are the most major S. 
pyogenes diseases with endemic incidences of impetigo [11].  The greatest burden of 
streptococcal diseases is encountered in low-income countries [11].  Streptococcal 
infections also result in a significant economic burden ranging in the hundreds of millions 
of dollars a year in the United States [12].  Genetically identical strains can cause both 
severe and non-severe disease, indicating an important role for host factors in determining 
the clinical outcome of streptococcal infections [13]. 
Serotypic classification of S. pyogenes has traditionally relied on variable surface 
antigens such as the M protein and the T antigen [14].  The M-protein is an anti-
phagocytic surface protein and the T antigen is a pilus protein that binds fibronectin and 
collagen [15] and is resistant to trypsin digestion [16].  At any given time, there are 
multiple serotypic lineages of S. pyogenes circulating within the human population.   
3 
 
 
Differences in the distribution of S. pyogenes serotypes vary both by year and 
geographically [17].  There are molecular differences in the M type of strains of S. 
pyogenes that circulate in Africa and in the Pacific region compared to high-income 
countries [11].  Certain M serotypes of S. pyogenes have been linked to the prevalence of 
certain types of infections.      
 
1.2. Infections by Streptococcus pyogenes 
1.2.1. Infection versus colonization versus asymptomatic colonization 
 Strictly by definition within the context of bacteriology colonization means that 
there is a presence of bacteria in a given area.  The implication of colonization may be 
that the bacteria will not cause disease.  Asymptomatic colonization specifically means 
that the presence of the bacteria within the host results in no appreciable or detectable 
symptoms of infection and may additionally imply variable lengths of colonization, either 
transient or persistent infection.  Finally, the definition of bacterial infection is the 
proliferation of a bacterium within a tissue which results in cellular injury and is 
symptomatic.  
 
1.2.2. Severe streptococcal infections 
Severe streptococcal disease includes necrotizing fasciitis (NF), streptococcal 
toxic shock syndrome (STSS) and chronic post-infection sequelae such as 
glomerulonephritis, streptococcal arthritis, and rheumatic fever (RF), which may 
ultimately lead to rheumatic heart disease (RHD).  Severe streptococcal infections can be 
the result of a previous streptococcal infection by S. pyogenes, nosocomial infections, or 
in up to 50% of cases there is no obvious portal of entry for the streptococcal infection 
[18].  Severe streptococcal diseases can be further sub-classified as being either invasive 
disease or post-infection sequelae.  Invasive diseases are defined as infections in which 
streptococci are isolated from an otherwise sterile site, whereas post-infection sequelae 
are defined as a severe consequence of a streptococcal infection.  Monitoring of invasive 
streptococcal diseases over an 8-year period in Ontario, Canada revealed that 12% of 
invasive streptococcal cases were hospital-acquired, and that the common modes of 
transmission were from patient to patient or by a staff carrier [19].  The major risk factors 
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for severe and invasive streptococcal infections are pre-existing wounds, chicken pox, use 
of immunosuppressive drugs, pregnancy and underlying illnesses [6, 18, 20].  In 
developing countries, half of the patients with severe streptococcal diseases have an 
underlying disease or chronic illness such as human immunodeficiency virus infections, 
cancer, diabetes, alcohol abuse, or chicken pox [21].   
It is estimated that there are approximately 18.1 million cases of severe 
streptococcal infections, including post-infection sequelae, and an additional 1.78 million 
new cases annually globally [10].  In the United States, there are 9,600-9,700 cases of 
invasive streptococcal diseases each year that result in 1,100-1,300 deaths [17].  In Halton 
Region in the province of Ontario, there were between 1 to 5 cases of severe streptococcal 
disease per 100,000 individuals between 1997 and 2009 [22-23].   
Necrotizing fasciitis is an infection of the subcutaneous tissue, fascia, and fat that 
can lead to tissue necrosis, severe illness, streptococcal toxic shock syndrome (STSS) and 
mortality [24].  S. pyogenes is the most common cause of NF [25], and is diagnosed by a 
positive culture for S. pyogenes from an otherwise sterile site such as blood, connective 
tissue, or fascial tissue with either gross cutaneous necrosis or histopathology that 
demonstrates necrosis and polymorphonuclear cell infiltration in the fascia, reticular 
dermis or subcutaneous fat [19, 25].  NF most commonly presents with localized pain 
described to be disproportionate to the size of injury, chills, fever, sore throat, and 
respiratory symptoms, rash and vomiting [25].  The incidence of NF in children in 
Canada has been reported to be between 1.3 and 2.93 cases per million [25-27] and is 
associated with up to 20% mortality, which occurs in a shorter timeframe than any other 
severe streptococcal disease [25, 28] and is often preceded by a Varicella infection 
(chicken pox) [25-26].    
Streptococcal toxic shock syndrome is a host immune-mediated systemic disease 
that is induced by superantigens (SAgs; described below) [29].  STSS is very severe in 
nature with a rapid onset that can result in hypotension and multiple organ failure [30].  
Streptococcal SAgs have been detected in patients with STSS and a lack of anti-SAg 
antibodies has been associated with an increased risk of STSS [31-32].  STSS often 
occurs in conjunction with other invasive streptococcal diseases such as cellulitis, 
bacteremia and necrotizing fasciitis, and can be the result of a tegumentary breech [29, 
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32], or have no apparent source.  The diagnostic criteria for STSS include hypotension, 
renal function impairment, disseminated coagulopathy, adult respiratory distress 
syndrome, erythematous macular rash, tissue necrosis and central nervous system 
disorders [33].  The early symptoms of STSS are flu-like with fever, swollen lymph 
nodes, irritated throat, vomiting, diarrhea, rash, and muscle and joint pain, which may be 
disproportionately severe [18, 32].  Resulting intravascular coagulation can result in 
circulatory impairment which may lead to gangrene and may require surgical intervention 
[18].  Mortality rates in patients with STSS have been estimated to be up to 81% [21].  
Glomerulonephritis is the immune-mediated swelling of and subsequent damage 
to the kidneys which may ultimately result in kidney failure.  This condition has been 
linked to preceding streptococcal infection, and typically occurs in children or young 
adults [34].  Symptoms of post-streptococcal glomerulonephritis are edema, hypertension, 
hematuria, urinary sediment abnormalities, fever and decreased serum complement levels 
[34].  Glomerulonephritis occurs after a latency period of an average of ten days 
following streptococcal infection for acute glomerulonephritis, and within three to six 
weeks for glomerulonephritis [34].  Nephrogenicity seems to be related to M protein 
serotypes, in particular with M49 serotype strains in instances of skin infection [35], but 
all strains within the same M serotype are not necessarily nephrogenic [34].  The 
incidence of skin infections and glomerulonephritis is seasonal, and peaks in the summer 
months in temperate climates, and is pharyngitis-associated acute glomerulonephritis in 
northern climates [34].  The median incidence of acute post-streptococcal 
glomerulonephritis in children in less developed countries was 24.3 cases per 100,000 
[10].  It is estimated that there are 470,000 global cases annually with deaths in about 1% 
of all cases, mostly in adults [10].  The incidence of glomerulonephritis has continually 
declined globally, but there are still parts of the world that have a high incidence such as 
Africa, the Caribbean, South America, New Zealand, and Kuwait [34]. 
Rheumatic fever is a disease linked to poverty which is a post-streptococcal infection 
sequelae that may develop 2-5 weeks after the initial streptococcal infection [36-38].  
Each year there are 470,000 estimated new cases of RF and 233,000 deaths attributable to 
RF or RHD [10].  A decrease in the incidence of RF in the developed world has been in 
part attributed to the lower incidence of streptococcal infection due to good nutrition, 
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good hygiene, and treatment with antibiotics [10, 39].  In developing countries S. 
pyogenes is the most common cause of invasive bacterial disease in young infants during 
the first two months of life [40]. This is due to both the greater incidence of any type of 
streptococcal infection, and the chances that infections are more likely to go untreated 
[38].  S. pyogenes are rarely recovered in RF cases because the preceding streptococcal 
infection occurs well before the first signs of RF .  Clinical diagnosis of RF is made 
according to updated Jones criteria [41] (Table 1).   The symptoms of RF are due to 
antibody cross-reactivity against shared epitopes from the streptococcal M-protein similar 
to epitopes found in cardiac myosin, synovial, and neuronal tissues, which ultimately 
results in autoimmunity [42-43].  Sera in patients with RF frequently have high 
concentrations of myosin-reactive antibodies [34].  This autoimmune reaction ultimately 
results in synovial inflammation (polyarthritis), neuronal tissue reactivity (Sydenham’s 
chorea) and inflammation of the heart.  Carditis is the most serious manifestation of RF 
with polyarticular arthritis being the most common manifestation.  RF-associated carditis 
is associated with permanent valve damage [34].  S. pyogenes M-serotypes that are 
associated with the development of RF are found to have increased virulence, higher M 
protein expression and form mucoid colonies with upregulated capsule production to 
prevent phagocytosis [38].   
RHD follows RF autoimmune reactivity to the heart resulting in lesions and 
inflammation in the heart valves that may lead to permanent and progressive cardiac 
damage [42].  The mitral valve is the most common valve affected, followed by the 
aortic, tricuspid, and occasionally the pulmonary valve [38].  With 15.6 million cases, 
RHD is the most common cause of heart disease in children worldwide and is the leading 
cause of cardiovascular death in the first five decades of life in developing countries [10, 
36, 44].  RHD can sometime cause strokes; it is estimated that 3-7.5% of strokes in all 
developed countries are due to underlying RHD, which results in 108,000-269,000 deaths 
due to strokes per year in developing countries [10].  There are an estimated 2.39 million 
cases of RHD globally in children aged five to fourteen years, and it is estimated that one 
and a half percent of those cases will result in death each year [10].  Mortality due to 
RHD varies geographically with the total number of deaths being approximately 23,877 
in more developed countries, and 468,164 in less developed countries [10].  The highest  
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Table 1.  Jones criteria for the diagnosis of rheumatic fever.  The diagnosis of RF requires 
the co-presence of either two major criteria, or one major criterion and two minor criteria, 
together with supporting evidence of a preceding infection with S. pyogenes [41]. 
Major Criteria Minor Criteria 
Migratory polyarthritis Fever 
Carditis Elevated acute-phase reactants 
Subcutaneous nodules Arthralgia 
Chorea Prolonged PR interval on 
electrocardiography 
Erythema marginatum  
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prevalence of RHD is found in sub-Saharan Africa where there are 5.7 cases per 1,000, 
approximately five times higher compared to developed countries [10].  It is estimated 
that two to three percent of children in Cambodia and Mozambique have RHD which is 
often undiagnosed [39], and that 60% of RF patients will develop RHD [10], which is 
why prophylaxis is often used to prevent subsequent cardiac damage. 
 
1.2.3. Mild-to-moderate streptococcal infections 
 Aside from serious, severe and invasive streptococcal diseases, S. pyogenes can 
also be the causative agent of less severe, mild-to-moderate infections such as scarlet 
fever, impetigo, and streptococcal pharyngitis.  These infections are more common than 
severe streptococcal infections and are more likely to go unreported and untreated.  Mild-
to-moderate S. pyogenes infections are often considered to be inconsequential, despite the 
potential complications of developing severe streptococcal disease. 
 Scarlet fever is a SAg-mediated streptococcal disease [45] that is characterized by 
the swelling of the tongue that gives it a strawberry colour and appearance, a distinctive 
sandpaper rash on the trunk of the body, fever, and exudative pharyngitis [46].  The 
incubation period for scarlet fever is one to two days.  The rash may persist for more than 
a week and as it fades may result in desquamation [46].    
Impetigo is a topical skin infection, often caused by S. pyogenes, that results in 
skin abrasions which most often form around the mouth [47].  Estimates of the prevalence 
of impetigo in the global population vary based on the study.  Studies done in Brazil, 
Ghana, and Mali found impetigo in 9.6-12.3% of the population; other studies have 
indicated that the prevalence of impetigo is between 0.2-35%; the range in prevalence 
may be due to differences in the definition of cases and bacteriological sampling 
techniques between groups [47].  S. pyogenes was isolated from approximately 95% of 
impetiginous lesions in studies in Brazil and Africa, which was consistent with previous 
American studies [47].  Impetigo is especially prevalent in children between the ages of 2 
and six years old, especially those in developing countries.  At any given time 111 million 
children in developing countries are estimated to have streptococcal pyoderma globally 
[10]. 
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 Streptococcal pharyngitis, otherwise known as ‘strep throat’, is a common illness 
in which a streptococcal infection of the pharynx results in swelling of the tonsular tissue 
and mucus production over the tonsils, and is often accompanied by fever.  Large 
numbers of S. pyogenes are isolated from the saliva of convalescents [7] and droplets 
containing infected saliva can be passed  by sneezing, coughing or talking [5]. 
  Pharyngeal infections are some of the most common streptococcal infections with 
an estimated 616 million pharyngeal infections globally each year [10].  It is estimated 
that annually in developed countries, approximately 15% of school-aged children and 
four to ten percent of the population will suffer from a symptomatic episode of 
streptococcal pharyngitis [10], and that the average cost in the treatment (both medical 
and non-medical) of each case is approximately $200, which amounts to an estimated 
224-539 million dollars per year cost for streptococcal pharyngitis in the United States 
alone [12]. The incidence of pharyngeal infection in less developed countries are 
estimated to be five to ten times greater than in the developed world [10].  Pharyngeal 
infections may resolve on their own or with aid of antibiotic treatment.  Streptococcal 
pharyngitis may potentially precede more severe streptococcal infections or post-infection 
sequelae. 
 
1.2.4. Asymptomatic colonization by Streptococcus pyogenes 
Streptococcus pyogenes association with humans may also result in asymptomatic 
persistence of the bacteria within the human population.  As this association is 
asymptomatic, there is no regular monitoring for the detection of S. pyogenes in healthy 
populations globally.  The prevalence of S. pyogenes carriage varies by age.  A general 
survey of the throat carriage of S. pyogenes in 2,626 asymptomatic individuals in 
Denmark revealed that 2.2% of the population was asymptomatically colonized.  The 
incidence of colonization was inversely correlated with the age of the individual.  The 
incidence of streptococcal colonization in individuals less than 14 years of age was 
between 10.9-12% [48-49], and the prevalence of streptococcal asymptomatic 
colonization in children under 5 was 24% [49].  The lowest incidence of streptococcal 
carriage was in individuals older than 45 years (0.6%) [48].   
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Asymptomatic carriers of S. pyogenes can be the cause of severe streptococcal 
infection in a healthcare environment [19].  There have been reported incidences of 
asymptomatic carriage of the same strains of S. pyogenes which were the cause of severe 
and invasive infections in an outbreak in healthcare and household contacts [21].  A study 
of 46 patients with invasive streptococcal infection in Ontario, Canada determined that 
the rate of streptococcal colonization in household contacts was 12% in throat cultures 
approximately 5-12 days after the onset of illness in the index patient.  It was determined 
that household contacts were more likely to be colonized if they had 4 or more hours of 
contact daily with the index patient, and if they were younger in age [21].  The 
asymptomatic persistence of a streptococcal serotype within the population, regardless of 
the previous association with an infectious disease outbreak, likely plays a role in the 
overall incidence of streptococcal disease, either mild or severe.   
 
1.2.5. Treatment of streptococcal infections  
Effective resolution of non-severe S. pyogenes infections (such as pharyngitis or 
impetigo) can prevent the potential complications of severe streptococcal disease or the 
development of post-infection sequelae.  Resolution of streptococcal infection is 
dependent on a fast and accurate diagnosis and effective treatment with antibiotics and, 
where necessary, supportive therapy [28].  S. pyogenes is most often treated with 
penicillin or amoxicillin, or alternatively in the case of penicillin allergy with clindamycin 
or macrolide antibiotics [25, 36, 50].  Prophylaxis is recommended in cases of 
colonization of healthcare workers carrying an outbreak strain of S. pyogenes [6]. 
Treatment of RF involves a two-pronged approach involving the treatment of the 
streptococcal infection with antibiotics and anti-inflammatory medications to treat the 
symptoms of RF.  Intravenous immunoglobulin (IVIG) has also been used as a treatment 
for carditis [38].  The best prevention of RF is primary prophylaxis to prevent subsequent 
streptococcal infections.  Long-term prophylaxis is recommended by the World Health 
Organization and the American Heart Association guidelines for people with a history of 
RF every three to four weeks until the age of 21 to prevent subsequent rheumatogenic 
incidents [10, 39].  When left untreated, episodes of RF resolve on their own within three 
months, but may ultimately result in cardiac damage.  Sixty-five to seventy-five percent 
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of patients recover from the carditis without any further consequences; this recovery rate 
decreases if there are subsequent RF occurrences or if the carditis is severe [38].   
There have been some reported cases of macrolide and multi-drug resistance in S. 
pyogenes including resistance to azithromycin, tetracycline, clindamycin, lincomycin, 
streptogramin, chloramphenicol and erythromycin [36, 51-52].  There are different 
incidences of antibiotic resistance reported in geographically distinct outbreaks that range 
from 1-48% [36], and antibiotic resistance has been considered to be a contributing factor 
to outbreaks of streptococcal disease [53].  Specifically, a recent report of a 2011 
outbreak of scarlet fever in Hong Kong, China reported that the causative strain of S. 
pyogenes had acquired resistance to macrolide-lincomycin-streptogramin and tetracycline 
and encoded a MATE efflux pump, which is thought to be associated with antimicrobial 
resistances [53-54].  Nevertheless, despite the long-term use of -lactam antibiotics to 
treat S. pyogenes infection, there has never been a documented case of penicillin 
resistance for this organism. 
 
1.3. Genetic diversity in Streptococcus pyogenes 
Streptococcal strains vary in genome size from 1.33 to 1.94 Mb in size.  The 
variable size is due to the insertion of mobile genetic elements into the base streptococcal 
genome (NCBI genome sequence database).  A large part of the genetic diversity in S. 
pyogenes is attributed to differences in the mobile genetic elements that are integrated 
into a base genome [55].  There is very little genetic change in the base genome between 
S. pyogenes serotypes [55].  There is limited variability in the clonal populations of S. 
pyogenes isolated in an outbreak.  On average, there are 49 single nucleotide 
polymorphisms and 11 insertion and deletion events in the core genome of surveyed 
clonal S. pyogenes strains that were surveyed over the course of fifteen years [56].  
Critically, the streptococcal population is not genetically static, but made of distinct sub 
clones that appear in each epidemic group [56]. 
Streptococci can acquire bacteriophage, transposons and integrative conjugative 
elements that often contain virulence factors and antibiotic resistance determinants [57].  
The acquisition or loss of virulence factors and antimicrobial resistance encoding 
deoxyribonucleic acids (DNA) has been linked with changes in infectious properties and 
12 
 
 
outbreaks [53, 58]. Integrative conjugative elements (ICE) have been associated with the 
acquisition of antibiotic resistance in streptococcal populations, but do not encode SAgs 
[53].  ICE differ in their GC content more than bacteriophage, which may suggest that 
they originate from organisms that are not streptococci [57]. 
Bacteriophages are viral particles that may infect and introduce foreign DNA into 
a bacterial host.  All sequenced strains of S. pyogenes are polylysogenic [55] and many of 
these bacteriophage elements encode virulence factors including SAgs [59].  Acquisition 
of a bacteriophage can change the infective properties of the streptococci due to the 
acquisition of new virulence factors.  Often there is excision and reintegration of the 
bacteriophage DNA during normal growth (Kasper and McCormick, Unpublished data) 
and this movement may be a method regulating gene expression in S. pyogenes [60].  The 
phage-associated hypermutation is growth phase dependent and may allow the bacteria to 
better adapt to a new or changing environment [60].   
Lysogenic bacteriophages found in S. pyogenes are mosaic in nature and may 
have pieces in common with other phages [61].  Bacteriophages that carry streptococcal 
SAgs can be transferred between different strains of S. pyogenes, and are not restricted by 
M serotypes.  Transfer has been detected between group A, group C and group G 
streptococci, indicating a potentially common pool of bacteriophage [62-64].  This body 
of work also indicated that toxigenic conversion can happen by lysogenic transfer [61].  
This lysogenic transfer, including the transfer of virulence factors, can provide plasticity 
that could be advantageous for adapting to a host challenge and may possibly result in 
increases in virulence.  A bacteriophage can be induced to enter the lytic cycle in the 
presence of mammalian cells, including in a mouse nasopharyngeal model [55], which 
may indicate that phages can be transferred in vivo in the host.  Toxin encoding lysogenic 
bacteriophages can be considered as early pathogenicity islands, which eventually 
undergo mutagenesis and selective pressure to alter sequences such that the island can no 
longer excise or enter the lytic cycle. This may be due to the selective advantage provided 
by the presence of the mobile genetic element and thus, pathogenicity islands and 
prophage can represent varying points of evolution, and depending on the stringency of 
the search criterion, may become indistinguishable from the surrounding genome [65].   
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The acquisition of bacteriophages that encode novel virulence factors may 
contribute to the increased fitness. The resurgence of the M1 strain of S. pyogenes that is 
widely circulating globally, is thought to be, in part, due to the acquisition of a 
bacteriophage encoding speA [2, 14].  The presence of the speA gene may also be a major 
contributing factor in the resurgence of severe and invasive streptococcal infections 
reported in the 1980s and 1990s [14].  It stands to reason that the introduction of a novel 
bacteriophage that encodes a SAg, or other phage-encoded virulence factor, could 
increase the efficiency of asymptomatic carriage, although this has yet to be shown 
experimentally.   
 
1.4. Regulation of streptococcal virulence factors 
Gene expression in S. pyogenes is dependent on two main types of regulatory 
proteins: stand-alone regulators and two component regulatory systems [66-67].  A two 
component regulatory system is comprised of a sensory histidine kinase that 
autophosphorylates in response to an environmental signal, and transfers the phosphate to 
a response regulator, which then affects gene transcription [68].  A stand-alone regulator 
is a regulatory protein that does not have an identified sensory kinase associated with it 
[66].  There are currently thirteen two-component systems described in S. pyogenes and 
multiple stand-alone regulators.  The two best-studied virulence regulators in S. pyogenes 
are the stand-alone regulator mga operon and the covRS two-component system. 
mga was the first positive acting gene regulator of a virulence network discovered 
in S. pyogenes [66].  All S. pyogenes have the mga operon which is required for the 
adaptation into new tissue sites and controls the expression of surface associated 
molecules such as the M protein, and secreted factors like C5a peptidase and the secreted 
inhibitor of complement, which are each necessary for immune evasion [66].  The mga 
operon controls genes in response to environmental conditions, such as the upregulation 
of C5a peptidase in response to elevated carbon dioxide levels, changes in osmolarity, 
temperature and iron restriction [66].  mga is encoded on what is believed to be an ancient 
pathogenicity island with the M-protein, whose integration into the streptococcal genome 
likely occurred prior to speciation [65].  Regulation by the mga regulon reaches its peak 
during the exponential phase of bacterial growth, which implies that mga regulated 
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proteins are necessary for adaptation of S. pyogenes to new tissue sites at early stages of 
infection [66]. 
Regulatory systems are very sensitive to the introduction of single nucleotide 
polymorphisms.  It has been observed that there is an overabundance of single nucleotide 
polymorphisms in transcriptional regulators between streptococcal strains [56].  Modest 
polymorphisms in regulatory genes can result in considerable differences in the 
streptococcal transcriptome which can result in differences in pathogenicity [56]. 
 The covRS two-component system influences the transcription of approximately 
15% of genes in S. pyogenes, including genes involved in stress adaptation, gene 
regulation, pathogenesis, and suppresses surface and secreted proteins.  Regulation by 
covRS is growth condition-dependent [69] and regulates many streptococcal virulence 
factors including the hyaluronic acid synthesis operon, streptokinase, cysteine protease, 
mitogenic factor, capsule and streptolysin S [70-74].  CovRS detects stressful conditions 
endogenous to the human body such as low iron, temperature of 39C, pH, exogenous 
Mg
2+
, and growth in the presence of saline [75-76], and is required for the adhesion to 
keratinocytes [70].  Single nucleotide polymorphisms in the covS gene have been linked 
to the ability of streptococcal strains to transition from causing pharyngeal infections to 
being more apt to cause invasive infections [77-79].  However, the reported mutations 
that are linked to invasive disease protein profile were reported to be present in both 
pharyngeal and invasive isolates; conversely, the pharyngeal covS mutations protein 
expression profile were also found in both pharyngeal and invasive isolates [80].  S. 
pyogenes isolated from a patient with scarlet fever from a 2011 outbreak in Hong Kong 
failed to switch to the covRS mutant SpeB-negative form 3 days post infection [53], as 
was reported to be characteristic.  This may indicate that mutations in covRS may not be 
the key determinant of the severity of streptococcal infections in all strains. 
Other regulatory systems have been identified and characterized to play a role in 
the regulation of virulence genes, often in response to external stimuli such as bacterial 
growth phase, temperature, gas concentrations, iron concentration and nutritional 
availability.  One example is the regulator CodY which regulates the production of 
DNases, protease, and hyaluronidase, in response to growth phase and the abundance of 
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nutrients, which may contribute to the dissemination of S. pyogenes and the hydrolysis of 
host macromolecules [81].  
There is surprisingly little known about the regulation of superantigens in 
Streptococcus pyogenes.  There is evidence that streptococcal superantigens are 
upregulated early on in infection [82].  In vitro streptococcal superantigens are 
upregulated in late log phase or stationary phase [83].  The rgg (also known as ropB) 
regulon upregulates transcription is higher in pharyngeal infections, and in general is 
affected by growth phase, pH, NaCl concentration and carbohydrate-poor and peptide-
rich nutrient environments.  Recently, chromatin immunoprecipitation revealed that Rgg 
binds upstream of speH [84]. 
  
1.5. Superantigens 
SAgs are a family of proteins that are produced by a limited number of bacterial, 
and viral species.  Staphylococcal enterotoxin A (SEA) was the first SAg to be identified 
and it was purified and characterized in 1966 [85], although it was not known to be a SAg 
at the time.  The term ‘superantigen’ was coined in 1989 when it was determined that the 
mitogenic capability of these toxins resulted in a massive expansion of T cells that 
occurred in a T cell receptor (TCR) variable -chain (V)-dependent manner [86].  SAgs 
stimulate both cluster of differentiation (CD) 4+ and CD8+ T cells polyclonally [87-88], 
and have been reported to stimulate contact-dependent T regulatory cells and invariant 
natural killer T cells in a concentration-dependent manner [87, 89].  Although they 
typically bind select TCR V families and major histocompatibility complex (MHC) 
class II molecules (Figure 1C-D), their binding selectivity can be less stringent at higher 
SAg concentrations [87, 90].    
 
1.5.1. Superantigen structure 
 Staphylococcal and streptococcal SAgs are between 22 and 31 kilodaltons (kDa) 
in size.  Although the SAg family vary greatly in their amino acid similarity, between 
15.5% to 90% amino acid sequence homology, they all share the same general ternary 
structure.  Staphylococcal and streptococcal SAgs may have evolved from a single 
ancestral SAg [31] and a recent phylogenic  tree has outlined the relatedness of all known  
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Figure 1.  Streptococcal superantigen structures and immunoreceptor interactions.  (A) 
Cartoon representations of all of the available streptococcal superantigen crystal 
structures including SpeA (PDB 1HA5) [91], SpeC (PDB 1KTK) [92], SpeH (PDB 
1ET9) [93], SpeI (PDB 2ICI) [94], SpeJ (PDB 1TY0) [95], SmeZ (PDB 1EU3) [93], and 
SSA (PDB 1BXT) [96]. (B) Cartoon representation of conventional antigen presentation 
[97] in which the TCR V (green) and V (yellow) chains recognize the specific peptide 
antigen presented by MHC class II (PDB IJ8W [98].  (C) Cartoon representation of a 
streptococcal superantigen which only has a low-affinity MHC class II binding site, such 
as SpeA and SSA.  The superantigen (grey) interacts with the TCR V chain (yellow) and 
the MHC class II -chain (blue) in a manner that is less-specific than conventional 
antigen presentation.  The V chain of the TCR makes contact with the  chain of MHC 
class II (red).  This model was constructed by superimposition of SEB-MHC class II 
(PDB 1D6E [99]) with SEB-TCR  chain (PDB 1SBB [100]), a mouse TCR was used to 
align the V chain  of the TCR (PDB 1U3H) [101]).  (D) The majority of the 
streptococcal superantigens have a zinc-mediated high-affinity MHC class II binding site 
in addition to a low-affinity MHC class II binding site.  These superantigens bind the V 
chain of the TCR and the -chain of the MHC class II in a manner similar to Panel C, and 
have an additional zinc-mediated high-affinity MHC class II binding site which binds to 
the -chain of the MHC class II binding site (red).  The model was constructed as detailed 
in [102] by superimposition of the SpeC-TCR structure (PDB 1KTK [92]) with the 
SEC3-MHC class II (low-affinity) structure (PDB 1JWM [103]), and the SpeC-MHC 
class II (high-affinity) structure (PDB 1HQR [104]), and with TCR-MHC class II 
structure (PDB 1FYT [97]) to align the -chain of the TCR.  (E) Despite significant 
differences in their primary amino acid sequences, all SAgs share a conserved ternary 
structure.  In red at the C-terminal end of the superantigen is a -grasp domain which is 
the site of the zinc-mediated high-affinity MHC class II binding site in SAgs.  In blue, at 
the N-terminal of the protein is a -barrel domain which is the site of the low-affinity 
MHC class II binding site.  In yellow is the T cell receptor binding site.  In the center of 
the superantigen structure in grey is an -helix that connects to two domains. 
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bacterial SAgs [105].  Each SAg contains a C-terminal -grasp domain, and an N-
terminal -barrel domain, arranged around a long central -helix (Figure 1A, 1E).  SAgs 
bind directly to the V-chain of the TCR [27, 81], and it has been demonstrated that the 
TCR -chain plays an important role in the stabilization of the ternary complex between 
some of the TCR-SAg-MHC class II complexes [106-107].   
The human MHC class II locus is a collection of genes known as the human 
leukocytic antigen (HLA) complex [108].  MHC class II molecules are heterodimeric 
glycoproteins with - and -chains that are expressed on the surface of macrophages, 
dendritic cells and B cells, and present peptides for recognition by CD4+ T cells.  MHC 
class II molecules associate with antigens before being expressed on the surface of the 
cell.  Human MHC class II has three loci, HLA-DR, -DQ, and –DP, and each individual 
has a maternal and paternal copy of each allele; 90% of all individuals are heterozygous 
for HLAs at each locus [108].  There are multiple allotypic forms of HLA-DR, HLA-DQ, 
and HLA-DP [109-110].  HLA haplotypes are expressed on the cell surface of APCs in 
different proportions, in the following general pattern: DR>DQ>DP [111].     
Superantigens associate with MHC class II and TCRs simultaneously which can 
result in a massive immune response.  Streptococcal SAgs have been reported to, in 
general, bind to HLA-DQ better than HLA-DR and –DP [32], and isotypic and allotypic 
variations can influence the immune response and the response to SAgs [88] in in vitro 
binding and proliferation assays [112], and can result in different clinical outcomes in 
streptococcal infection [112-114].  The MHC class II polymorphisms have been 
demonstrated to contribute to the magnitude and quality of the T cell response to SAgs 
[112], and protective MHC class II haplotypes are associated with higher IL-10 
production and lower levels of pro-inflammatory cytokines [115]. 
Streptococcal SAgs bind to MHC class II through their two MHC class II binding 
sites.  Streptococcal SAgs can either bind to MHC class II through a low-affinity MHC 
class II -chain binding site (as is the case for SpeA and SSA) [116] (Figure 1C), or 
through both the low-affinity interaction, and an additional zinc-mediated high-affinity 
MHC class II -chain binding site [117] (Kasper and McCormick, unpublished) (Figure 
1D).  Streptococcal SAgs have a higher affinity for human MHC class II than for mouse 
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MHC class II, explaining why they are more potent in activating human T cells as 
compared to mouse T cells [31]. 
 
1.5.2. Staphylococcal Superantigens 
 Staphylococcal enterotoxins (SEs) were initially characterized based on their 
emetic ability at concentrations less than 1 g, which causes diarrhea and vomiting in 
staphylococcal food poisoning [31].  However, many of the staphylococcal SAgs do not 
possess emetic activity, or have not been tested, and these are referred to as the SAg-like 
toxins (SE-like or SEl).  Staphylococcal SAgs are associated with illnesses such as 
staphylococcal food poisoning, toxic shock syndrome (both menstrual and non-menstrual) 
and are potentially also linked to diseases in which SAgs may play a contributing role 
such as Kawasaki disease, chronic rhinosinusitis, atopic dermatitis and guttate psoriasis 
[105].  The toxic shock syndrome toxin-1 (TSST-1) SAg is associated with menstrual and 
non-menstrual toxic shock syndrome and is fairly unique among the superantigen family.  
TSST-1 is both evolutionarily distinct [118-119], and engages both TCR V and MHC 
class II with a unique architecture by making peptide-contacts [120-121]. Staphylococcal 
enterotoxin B (SEB), and sometimes SEC, are also historically associated with the non-
menstrual form of toxic shock syndrome [122].  The role of staphylococcal SAgs in 
colonization is unclear [105].  The work presented in this study focuses exclusively on 
streptococcal SAgs, and further information on the staphylococcal SAgs can be found in a 
recent review by Xu and McCormick [105]. 
 
1.5.3. Streptococcal Superantigens 
There are currently eleven known SAgs that have been characterized from S. 
pyogenes: streptococcal pyrogenic exotoxin SpeA, SpeC, SpeG-M, streptococcal 
mitogenic exotoxin Z (SmeZ), and streptococcal SAg (SSA) [116, 123-125]. 
Streptococcal SAgs that have been crystallized are shown in Figure 1 [91-93, 95-96].  
SpeB and SpeF were previously labelled as SAgs, but have since been found to encode a 
cysteine protease and deoxyribonuclease (DNase), respectively.  All sequenced strains of 
S. pyogenes encodes multiple SAgs within their genomes, and distinct streptococcal 
strains express different compliments of SAgs [126].  Although, there is no common SAg 
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profile linked to a particular strain or to invasive diseases such as STSS [2, 127], SpeA 
has historically been associated with STSS [128-129], and has been detected in the serum 
of mice infected with an invasive streptococcal infections at microgram (g) levels [130], 
and in the serum of acute phase patients at pictogram levels [130-132].  
Although SAgs have been associated with severe diseases like STSS, many 
healthy adults who have not previously developed severe SAg-mediated diseases, 
produce antibodies against these toxins, suggesting that SAgs are also made during mild 
or asymptomatic streptococcal infections [133-134].  Streptococcal superantigens are 
upregulated in pharyngeal infections in a macaque model of pharyngeal infection [82], 
which also indicates that streptococcal superantigens may play a role in mild infections or 
asymptomatic colonization by Streptococcus pyogenes. 
Certain streptococcal superantigens have been found to preferentially bind HLA-
DR or –DQ such as SpeA, which preferentially bind HLA-DQ [59], but that SpeA did not 
react differently to allotypic variations between HLA-DQ6 and –DQ8 [88].  SpeC was 
better-presented by HLA-DR than –DQ alone [135].  Streptococcal superantigens also 
have the ability to stimulate different immune system responses depending on the 
concentration of superantigens [87].  At high concentrations superantigens stimulate 
inflammatory responses and low stimulating concentrations of superantigens at the 
picogram and femtogram levels stimulate the production of IL-10 which can stimulate the 
suppression of co-stimulatory ligands on APCs such as activated B cells and monocytes 
[87]. 
The true evolutionary function of SAgs within S. pyogenes is not understood, 
however it is likely that these toxins have evolved in the context of asymptomatic 
persistence of S. pyogenes within the human population. 
 
1.6. Streptococcal strains 
There are many serotypes of S. pyogenes circulating in the human population at 
any given time.  The specialization of S. pyogenes as an obligate human pathogen is 
thought to be due to a lack of biosynthetic genes, and the expression of a large number of 
scavenging systems which are thought to be typical of human specialization [136].  The 
efficiency of S. pyogenes to persist within a human host is largely thought to be due to the 
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inherent virulence factors produced by the bacteria, in combination with the sensitivity of 
the host immune system to streptococcal infections.  Closely related streptococci, such as 
Streptococcus canis and Streptococcus dysgalactiae, lack host specific adaptation which 
indicates that the ancestor to S. pyogenes was unlikely to be human-specific [137].  This 
further suggests that a primary feature in the evolution of S. pyogenes was the stringent 
adaptation to humans.  
 
1.6.1. Streptococcus pyogenes MGAS5005 
Streptococcus pyogenes MGAS5005 serotype was isolated from the cerebrospinal 
fluid in 1996 from a patient in Toronto, Ontario, Canada, and is an M1 serotype which 
has been indicated to be the most widely-circulating cause of invasive streptococcal 
infections in North America, and Western Europe [138]. This specific strain was 
originally isolated from a patient with an invasive case of S. pyogenes in Ontario, Canada 
[138].  The total size of the S. pyogenes MGAS5005 genome is 1.838554 megabases 
(Mb).  The strain contains 4 mobile genetic elements including three bacteriophage 
elements and one ICE and encodes four SAgs.  The gene for speA is encoded on the 
bacteriophage 5005.1.  This lineage of S. pyogenes has persisted globally for more than 
25 years and has been isolated from both severe and mild cases [14].  Genetically 
identical M1 isolates can cause both severe and non-severe disease [13].    
 
1.6.2. Streptococcus pyogenes MGAS8232 
Streptococcus pyogenes MGAS8232 is an M18 serotype of S. pyogenes and this 
strain was isolated from a patient with ARF in 1987 [136].    The M18 serotype strains are 
often associated with incidences of ARF in the USA. The genome is 1.895017 Mb, and 
contains five bacteriophages and no ICE.  Of the six SAgs encoded in the MGAS8232 
genome, four are encoded on bacteriophage.  The 8232.1 bacteriophage encodes speA1; 
speC is encoded on 8232.2; and speL and speM are encoded close together on 8232.3 
[136].  Streptococcus pyogenes MGAS8232 has a common genetic backbone to other 
streptococcal strains with some large regions of insertion but no major rearrangements 
[136]. 
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1.7. Murine strains as experimental tools in investigating Streptococcus pyogenes  
In order to study the role of virulence factors in the context of colonization, mild 
infections and disease, it is important to use a model system that is sensitive to the 
virulence factors produced by the pathogen being assessed.  It is also important to 
reiterate that most mouse MHC class II molecules do not interact efficiently with 
streptococcal SAgs [139], and thus many experiments have utilized exogenous or 
chemical agents, such as the liver damaging agent D-galactosamine to sensitize mice to 
SAg-mediated responses [140].  These agents can also potentially mask or exaggerate 
significant pathogenic effects of the bacterial infection on the animal [140].   
Mice expressing transgenic human MHC class II molecules have been described 
to have a greater sensitivity to SAg activation and are considered to be better models for 
the study of SAg-mediated pathogenesis [112-113, 141]. These transgenic mice have 
been used to determine the impact that various human MHC class II molecules could 
potentially have on the clinical outcomes of severe and invasive infections [112-113, 
141].     
 
1.8. Pathophysiological structure of the murine nose and oropharynx 
 In mice, as in all mammals, the nose is both a portal of entry into the respiratory 
system and the sensory organ for olfaction.  Nasally inspired air is passed through the 
nasal passage which extends, bi-laterally divided by the septum, from the nostrils to the 
nasopharynx [142] (Figure 2).  The complex folding of the nasal structure warms and 
conditions the air before it enters the lungs [143].  The nasal passage is lined by ciliated 
nasal mucosa, which beat to move nasal mucus, produced by goblet cells, distally to the 
oropharynx where it is swallowed [142].    
There are five types of epithelia in the nose: neuroepithelium, respiratory 
epithelium, squamous epithelium, lymphoepithelium, and transitional epithelium.  
Squamous epithelium is located in the nasal vestibule just inside the nostrils and is similar 
to the epidermis in the skin.  The translational epithelium is situated between the 
squamous epithelium and the respiratory epithelium.  Respiratory epithelium is more 
distal from the nares and makes up the majority of the non-olfactory epithelium.   
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Figure 2.  The physiological location of the ethmoid turbinates, nasal-associated 
lymphoid tissue and the maxillary sinuses.  A cross-section drawing of the head of a 
mouse indicates where standard sections are taken for histological analysis at T3 and T4. 
The nose (No), and brain (B) are identified for orientation.  The T3 section is located 
anterior of the T4 section and slices through the ethmoid turbinate (ET) ahead of both the 
molar teeth and the eye (E).  The NALT (N) is located bilaterally at the base of the 
ethmoid turbinates.  Lateral to the NALT in the T3 section is the maxillary sinus (MS).  
The T4 section cuts through both the brain and the eye.  The ethmoid turbinate is better-
separated and the NALT is located bilaterally at the base of the ethmoid turbinates. 
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Respiratory epithelium and neuroepithelium are both ciliated, although the cilia beat more 
slowly to locomote the mucus distally over the neuroepithelium than the respiratory 
epithelium.  The fifth type of nasal epithelium is the lymphoepithelium; this epithelium 
covers the discrete foci of nasal-associated lymphoid tissue (NALT) that run bilaterally 
on the ventral face of the nasopharyngeal meatus, which is otherwise lined with 
respiratory epithelium. 
 
1.8.1. Pathophysiological comparison of nasal tissue between mice and humans 
Although there are many similarities in the function and structure of the nasal 
epithelia between mice and humans, there are also some notable differences [143].  The 
nasal passage in both mice and humans is separated by a septum and the nasal passage 
extends from the nostrils to the nasopharynx.  Unlike humans and other primates who are 
able to breathe orally and nasally, mice are obligate nose breathers [142].  
Physiologically, mice lack hair in the vestibule just inside the nasal opening [142] and 
have more complicated nasal turbinates in their folding and branching patterns [143].  In 
particular, the extremely complex folded shape of the ethmoid turbinates which are lined 
with olfactory neuroepithelium, and respiratory epithelium in mice [143] are thought to 
be designed for acute, more sensitive olfaction [142].   
 
1.8.2. Nasal-associated lymphoid tissue 
Human tonsils, otherwise known as Waldeyer’s ring, are composed of the human 
adenoid, bilateral tubule, palatine, and lingual tonsils [142].   Similar analogous structures 
have been reported in monkeys, horses, cattle, rats, and mice [144-145].  The tonsular 
surface is highly invaginated which increases the surface area of the tonsils and aids in 
the capture of foreign materials for immune surveillance [146].  The human tonsils are the 
primary site of streptococcal colonization.  Tonsils that were excised from healthy 
individuals due to recurrent pharyngotonsillitis had a carrier rate for S. pyogenes of 25%, 
and in healthy individuals with hypertrophic tonsils, this carrier rate for S. pyogenes was 
7%, which suggests that the tonsils are an important reservoir for asymptomatic carriage 
of S. pyogenes, which may seek refuge intracellularly [147].  The NALT in mice has been 
reported to correlate functionally to Waldeyer’s ring in humans [142].  The location of the 
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NALT within the nasal passage is strategic in that all antigenic-laden inspired air must 
pass across the area [142]. 
The NALT is overlaid by the lymphoepithelium, which includes cuboidal cells 
with luminal microvilli called membranous cells (M cells) that are involved in the uptake 
and translocation of inhaled antigens to the underlying lymphoid structures [142-143].  
The NALT and the nasal mucosa drains directly to the cervical lymph nodes and is a 
major mucosal inductive site [148].  It is an organized tissue with T lymphocyte- and B 
lymphocyte-enriched zones [149].  NALT is an immune inductive and tolerogenic site 
which contains T cell precursors which are thought to downregulate T cell activation.  It 
has been suggested that NALT may be capable of both mucosal and systemic immune 
response [142, 150].   
 
1.8.3. Streptococcal colonization and the murine nasal infection model 
 Streptococcal colonization of the nasal passage in mice is thought to be analogous 
to tonsular asymptomatic colonization or mild pharyngeal infection and has been 
previously described in papers from the Cleary laboratory [149, 151-153].  It has been 
determined that BALB/c mice infected with 5  108 colony forming units (cfu) of S. 
pyogenes remained infected with detectable concentrations of bacteria for seven days in 
the nasal cavity, and that the greatest concentration of streptococci was located in the 
NALT at 48 hours post-inoculation [154].  Kinetically, it was observed that after an initial 
clearance of the bacteria, as imaged at four and a half hours, the streptococcal burden 
recovered at 24 hours and reached the maximum concentration at 48 hours [154].   
Streptococci are indicated to survive intracellularly in NALT infection models as 
indicated by antibiotic protection assays of infected NALT tissue with S. pyogenes 
resulted in about 1-10% bacterial recovery [154].  Similar studies done with excised 
human tonsils also observed S. pyogenes existing intracellularly [147].  The uptake of S. 
pyogenes into the NALT was downregulated by pre-treatment with UEA-1 lectin which 
indicates that the portal of entry into the NALT is via the M cells [149].  Streptococcal 
induction of TGF- upregulates the expression of 51 integrins and fibronectin in 
tonsular fibroblasts which are necessary for S. pyogenes internalization into the host cells 
[155], additionally it also increases Th17 and T regulatory cells which may dampen 
27 
 
 
cellular responses to antigens and increases the infiltration of neutrophils and 
macrophages into infected host tissues [155].  Similar Th17 response was observed in 
both mouse nasal and tonsular tissue [155]. 
  
1.9. Rationale and hypothesis 
Scientific and clinical studies in the literature are largely focused on the 
examination of severe and invasive streptococcal infections.  There are relatively fewer 
clinical papers, however, that examine mild streptococcal infections or asymptomatic 
persistence of S. pyogenes within the human population [49, 156-158].  It can be argued 
that although severe streptococcal diseases are dramatic and important, mild or 
asymptomatic infections occur much more frequently and are thus of greater significance 
for streptococcal persistence within the host, and within the human population as a whole, 
as well as for the mechanisms of evolution of these bacteria.  Streptococcal superantigens 
have been shown to be upregulated in a pharyngeal infection model in Cynomolgus 
macaques, which implies that streptococcal superantigens play a role in mild 
streptococcal infection or streptococcal colonization [82], however the relationship and 
contribution of streptococcal superantigens to the establishment of mild infection and 
colonization has not been systematically assessed. As a result, the study of the 
mechanisms that S. pyogenes will use to persist within the population are extremely 
important.  Although the role of streptococcal SAgs in severe disease such as STSS is 
clear, the natural niche of S. pyogenes is in a state of colonization or mild infection, and 
as such we hypothesize that these toxins have likely evolved within the context of mild 
infection or colonization.  Therefore, the hypothesis of this thesis is that SAgs play an 
important role in the course of colonization of S. pyogenes in an appropriate SAg-
sensitive nasal mouse model.   
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Chapter 2:  Materials and Methods 
  
29 
 
 
 
2.1. Bacterial growth conditions 
2.1.1. Escherichia coli growth conditions 
 Escherichia coli strains used in this study are listed in Table 2.  All E. coli were 
grown aerobically at 37C in either Difco Luria-Bertani (LB) broth (Becton, Dickinson 
and Company, Sparks, MD, USA) or Brain Heart Infusion (BHI) medium (Becton, 
Dickinson and Company, Franklin Lakes, NJ, USA) or on solid LB or BHI media 
supplemented with 1.5% agar (BD, Franklin Lakes, NJ, USA).  The media were prepared 
to contain antibiotics appropriate to the plasmids within those strains (Table 3).  
Ampicillin (Amp) (EMD, Darmstadt, Germany) was used at a concentration of 150 
g/ml, and kanamycin (Kan) (Sigma Aldrich, St. Louis, MO, USA) at a concentration of 
50 g/ml.  Erythromycin (Erm) (Acros Organics, NJ, USA) was used at a concentration 
of 150 g/ml in.  All antibiotics were filter sterilized through a 0.2 m syringe filter (Pall 
Life Sciences, Ann Arbor, MI, USA).  Viable stocks of E. coli were maintained and 
stored in LB or BHI containing the appropriate antibiotics and 20% (v/v) glycerol at -
80C.   
 
2.1.2. Streptococcus pyogenes growth conditions 
S. pyogenes strains used in this study are listed in Table 2.  All S. pyogenes 
cultures were grown without aeration at either 30C, 37C, or 40C in Todd Hewitt media 
(Becton, Dickinson, and Company, Sparks, MD, USA) supplemented with 1% (w/v) with 
yeast extract (EMD Chemicals Inc., Darmstadt, Germany)  (THY).  Media was prepared 
to contain 1 g/ml Erm for growth with plasmids as necessary (Table 3).  After the SAg 
genes were inactivated (described below), of all of the S. pyogenes were grown in THY 
media supplemented with 10% human plasma (HP) to restore the streptococcal capsule 
[159].  Human plasma was collected after being diluted 1:1 in Roswell Park Memorial 
Institute medium (RPMI) 1640 and reserved from peripheral blood mononuclear cells
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Table 2.  Bacterial strains used in this study 
Strain Description Source 
Escherichia coli XL1 Blue  recA1 endA1 gyrA96 thi-1 supE44 relA1 lac 
[F’proABlaclqZ∆M15 Tn10 (Tetr)] 
Novagen 
Stratagene 
Escherichia coli BL21 (DE3) F- ompT[lon] hsdSB with λDE3 prophage 
carrying the T7 RNA polymerase gene 
Novagen 
Streptococcal strains 
Streptococcus pyogenes 
MGAS5005 wild type 
M1 streptococcal strain isolated from an 
invasive case in Ontario 
Sumby et al. [138]   
Streptococcus pyogenes 
MGAS5005 speA 
S. pyogenes MGAS5005 with speA disrupted This study 
Streptococcus pyogenes 
MGAS5005 speG 
S. pyogenes MGAS5005 with speG disrupted This study 
Streptococcus pyogenes 
MGAS5005 speJ 
S. pyogenes MGAS5005 with speJ disrupted This study 
Streptococcus pyogenes 
MGAS5005 smeZ 
S. pyogenes MGAS5005 with smeZ disrupted This study 
Streptococcus pyogenes 
MGAS5005 speA/speJ/smeZ 
S. pyogenes MGAS5005 with speA, speJ, and 
smeZ disrupted 
This study 
Streptococcus pyogenes 
MGAS8232 wild type 
M18 streptococcal serotype associated with 
acute rheumatic fever outbreaks in USA.  
Isolated from a patient with acute rheumatic 
fever. 
Smoot et al. [136] 
Streptococcus pyogenes 
MGAS8232 speA 
S. pyogenes MGAS8232 with speA disrupted This study 
Streptococcus pyogenes 
MGAS8232 speC 
S. pyogenes MGAS8232 with speC knocked 
out 
This study 
Streptococcus pyogenes 
MGAS8232 speG 
S. pyogenes MGAS8232 with speG disrupted This study 
Streptococcus pyogenes 
MGAS8232 speL/speM 
S. pyogenes MGAS8232 with speL and speM 
disrupted 
This study 
Streptococcus pyogenes 
MGAS8232 smeZ 
S. pyogenes MGAS8232 with smeZ disrupted This study 
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Streptococcus pyogenes 
MGAS8232 SAg 
S. pyogenes MGAS8232 with speA, speC, 
speG, speL, speM, and smeZ disrupted 
This study 
Streptococcus pyogenes 
MGAS8232 SAg + speA 
S. pyogenes MGAS8232 SAg complemented 
with speA  
This study 
Superantigen expression strains 
Escherichia coli BL21 with SpeA pET28a::TEV::speA wild type [160] 
Escherichia coli BL21 with SpeC pET41a::TEV::speC wild type [161] 
Escherichia coli BL21 with SpeG pET28::TEV::speG wild type [160] 
Escherichia coli BL21 with SpeJ pET28::TEV::speJ wild type [160] 
Escherichia coli BL21 with SpeL pET28::TEV::speL wild type Shipa Gupta, 
unpublished 
Escherichia coli BL21 with 
SpeM 
pET28::TEV::speM wild type Shipa Gupta, 
unpublished 
Escherichia coli BL21 with 
SmeZ 
pET41a::TEV::smeZ wild type Christine Herfst, 
unpublished 
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Table 3.  Plasmids used in this study 
Plasmid Description Source  
pG+host5 Erythromycin resistance, Gram-negative 
origin of replication, Gram-positive 
temperature-sensitive origin of replication 
Appligene, 
[162] 
pG+host5::I-SceI pG+host5 base plasmid with I-SceI restriction 
enzyme cut site 
This study 
pG+host5::I-SceI::MGAS8232 speA Plasmid to knock out speA in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS8232 speC Plasmid to knock out speC in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS8232 speG Plasmid to knock out speG in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS8232 
speL/M 
Plasmid to knock out speL and speM  in S. 
pyogenes MGAS8232 
This study 
pG+host5::I-SceI::MGAS8232 smeZ Plasmid to knock out smeZ in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS5005 speA Plasmid to knock out speA in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS5005 speG Plasmid to knock out speG in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS5005 speJ Plasmid to knock out speJ in S. pyogenes 
MGAS8232 
This study 
pG+host5::I-SceI::MGAS5005 smeZ Plasmid to knock out smeZ in S. pyogenes 
MGAS5005 
This study 
pG+host5::I-SceI::Int MGAS5005 pG+host5::I-SceI containing sequence for 
homologous recombination between tsf and 
pepO of S. pyogenes MGAS5005 with 
multiple cloning site 
This study 
pG+host5::I-SceI::Int MGAS8232 pG+host5::I-SceI containing sequence for 
homologous recombination between tsf and 
pepO of S. pyogenes MGAS8232 with 
multiple cloning site 
This study 
pG+host5::I-SceI::Int MGAS8232 speA 
Comp 
Plasmid for complementation of speA 
between tsf and pepO of S. pyogenes 
MGAS8232 
This study 
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(PBMC) isolation.  THY media with 10% HP was filtered in 0.2 m filters (Pall Life 
Sciences, Ann Arbor, MI, USA) into sterile bottles.  Viable stocks of S. pyogenes were 
maintained and stored in THY with 20% (v/v) glycerol at -80C.   
 
2.2. Genetic isolation 
2.2.1. Plasmid isolation from Escherichia coli 
 Plasmid DNA was isolated using the QIAprep spin miniprep kit (QIAGEN 
Sciences, MD, USA) as per manufacturer instructions.  Plasmid DNA was eluted in 
distilled water and was stored at -20C. 
 
2.2.2. Isolation of genomic deoxyribonucleic acid from Streptococcus pyogenes 
 Genomic DNA was isolated by pelleting 1-2 ml of an overnight culture of S. 
pyogenes.  The bacterial pellet was washed in 1 ml of 0.2 M sodium acetate (Sigma 
Chemical Company, St. Louis, MO, USA) and resuspended in 350 l of S. pyogenes lysis 
buffer [50 mM ethylenediaminetetraacetic acid (EDTA; Sigma Chemical Company, St. 
Louis, MO, USA), 0.2% sodium dodecyl sulfate (SDS; Sigma Chemical Company, St. 
Louis, MO, USA)] and incubated at 75C for 30-40 minutes.  Lysed streptococci were 
treated 100 l with 5 M potassium acetate (EMD Chemicals Inc., Darmstadt, Germany) 
and placed in the -20C for 1 hour.  The frozen lysate was spun at 21,130  g for 10 
minutes.  Supernatant was drawn off and added to 1 ml of -20C 100% ethanol 
(Commercial Alcohols, Brampton, Canada) and placed in the -20C freezer for 30-40 
minutes.  DNA was spun at 21,130  g for 10 minutes.  Ethanol is poured off and 1 ml of 
-20C 70% ethanol was added and spun at 21,130  g for 1 minute.  The ethanol was 
poured off and the pellet was dried.  To isolate total genetic material (DNA and RNA) the 
pellet was resuspended in distilled water. To isolate DNA alone the pellet was 
resuspended in tris-EDTA buffer (TE) 10 mM Tris, 1 mM EDTA with 10 g/ml 
ribonuclease A (RNaseA) (Sigma-Aldrich Company, St. Louis, MO, USA), pH 8.0).  
 
2.3. Deoxyribonucleic acid visualization 
2.3.1. Agarose gel electrophoresis 
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 DNA was visualized on ethidium bromide-stained tris-acetate EDTA buffer 
(TAE) (40 mM Tris-acetate, 1 mM EDTA) agarose gels.  DNA loading dye (5% glycerol, 
0.04% (w/v) bromophenol blue (International Biotechnologies, New Haven, CT, USA), 
0.04% xylene cyanol) was mixed with the samples prior to loading the gel.  A 1 kilobase 
(Kb) standard DNA molecular weight ladder (Invitrogen, Burlington, ON, Canada) was 
included in the gels as a size standard.  Agarose (Invitrogen, Burlington, ON, Canada) 
gels were prepared at concentrations from 0.8% to 2% depending on the desired 
resolution of a given product.  Gels were stained in 0.05% (w/v) ethidium bromide 
(EMD, Darmstadt, Germany) in 1  TAE for 10-20 minutes before being rinsed in water 
and visualized and photographed under ultraviolet light. 
 
2.3.2. Deoxyribonucleic acid agarose gel extraction 
 DNA fragments were purified from agarose gels by excising the DNA band of the 
appropriate size from the gel with a fresh scalpel blade.  The gel fragment was placed in a 
microfuge tube and frozen at -20C for at least an hour or -80C for at least 20 minutes.  
The gel fragment was centrifuged at 21,130  g for 10 minutes.  The supernatant was 
drawn off and retained and the agarose pellet was spun a second time.  The pooled 
supernatant was purified by a QIAquick PCR purification kit (QIAGEN Sciences, MD, 
USA) as specified by manufacturers instructions for DNA purification.  Samples were 
eluted in 20-50 l of distilled water. 
 
2.4. Polymerase chain reaction 
2.4.1. Standard polymerase chain reaction methods 
 Polymerase chain reaction (PCR) products were amplified in a Peltier 
Thermocycler PTC-200 (MJ Research, Waterdown, MA, USA).  All oligonucleotide 
primers were obtained from Sigma-Genosys and are described in Table 4.  Reactions 
were prepared in 100 l reaction volumes or master mixes containing 1  high fidelity 
(HF) buffer (New England Biolabs, Ipswich, MA, USA), 100 mM deoxyribonucleotide 
triphosphate (dNTP) mixture (Roche Diagnostics, Mannheim, Germany), 2 mM MgSO4 
(Sigma Chemical Company, St. Louis, MO, USA), 200 pM of each of the forward or 
reverse primers, 1 l of template DNA and 1 Unit of Phusion polymerase (New England  
35 
 
 
Table 4.  Primers used in this study  
Primer Sequence (5’-3’)a Purpose 
Sequencing and screening primers 
M13 For GTAAAACGACGGCCAGTGAG  Sequencing and screening 
M13 Rev CAGGAAACAGCTATGACCATG Sequencing and screening 
Int/Screen speA 5005 
For 
GCAAGCTACGGTTACGAAATTG Integration, screening and 
sequencing 
Int/Screen speA 5005 
Rev 
CAGGTTTGGGATAAGGACACAC Integration, screening and 
sequencing 
speA Screen II 8232 
Rev 
CCATCCTTTTTTGATTCTCC Integration, screening and 
sequencing 
speC Int II For GCAAAGCACTGGTTCGATGT Integration, screening and 
sequencing 
speC Int II Rev GGATAACCTTAACCGCGCTAC Integration, screening and 
sequencing 
speG 5005 Int/Screen 
II For 
GAAGCCGGCGTCAAACTG Integration, screening and 
sequencing 
speG 5005 Int/Screen 
II Rev 
CAGCTTCTGTTACTTGGCCTTG Integration, screening and 
sequencing 
speG int II For GCCCTCGTCAGAATGACTGT Integration, screening and 
sequencing 
speG Screen II Rev CCGATACCGATCACCACAAG Integration, screening and 
sequencing 
Int/Screen speJ 5005 
For 
GACGCTAGCCGGTACTGTC Integration, screening and 
sequencing 
Int/Screen speJ 5005 
Rev 
CCTTATGGTACCCAACATAC Integration, screening and 
sequencing 
speL/M Int II For GGCTTGAGTTATGTGTCTTTA Integration, screening and 
sequencing 
speL/M Screen II 
Rev 
GTTTGGTGGTATAGATGTAGCAAGG Integration, screening and 
sequencing 
smeZ Int II For CATGCCTGCTCAAACAAGATT Integration, screening and 
sequencing 
smeZ Screen II Rev ATACGACTCCATCTCATTATAGC Integration, screening and 
sequencing 
Plasmid construction 
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I-SceI OH 1 CTAGTTAGGGATAACAGGGTAATT Construction of pG+host5::I-SceI 
I-SceI OH 2 CTAGAATTACCCTGTTATCCCTAA Construction of pG+host5::I-SceI 
KpnI-tsf For GGGGGGGGTACCACTTGCTCAATTG
AACCACG 
Constructing pG+host5::Int 
complementation plasmid 
EcoRI-MCS-tsf  Rev TTTTTTGAATTCGATATCAAGCTTAT
CGATACCGTCGACCTCGAGGGGGGG
CCCTCCGTTTGACACAACAAAAAGA 
Constructing pG+host5::Int 
complementation plasmid 
EcoRI-MCS-pepO  
For 
GGGGGGGAATTCCTGCAGCCCGGG
GGATCCACTAGTTCTAGACACCAAT
AAGGAAGCAAAAA 
Constructing pG+host5::Int 
complementation plasmid 
NotI-pepO Rev GGGGGGGCGGCCGCAGCCTAAATG
ATTGGTGGA 
Constructing pG+host5::Int 
complementation plasmid 
BamHI-upstream 
speA5005 For 
CCCGGATCCTTATCTAGCACACAGG
CTGATGTG 
Superantigen deletion construct 
KpnI-downstream 
speA 5005Rev 
CCCGGTACCGGACGTGGGTTCGACT
CCC 
Superantigen deletion construct 
BamHI-upstream 
speA MGAS8232 
For 
CCCGGATCCGCCAAGTTATGCCATT
ACTGTGTTG 
Superantigen deletion construct 
PstI-upstream speA 
MGAS8232 Rev 
CCCCTGCAGGAAGTCTACCTAACAA
CCAAGTAA 
Superantigen deletion construct 
PstI-downstream 
speA MGAS8232 
For 
CCCCTGCAGCAATACTTTTTTATTGT
TTTCCATTAATAT 
Superantigen deletion construct 
KpnI-downstream 
speA MGAS8232 
Rev 
CCCGGTACCGCAAATGACAAATCGC
TATATCAATAA 
Superantigen deletion construct 
SpeI-speA Comp For GGGGGGACTAGTATTTTATAATAAA
ATTATTAATATAAGTTAA 
Superantigen complementation 
construct 
SalI-speA Comp Rev GGGGGGGTCGACAAAACCGCTCATC
AAATGA 
Superantigen complementation 
construct 
PstI-downstream 
speC MGAS8232 
For 
CCCCTGCAGTTTGATGATGTTAATCT
TTTTCAT   
Superantigen deletion construct 
KpnI-downstream 
speC 
MGAS8232Rev 
CCCGGTACCCGGATATCAATTTTGT
GGATTAAACG 
Superantigen deletion construct 
37 
 
 
BamHI-upstream 
speC MGAS8232 
For 
CCCGGATCCCGGTTACACCATGCGC
ACTGTCG 
Superantigen deletion construct 
PstI-upstream speC 
MGAS8232 Rev 
CCCCTGCAGTTCGATATTTATCTTGA
AAAATAATTCATC 
Superantigen deletion construct 
BamHI-upstream 
speG MGAS5005 
For 
CCCGGATCCGAATCGGTATTAGAAG
GTTTGCTAGTG 
Superantigen deletion construct 
PstI-upstream speG 
MGAS5005 Rev 
CCCCTGCAGAATTGTCAAAATGTTT
GTTTTCATTTAAAA 
Superantigen deletion construct 
KpnI-downstream 
speG MGAS5005 
Rev 
CCCGGTACCCATGTTGTCCCGCAAA
TGAC 
Superantigen deletion construct 
BamHI-upstream 
speG MGAS8232 
For 
CCCGGATCCGCCCAGCTTCAAGACG
TTGGTTAA 
Superantigen deletion construct 
PstI-upstream speG 
MGAS8232 Rev 
CCCCTGCAGAAATTCTAAAATGAAC
TTAGCCAC 
Superantigen deletion construct 
PstI-downstream 
speG For 
CCCCTGCAGGATATCTACTTAAAAA
CGCACTAG 
Superantigen deletion construct 
KpnI-downstream 
speG MGAS8232 
Rev 
CCCGGTACCGGAAGATCAAGCCAAC
CCAAGAAA 
Superantigen deletion construct 
BamHI - downstream 
speJ  MGAS5005 
For 
CCCGGATCCGATGGAAGAGAGACTC
TTAGAGAAGC 
Superantigen deletion construct 
PstI-downstream 
speJ MGAS5005 
Rev 
CCCCTGCAGTACCTTTGGACTAAAT
AAGATAGGAGC 
Superantigen deletion construct 
PstI-upstream speJ 
MGAS5005-For 
CCCCTGCAGTTTTATTATTCTTTTCA
TACCTCTCCTCG 
Superantigen deletion construct 
KpnI-upstream speJ 
MGAS5005-Rev 
CCCGGTACCGAGTCACTTTGACATT
CAGAGATGAAG 
Superantigen deletion construct 
BamHI-upstream 
speL/M MGAS8232 
For 
CCCGGATCCCCTATGGACGTAGACA
AATATGTTG 
Superantigen deletion construct 
PstI-upstream CCCCTGCAGTTATTCACAAACAAAG Superantigen deletion construct 
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speL/M MGAS8232 
Rev 
AAAATTAATTAGTA 
PstI-downstream 
speL/M MGAS8232 
For 
CCCCTGCAGCAAAGTCAAGGTATTT
TTTTTCAT 
Superantigen deletion construct 
KpnI-downstream 
speL/M MGAS8232 
Rev 
CGCGGTACCCGGTGTATTGACATTG
ATGTATTC 
Superantigen deletion construct 
BamHI-upstream 
smeZ MGAS8232 
For 
GGGGGATCCGGGGAATTATGCCAAT
TGTCTCTA 
Superantigen deletion construct 
PstI-upstream smeZ 
MGAS8232 Rev 
CCCCTGCAGAAAAATAAGTTTTGTT
TTTTTCATAAATAG 
Superantigen deletion construct 
PstI-downstream 
smeZ MGAS8232 
For 
CCCCTGCAGTTAGATATAGAAATTG
ACTCCTAATTC 
Superantigen deletion construct 
KpnI-downstream 
smeZ MGAS8232 
Rev 
GGGGGTACCGGGCAATTGTTTAACT
GGTTAATTAG 
Superantigen deletion construct 
Superantigen internal screening primers 
speA RT For AAAGTTGCCATCTCTTGGTTC Internal screening primer 
speA RT Rev CAAGAGGTATTTGCTCAACAAGAC Internal screening primer 
speC RT For TTTGAGCAGGCGTAATTCCT Internal screening primer 
speC RT Rev TTCAACGACACACACATTAAACA Internal screening primer 
speG RT For ACCCCATGCGATTATGAAAA Internal screening primer 
speG RT Rev GGGAGACCAAAAACATCGAC Internal screening primer 
speJ RT For GCTCTCGACCTCAGAATCAA Internal screening primer 
speJ RT Rev CTTTCATGGGTACGGAAGTG Internal screening primer 
speL RT For ATAAGTCAGCACCTTCCTCTTTC Internal screening primer 
speL RT Rev AAATCTCCCGTTACCTTCCA Internal screening primer 
speM RT For AACTTCTTCTTCCTTAAAGCGTCT Internal screening primer 
speM RT Rev TGCTGTGTTGGTTAATAGCGA Internal screening primer 
smeZ RT For TTTCTCGTCCTGTGATTGGA Internal screening primer 
smeZ RT Rev AATGGGACGGAGAACATAGC Internal screening primer 
DR4/DQ8 genotyping primers 
DQA (1027) For GAAGACATTGTGGCTGACCATGTTG Mouse genotype 
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CC 
DQA (1029) Rev AGCACAGCGATGTTTGTCAGTGCAA
ATTGCGG 
Mouse genotype 
DQ8b (vA) For1 AGGATTTGGTGTACCAGTTTAAGGG
CAT 
Mouse genotype 
DQ8b (vT) For 2 AGGATTTGGTGTTCCAGTTTAAGGG
CAT 
Mouse genotype 
DQ8b (vii) Rev TGCAAGGTCGTGCGGAGCTCCAA Mouse genotype 
DR4A (1101) For GGAGATAGTGGAACTTGCGG Mouse genotype 
DR4A (1104) Rev CCGATCACCAATGTACCTCC Mouse genotype 
DR4B (1098) For GTTTCTTGGAGCAGGTTAAACA Mouse genotype 
DR4B (1099) Rev CTGCACTGTGAAGCTCTCAC Mouse genotype 
a
 Underline in primer sequences indicates restriction endonuclease sites used for cloning 
purposes. 
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Biolabs, Ipswich, MA, USA).  General cycle conditions were as follows: 98C for 5 
minutes; 98C for 30 seconds; primer-specific annealing temperature which was in 
general Tm + 4C for 30 seconds; 72C for a time appropriate for the gene being 
amplified at 15 seconds per 1 Kb; steps 2 to 4 were repeated 35 times; 72C for 5 
minutes; 4C indefinitely.  PCR products were purified using QIAquick PCR purification 
kit (QIAGEN Sciences, MD, USA) as per manufacturer’s instructions and were eluted in 
20-50 l of distilled water or 10 mM Tris-Cl, pH 8.5. 
 
2.4.2. Escherichia coli colony screening by polymerase chain reaction 
 To screen for recombinant plasmids in E. coli, colony-screening PCR was 
performed on ligation-transformed E. coli colonies.  A standard master mix for PCR was 
prepared with the exception of added template and aliquoted into 10-20 l across the 
number of reaction tubes.  Single colonies were picked from the plates and dipped into 
the aliquoted master mix before being placed in a snap cap tube with appropriate media 
and antibiotics.  Resulting PCR products were analyzed by agarose gel electrophoresis. 
 
2.4.3. Deoxyribonucleic acid sequencing 
 All DNA sequencing was performed at the John P. Robarts Research Institute 
Sequencing Facility at Western University in London, Ontario, Canada.  Sequencing was 
performed with appropriate primers (Table 4). 
 
2.5. Molecular cloning 
2.5.1. Restriction digestions 
 Restriction digestions were performed in a 90 l reaction volume containing 30-
70 U of each restriction enzyme in 1  the appropriate reaction buffer supplemented with 
1 l of bovine serum albumin as indicated, and incubated following the manufacturer’s 
recommended temperature.  Enzymes were purchased from Invitrogen (Burlington, ON, 
Canada), New England Biolabs (Ipswich, MA, USA) or Roche Diagnostics (Mannheim, 
Germany).  Once the DNA was cut to completion it was purified using the QIAquick 
PCR purification kit (QIAGEN Sciences, MD, USA).  Antarctic phosphatase (New 
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England Biolabs, Ipswich, MA, USA) was used in stock plasmid digestions to reduce the 
incidence of non-specific empty vector ligation. 
 
2.5.2. Deoxyribonucleic acid ligation 
 All ligations were performed in 25 l reaction volumes containing 40 U of T4 
DNA ligase (New England Biolabs, Ipswich, MA, USA) and an excess of insert to vector.  
Reactions were incubated at either room temperature for 1 hour or overnight at 17C 
before transformation. 
 
2.5.3. Deoxyribonucleic acid ethanol precipitation 
 Plasmid DNA, previously isolated from a QIAprep spin miniprep kit (QIAGEN 
Sciences, MD, USA), was mixed with 2-3 volumes of -20C 99% ethanol supplemented 
with 0.1 volumes of 3 M Sodium Acetate  (Sigma, St. Louis, MO, USA) and placed at -
20C for 1 hour or more.  The precipitated DNA was spun at 21,130  g for 10 minutes 
before the supernatant was poured off.  The pellet was washed with 1 ml of -20C 70% 
ethanol without mixing, and spun for 1 minute at 21,130  g and the supernatant was 
poured off.  The pellet was dried and resuspended in HPLC water (Fisher Scientific, Fair 
Lawn, NJ, USA). 
 
2.5.4. Preparation of rubidium chloride competent Escherichia coli 
 Escherichia coli XL1-Blue and E. coli BL21 (DE3) competent cells were prepared 
by growing 100 ml culture in PSI broth (5 g/L Bacto yeast extract, 20 g/L Bacto tryptone, 
5 g/L magnesium sulphate, pH 7.6 with KOH) to an OD600 of 0.4.  Cells were placed on 
ice for 15 minutes and were then centrifuged at 3,000  g at 4C for 5 minutes.  The cell 
pellet was resuspended in 40 ml of TfbI buffer [30 mM KAc (EMD Chemicals Inc., 
Darmstadt, Germany), 100 mM RbCl2 (Alfa Aesar, Ward Hill, MA, USA), 10 mM CaCl2 
(Sigma Chemical Co., St Louis, MO, USA), 50 mM MnCl2 (Sigma-Aldrich Co., St. 
Louis, MO. USA), 15% glycerol, pH 5.8] and put on ice for 15 minutes.  Cells were again 
centrifuged at 3,000  g at 4C resuspended in 4 ml of TfbII buffer [10 mM MOPS 
(Sigma Chemical Co., St. Louis, MO, USA), 10 mM RbCl2, 75 mM CaCl2, 15% glycerol, 
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pH 6.5]. Cells were aliquoted on ice into 100 l volumes and flash frozen in an ethanol 
bath and stored at -80C. 
 
2.5.5. Escherichia coli transformations 
 Escherichia coli XL1-Blue and E. coli BL21 rubidium chloride competent cells 
were thawed on ice for approximately 10 minutes.  Plasmid DNA or ligation mixtures 
were added to the thawed E. coli cells and were left on ice for up to 30 minutes.  The cells 
were heat shocked at 42C for 45 seconds and then placed on ice for 2 minutes and 900 l 
of LB broth was subsequently added.  The cells were then incubated at 37C for 1 hour 
with shaking.  The transformation was plated on the appropriate media plates with 
antibiotic and grown overnight at 37C. 
 
2.5.6. Preparation of electrocompetent Streptococcus pyogenes 
 Electrocompetent S. pyogenes was prepared by subculturing 1 ml an overnight 
culture into 100 ml of pre-warmed THY + 0.6% glycine (Fisher Scientific, Fair Lawn, NJ, 
USA) which was then grown at 37C without shaking.  After 1.5 hours, 8 mg of 
hyaluronidase (Sigma Chemical Co., St. Louis, MO, USA) was added and the culture was 
returned to the 37C incubator until the OD600 reached 0.21.  The culture was pelleted at 
6,000  g for 10 minutes.  The cells were washed twice in 10-20 ml of ice cold 15% 
sterile glycerol.  Cells were resuspended after a final wash in 4 ml ice cold 15% glycerol 
and aliquoted in 220 l aliquots.  Aliquots were flash-frozen in a dry-ice ethanol bath and 
stored at -80C. 
 
2.5.7. Electroporation of Streptococcus pyogenes 
 Plasmids to be electroporated into S. pyogenes were ethanol precipitated and 
resuspended in HPLC water (Fisher Scientific, Fair Lawn, NJ, USA).  DNA (1-2 g) was 
added to ice-thawed electrocompetent S. pyogenes.  Cells were electroporated at 2500 
volts (V), 600 ohms (), and 25 microfarads (F) in 2 mm electroporation cuvettes 
(VWR, Westchester, PA, USA) in a Biorad Gene Pulser XCell electroporator.  After 
electroporation, cells were immediately transferred to 10 ml THY broth at room 
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temperature and placed in a 30C incubator to recover for 1 hour before a sub-inhibitory 
concentration of erythromycin (0.01 g/ml) was added.  Cells were returned to 30C for 
an additional four hours before being pelleted and resuspended in 1 ml THY broth plated 
on THY plates with the appropriate antibiotics for the plasmids.  Cultures were grown for 
up to 3 days at 30C. 
 
2.5.8. Streptococcal genome mutagenesis 
 In-frame deletions were made of all of the streptococcal SAgs in S. pyogenes 
MGAS5005 (Figure 3) and S. pyogenes MGAS8232 (Figure 4).  The construction of the 
streptococcal SAg mutants was made in a manner similar to the procedure reviewed in 
Cho et al. [163].  Briefly, S. pyogenes were electroporated with a pG+host5-based 
plasmid (Table 3) [162] including the mutation flanked by the contextual upstream and 
downstream homologous regions.  The bacterial transformants that grew on THY + 1 
g/ml erythromycin (THY Erm1) at 30C were picked and grown in THY Erm1 broth at 
30C.  A total nucleic acid preparation was made of this culture and the presence of the 
plasmid was confirmed by PCR.  Transformed bacteria were plated on THY Erm1 plates 
and incubated at 40C.  Resulting colonies were picked and grown in THY Erm1 broth at 
40C.  DNA was isolated and the integration of the construct was confirmed by PCR.  
Bacteria with confirmed integrations were subcultured into THY broth without antibiotics 
and grown at 30C with daily subculturing at 1%.  Cultures were screened for the loss of 
the pG+host5-based plasmid by replicate plating onto THY, THY Erm1, and TSAII plates 
that are supplemented with 5% defibrinated sheep blood [Becton, Dickinson, and 
Company, Franklin Lakes, NJ USA; 1.45% pancreatic digest of casein (w/v), 0.5% papaic 
digest of soybean meal (w/v), 0.5% NaCl (w/v), 1.4% agar (w/v), 0.15% (w/v) growth 
factors, 5% (v/v) sheep blood, defibrinated].  Beta-haemolytic cultures that were sensitive 
to erythromycin were grown in THY broth culture and were screened by total nucleic acid 
isolation and PCR for excision or insertion of the targeted gene of interest.  PCR primers 
used for S. pyogenes mutagenesis are listed in Table 4 and the mutagenesis strategy is 
depicted in Figure 5.  All strains of S. pyogenes were sub-cultured daily at 1% in filter-
sterilized THY + 10% HP for 5 days before glycerol stocks were made and stored at  
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Figure 3. Streptococcus pyogenes MGAS5005 superantigens in genomic context.  (A)  
The genome of S. pyogenes MGAS5005 contains three bacteriophage like-elements 
(triangles), and four SAgs within its 1.839 Mb genome.  (B) S. pyogenes MGAS5005-
encoded SAgs in their immediate genetic context.  The speA gene is flanked upstream by 
a hypothetical phage protein spy_0995 and downstream by phage proteins spy_0997 and 
spy_0998 that are oriented in the opposite direction of the speA2 gene.  The speG gene is 
flanked upstream by the spy_0180 gene, which is in reverse orientation and is an S-layer-
like domain containing protein. Directly upstream of speG in the same orientation is 
spy_0181 which is a hypothetical cytoplasmic protein.  Downstream of speG are three 
genes that are in the same orientation as the speG gene, spy_0183, which is a hypothetical 
protein, spy_0184, which is a predicted cytoplasmic proteins and glucose-6-phosphate 
isomerase.  speJ is flanked by two hypothetical proteins.  The upstream protein is in the 
same orientation as speJ and the downstream protein is in reverse orientation.  The smeZ 
gene is flanked upstream by two genes in the same orientation.  spy_1700 encodes an 
acetyltransferase and spy_1701 encodes a topology modifying protein.  Immediately 
downstream of smeZ there is a gene in reverse orientation that is a hypothetical 
cytoplasmic protein and beyond that there is a gene in the same orientation that is a 
dipeptide binding protein. 
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Figure 4. Streptococcus pyogenes MGAS8232 superantigens in genomic context.  (A) 
The 1.895 MB genome of S. pyogenes MGAS8232 encodes five bacteriophage-like 
elements (triangles).  Four of the six SAgs encoded in the chromosome of S. pyogenes 
MGAS8232 are bacteriophage-encoded including speA1 encoded on 8232.1, speC on 
8232.2, and speL and speM are encoded on 8232.3.  (B) Within the immediate genetic 
context speA is flanked upstream by two genes that are in the opposite orientation to speA 
and encode hypothetical proteins, and downstream by spyM18_0391 which encodes N-
acetylmuramoyl-L-alanine amidase which is also in reverse orientation.  The speC gene is 
flanked upstream in the same orientation by mf2 and downstream by a hypothetical 
protein in reverse orientation.  The speG gene is flanked upstream by spyM18_0199 
which is a transposase that is in the reverse orientation.  Downstream of speG are two 
genes in the same orientation, a hypothetical protein and glucose-6-phosphate isomerase.  
The speL and speM genes are encoded beside one another in the same orientation.  The 
genes directly flanking speL and speM are both hypothetical proteins oriented in the same 
orientation. The smeZ gene is flanked by hypothetical proteins in the opposite direction.  
Further upstream of smeZ is a topology modulation protein, and further downstream is 
dppA which is a surface lipoprotein. 
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Figure 5.  Markerless mutagenesis in Streptococcus pyogenes.  To create precise 
markerless deletions of each superantigen, all constructs were generated in 
pG+host5::I-SceI (Table 3) by cloning PCR products containing ~500 bp 
homologous regions both upstream and downstream of the superantigen gene, but 
leaving the first and last three codons of the superantigen intact.  S. pyogenes 
containing the integration plasmids were grown at 40C with erythromycin to 
select for a single cross-over integration of the plasmid within the streptococcal 
genome.  The integration was confirmed by PCR and bacterial growth was shifted 
to the permissive temperature of 30C without antibiotics to allow for the second 
cross-over event and eventual clearance of the plasmid.  Erythromycin-sensitive S. 
pyogenes were screened for the superantigen deletion and clearance of the plasmid 
with specific primers by PCR. 
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minus 80C.  All stocks at -80C were tested for growth defects by doing a computer-
automated optical density of 600 nm (OD600) growth curve using a Bioscreen C MBR 
(Piscataway, NJ, USA). 
 
2.5.9. Complementation of speA into the superantigen deletion strain of Streptococcus 
pyogenes MGAS8232 
 Streptococcus pyogenes MGAS8232 complete superantigen deletion strain was 
complemented with the speA gene with its native promoter as determined by promoter 
mapping by PPP software (http://bioinformatics.biol.rug.nl/websoftware/ppp) [164].  The 
complementation cassette was created in pG+host5 using homologous recombination 
sites for insertion between pepO and tsf.  The process by which speA was introduced was 
similar to the superantigen deletion protocols outlined in Figure 5 in that it used the 
Gram-positive temperature-sensitive origin of replication to ensure integration of the 
plasmid into the genome and relied on antibiotic sensitivity to indicate the loss of the 
plasmid and PCR screening to confirm each step.   
 
2.6. Protein visualization 
2.6.1. Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
All proteins were visualized by Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE).  Separating gels were made with 12% polyacrylamide 
[0.1% (w/v) SDS (Fisher Scientific, Fair Lawn, NJ, USA), 0.25% (v/v), 1.5 M Tris-HCl 
(EMD Chemicals Inc., Darmstadt, Germany), pH 8.8, 12% (v/v) acrylamide (EMD 
Chemicals Inc., Darmstadt, Germany), 0.1% (w/v) ammonium persulfate (APS) (Sigma 
Chemical Co., St. Louis, MO, USA) and 0.15% (v/v) tetramethylenediamine (TEMED) 
(EMD Chemicals Inc., Darmstadt, Germany)] with 5% acrylamide stacking gels [1.3% 
(w/v) SDS, 25% (v/v), 0.5 M Tris-HCl, pH 6.8, 5% (v/v) acrylamide, 0.1% (w/v) APS 
and 0.2% (v/v) TEMED], using a BioRad Mini-PROTEAN 3 system.  Laemmli buffer 
[125 mM Tris pH 6.8, 50% glycerol, 4% SDS, 5% -mercaptoethanol [Omni Pur, 
Calbiochem, EMD Chemicals Inc., Gibbstown, NJ, USA], and 0.1% (w/v) bromophenol 
blue] was added to each protein sample before being boiled for five minutes.  Broad-
Range molecular weight marker (New England BioLabs, Ipswich, MA, USA) was used.   
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Gels were run in tris-glycine electrophoresis buffer (25 mM Tris, 190 mM glycine, 1% 
SDS) for 30 minutes at 85 V and then at 150 V for an additional 90 minutes.  Gels were 
stained in coomassie [45% methanol, 10% glacial acetic acid (Caledon, Georgetown, ON, 
Canada), 0.1% (w/v) coomassie brilliant blue stain R-250) for at least 1 hour and then 
destained for visualization (45% methanol (Caledon, Georgetown, ON, Canada), 10% 
acetic acid (Caledon, Georgetown, ON, Canada)]. 
 
2.6.2. Western blots 
 Proteins for Western blots were run on 12% SDS-PAGE gels and were then 
transferred to a polyvinylidene difluoride (PVDF) Amersham HybondP membranes (GE 
Healthcare, Little Chalfont, Buckingshire, UK) using a BioRad Trans-Blot system.  A 
piece of PVDF membrane was immersed in 100% methanol for 10 minutes and then 
equilibriated in transfer buffer (182 mM glycine, 34 mM Tris, 20% methanol) for 10 
minutes.  SDS-PAGE gels were also equilibrated in transfer buffer.  The PVDF 
membrane was placed on top of the protein gel and sandwiched between 6 pieces of filter 
paper and was placed in the transfer apparatus.  Proteins were transferred for one hour at 
100 V at 4C or overnight at 25 V at 4C.  Membranes were subsequently blocked with 
5% (w/v) skim milk (Equality) diluted in 1  phosphate buffered saline (PBS) [125 mM 
NaCl (BDH, Westchester, PA, USA), 1.5 mM KH2PO4 (Sigma Aldrich Co., St. Louis, 
MO, USA), 8 mM Na2HPO4 (EMD Chemicals Inc., Darmstadt, Germany), 2.5 mM KCl 
(Sigma Aldrich Co., St. Louis, MO, USA), pH 7.6] for 1 hour at room temperature.  The 
blocking buffer was replaced with the appropriate dilution of primary antibody diluted in 
1% (w/v) skim milk in PBS incubated at room temperature for 1 hour.  The membranes 
were washed three times for 5 minutes in PBS with 0.01% (v/v) tween20 (PBST) and 
then once for 15 minutes in PBS.  The secondary antibody was incubated with the 
membrane in 1% (w/v) skim milk in PBS for an hour.  The membrane was washed as 
before.  All Western blots were visualized on LI-COR Odyssey (LI-COR Biosciences, 
Lincoln, NB, USA). 
 
2.7. Protein expression and purification 
2.7.1. Histidine-tagged superantigen purification 
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Histidine-tagged SAgs were expressed from pET-based expression plasmids in E. 
coli BL21 (DE3).  Expression strains of E. coli were grown in LB supplemented with 
Kanamycin at 50 g/ml (Kan50).  Overnight cultures of bacteria were subcultured (0.1%) 
into 1 L of LB Kan50 and grown at 37C with shaking for 3 hours before being induced 
with 200 M isopropyl -D-1-thiogalactopyranoside (IPTG) and the culture was returned 
to 37C incubator with shaking overnight.  Cultures were pelleted at 3,500  g (Avanti J-
25 centrifuge, Beckman Coulter) for 10 minutes.  The pellet was resuspended in 10 ml of 
1  hepes buffer [10 mM Hepes (BDH, VWR, West Chester, PA, USA), 150 mM NaCl 
(BDH, VWR, West Chester, PA, USA), pH 7.4] with 10 l DNaseI and 50 l of 10 
mg/ml lysozyme in a shaking ice bath for 1 hour. Bacteria were sonicated in 3 rounds of 
50 pulses of 40% duty cycle, output 4 on Branson Sonifier (Danbury, CT, USA) and 
allowed to rest on ice between each round of sonication.  Cellular debris was pelleted at 
10,000  g at 4C for 10 minutes and the supernatant was passed over a Ni NTA His Bind 
Resin nickel affinity chromatography column (Novagen, San Diego, CA, USA) and 
histidine-tagged SAgs were eluted in either the 60 mM or 200 mM imidazole in 1  hepes 
buffer elution fractions.  The proteins were dialyzed 3 times against 1 L of 1  hepes 
buffer for 1 hour.  The SAgs were cleaved with either tobacco etch virus protease 
(McCormick lab) or thrombin for 24-72 hours at 4C.  Cleaved proteins were passed 
again over a nickel affinity chromatography column, and eluted from the column in the 
15 mM or 30 mM imidazole fractions in 1  hepes buffer.  The proteins were dialyzed 3 
times against 1 L of 1  hepes buffer, 0.9% saline or distilled water for 1 hour.  The purity 
of the SAgs was assessed by SDS PAGE and the concentration of the SAgs was assessed 
by BCA assay (Thermo Scientific, Rockland, IL, USA).  Proteins were diluted to the 
correct concentration in either 1  hepes buffer or 0.9% saline, aliquotted and stored in -
20C.  For antibody production proteins dialyzed into water were lyophilized. 
 
2.7.2. Trichloroacetic acid streptococcal supernatant protein precipitation 
 Streptococcal cultures were subcultured into 100 ml pre-warmed THY broth and 
grown to late exponential phase. The bacteria were pelleted and 90 ml of culture 
supernatant was removed and 50% trichloroacetic acid (TCA) was added to reach a final 
53 
 
 
concentration of 6%.  The supernatant was chilled on ice for 30 minutes.  Precipitated 
supernatants were pelleted at 10,000  g for 10 minutes at 4C.  The supernatant was 
removed and the pellet was washed once in 10 ml of -20C acetone and spun at 10,000  
g for 10 minutes.  The supernatant was removed and the pellet was dried and resuspended 
in 900 l of 8M urea for a final concentration of 10:1. 
 
2.8. Antibody generation 
2.8.1. Antibody production 
Purified and lyophilized SpeA, SpeC, SpeG, SpeL, SpeM, and SmeZ were sent to 
ProSci Incorporated (Poway, California, U.S.A.).  SAgs were resuspended in 0.9% saline 
and were injected at a concentration of 200 g in complete Freund’s adjuvant at week 0.  
Rabbits were boosted with 100 g of SAg in incomplete Freund’s adjuvant at weeks 2, 4 
and 6.  Serum samples were collected at week 0, 5 and 7 with a terminal bleed taken at 
week 8.  Serum samples were assessed for antibody titres, aliquoted and were stored  at 
minus 80C. 
 
2.8.2. Antibody titres 
Antibody titres were determined by enzyme-linked immunosorbant assay 
(ELISA).  SAgs were diluted to a concentration of 10 g/ml in 50 mM carbonate buffer 
(Na2CO3 0.0015 M; NaHCO3 0.0349 M; NaN3 0.00307 M; pH to 9.5) in Costar ELISA 
96-well plates (Costar, Corning, NY, USA).  Coated plates were incubated at room 
temperature wrapped in aluminum foil.  Plates were washed twice with PBST wash buffer 
and then blocked with blocking buffer [1% BSA (Sigma Aldrich Co., St. Louis, MO, 
USA), 0.02% tween20 (Fisher Scientific, Fair Lawn, NJ, USA) in 1 x PBS] for 2 hours in 
the dark at room temperature.  Dilutions of serum were prepared in dilution buffer (0.1% 
BSA, 0.02% tween20 in 1  PBS).  Plates were washed twice after blocking with PBST 
and flipped on Whatman paper to dry between washes.  One hundred microliters of each 
diluted sample was added to the plates in triplicate.  Samples were incubated for 2 hours 
at room temperature in the dark.  Plates were washed three times with PBST, and three 
times with distilled water.  Goat anti-rabbit antibody conjugated with horseradish 
peroxidise (HRP) (Rockland, Gilbertsville, PA, USA) at a dilution of 1:10,000 in 1  PBS 
54 
 
 
with 1% BSA, 0.02% Tween-20 was incubated in the plates for 2 hours at room 
temperature in the dark.  Plates were washed with PBST five times, followed by 5 washes 
with distilled water.  One hundred microliters of BD EIA 3,3’,5,5’ tetramethyl benzidine 
(TMB) substrate reagent (Becton, Dickinson, Company, Sparks, MD, USA) developed 
the reaction for 10 minutes at room temperature in the dark before being stopped by 
adding 50 l of 1 N H2SO4.  Plates were immediately read at OD450 with a reference of 
OD570 
 
2.9. Mouse housing and breeding 
2.9.1. Housing 
 Mice were housed in an inclusion/exclusion facility during experimentation in 
micro-isolator cages.   Transgenic DR4, DQ8, and DR4/DQ8 breeding pairs were housed 
and cared for at the West Valley Barrier Facility at Western University, Canada in 
positive pressure microisolator system Micro-VENT System cages (model # MD75 
Ju14OMVS PCD3, Allentown Inc., Allentown, New Jersey, USA).   
 
2.9.2. Mice  
A list of all mice used in this study can be found in Table 5.  Human MHC class II 
transgenic mice were bred from McCormick Laboratory colonies specifically for this 
study and were in a C57BL/6 (B6) background.  Transgenic H-2 null, MHC class II 
human leukocytic antigen-DR4 (DR4) mice originated from a colony housed at Western 
University, West Valley Barrier Facility and were a kind gift from Dr. Ewa Cairns.  
Expression of the transgenic HLA-DR4 immunoreceptor was confirmed by flow 
cytometry at regular intervals (data not shown).  H-2 null, HLA-DR4/DQ8 transgenic 
mice were a kind gift from Dr. M. Kotb at the University of Cincinnati, Cincinnati, OH, 
U.S.A.  HLA-DQA1*0301 and DQB1*0302 (DQ8) mice were originally developed by 
the C.S. David group to examine the contribution of HLA-DQ type to the development of 
human polyarthritis in a collagen-induced arthritis model [165].  The DQ8 alleles were 
introduced into a mouse that was mouse class II-deficient H-2Ab
0
 by cosmid injection 
into mouse embryos [165].  Mice were also developed to express DRB1*0402 in addition 
to DQ8 are classified as DR4/DQ8 mice [166].  Mice were isolated in quarantine and  
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Table 5.  Mouse strains used in this study 
Strain Name Characteristics MHC class II Source Stock Number 
C57BL/6 Inbred black mouse  H-2
b
 The Jackson 
Laboratory 
000664 
BALB/cJ Inbred white mouse H-2
d
 The Jackson 
Laboratory 
000651 
FVB/NJ Inbred white mouse H-2
q
 The Jackson 
Laboratory 
001800 
A/J Inbred white mouse H-2
a
 The Jackson 
Laboratory 
000646 
DR4 Inbred homozygous 
transgenic black 
mouse 
H-2 null, Human 
HLA-DR4 
Gift from Dr. E. 
Cairns [167] 
McCormick Lab 
Breeding colony 
DQ8 Bred from a 
heterozygous 
DR4/DQ8 mouse 
H-2 null, Human 
HLA-DQ8 
Bred from 
DR4/DQ8 
heterozygous 
mice 
McCormick Lab 
Breeding colony 
DR4/DQ8 Expressed human 
MHC class II HLA-
DR4 and HLA-DQ8 
H-2 null, Human 
HLA-DR4 and 
HLA-DQ8 
Gift from Dr. M. 
Kotb, [113, 166] 
McCormick Lab 
Breeding colony 
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were assessed for enteric pathogens before being transferred to the West Valley 
Barrier Facility to be bred specifically for this study.  All other mice were purchased from 
The Jackson Laboratories.  Mice were used between nine and thirteen weeks old for nasal 
infection and both male and female mice were used in the study.  
 
2.9.3. Genotyping 
Transgenic HLA-DR4/DQ8 mice were genotyped to verify the presence of the 
transgenes.  The breeding colony was confirmed to be homozygous for the HLA-DQ8 
allele but heterozygous for the HLA-DR4 allele.  As such, all mice used were genotyped.  
Unsuccessful attempts were made to establish a completely homozygous breeding colony. 
Mice (10-14 days old) were ear punched to identify individuals and the ear punches were 
used to isolate DNA from the tissue using the QIAGEN DNeasy blood and tissue kit 
(QIAGEN Sciences, MD, USA) using the manufacturer’s directions.  Resulting DNA 
preparations were used with primers specific to the alpha and beta chains of the HLA-
DR4 and HLA-DQ8 alleles (Table 4). 
 
2.10. Streptococcal colonization and persistence in a mouse model 
2.10.1. Bacterial preparation 
 Streptococcus pyogenes cultures that had been grown in serial culture in un-
autoclaved, 0.2 m-filtered THY media supplemented with 10% human serum for five 
consecutive days before storage in -80C were started in 10 ml THY media in a 15 ml 
falcon tube.  Cultures were subcultured at 1:100 in THY broth daily for two days.  On the 
third day the culture of S. pyogenes was subcultured at 5% into a pre-warmed 150 ml 
bottle of 100 ml of THY and grown for 3-4 hours at 37C, which allowed the cultures to 
reach logarithmic phase which was considered to be when the OD600 was between 0.150 
and 0.350.  Optical density was measured at 600 nm and was used to calculate the number 
of bacteria in a millilitre of culture.  The volume of bacteria necessary to prepare the 
inoculation was calculated, measured and spun at 3,000 RPM (Allegra 6 centrifuge; 
Beckman Coulter) for 10 minutes.  Supernatant was gently poured off without disturbing 
the pellet.  The pellet was transferred to a microfuge tube and the culture was spun at 
21,130  g for one minute and the supernatant was drawn off and the pellet was washed 
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in 1 ml of 1  Hanks Balanced Saline Solution without phenol red (HBSS; Hyclone 
Laboratories, South Logan, UT, USA), S. pyogenes were re-pelleted and again the 
supernatant was removed.  The culture was prepared so that it was resuspended in 15 l 
of HBSS per dose of bacteria at room temperature. 
 
2.10.2. Mouse nasal inoculation 
Mice between 9 and 13 weeks of age were anesthetized with isoflurane (Baxter 
Corp., Mississauga, ON, Canada) and were monitored in accordance with the Western 
University animal care and veterinary services post-operative/post-anesthetic care 
protocol for rodents (standard operating procedure # 330-03).  Mice were scruffed and 7.5 
l of the bacterial preparation was used to inoculate each nostril of the mouse very slowly 
so that there was no accumulation of inoculum on the nares of the mouse while the dose 
was being given.  The mouse was allowed to recover and was monitored for the duration 
of the experiment. 
 
2.10.3. Endpoint surgery  
 Mice were sacrificed at the end of the experiment as per the animal protocol 
approved by the Western University Animal Ethics Board.  Endpoint timing was 
determined by desired readout.  To analyze the establishment of colonization data all 
mice were sacrificed at 48 hours.  To examine the persistence of colonization, mice were 
sacrificed at 24, 48, 72, 96, and 144 hours post-infection.   
 At the desired endpoint mice were anesthetized with isoflurane until they were not 
responsive to pain and anesthesia was maintained on a nose cone for the duration of the 
surgery.  Mice were opened down the ventral midline with small straight sterile scissors.  
Organs were moved to the animal’s left exposing the dorsal abdominal wall.  Blood was 
drawn from the portal vein into a 1 ml syringe (Becton, Dickinson, and Co., Sparks, MD, 
USA) with a 25 gauge needle coated with Heplean heparin (Organon Canada Ltd., 
Toronto, Ontario, Canada).  After the blood draw, the animal was sacrificed by breaking 
the diaphragm and decapitation with scissors.  The spleen, kidneys, liver (with 
gallbladder removed), lungs and heart were harvested.  Organs were surgically removed 
into tubes containing 4 ml HBSS.  Organs and blood samples were placed on wet ice until 
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homogenization.  To remove the complete nasal turbines including the NALT and the 
maxillary sinuses, the head was positioned so that the snout of the head was facing the 
surgeon upside down on the surgical platform.  The head was stabilized using tweezers to 
hold the lower jaw, gripping the tongue to the roof of the mouth.  Sturdy large scissors 
were inserted pointed end into the mouth all the way to the back and held so that they 
were parallel to the soft palate and used to sever the lower jaw from the upper portion of 
the head.  Curved tweezers were then used to grip the cheek with the curve of the 
tweezers pointing away from head.  Large scissors were used to cut between the tweezers 
and the head to cut away and remove excess cheek tissue from both cheeks, without 
cutting the skull bones, all the way to the ears.  Tweezers were subsequently used to grip 
the tip of the nose and the sturdy scissors were used to cut behind the front teeth to 
remove the nose and the front teeth.  With the nose of the head still pointing directly at 
the surgeon and the head positioned so that the soft palate is facing up, and cross-pinned 
the head behind the palate.  A fresh needle was used as a micro-scalpel to slice a very 
shallow cut midline through the soft palate.  The soft palate was peeled off using very 
fine curved tweezers.  Small curved scissors were inserted pointed side up shallowly into 
one side of the curved jaw bone back to the back teeth.  The NALT and maxillary sinuses 
are attached to the ventral surface of the ethmoid turbinate, so it is important that the cut 
of the curved part of the jaw bone is very shallow as to not disturb the ethmoid turbinates.  
The bone was cut and the facial bone with remaining tissue was gently and slowly 
rolled/pressed away from the septum.  The entire nasal turbines including the NALT and 
the maxillary sinus were removed without disturbing the septum by breaking and 
removing the cartilage at the front of the tissue and breaking the ethmoid turbinates free 
from the back.  This harvested tissue will henceforth be referred to as the ‘complete nasal 
turbinates’ (cNT).  The other side cNT was removed in the same manner.  The cNT were 
collected in a microfuge tube with 500 l HBSS and stored on ice until processed (Figure 
6). 
  
2.10.4. Tissue processing and plating 
 Isolated tissues were processed by homogenization for determination of colony 
forming units (cfu).  Spleen, kidneys, liver, lung, and heart were processed with a   
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Figure 6.  Surgical removal of the murine complete nasal turbines.  The head (A) was 
prepared by the removal of the lower jaw (B) and cheek muscles on either side of the 
head (C).  The nostrils were removed by cutting posterior to the incisors (D).  The head 
was pinned down just ahead of the ear canals and a needle was used as a microsurgical 
tool to make a very shallow cut in the centre of the palate (F) and the palate was peeled 
off with fine smooth curved tweezers (G) to expose the top of the premaxilla on either 
side of the septum (H).  Very fine curved scissors are inserted very shallowly under the 
top edge of the premaxilla all the way back to the back of the molars, the premaxilla was 
cut and moved away from the tissue beneath it (I) which exposed the nasal turbines and 
the ethmoid turbinate which were posterior to the more bony maxilloturbinate and 
nasoturbinate (I, J).  The maxilloturbinate and nasoturbinate can be distinguished from the 
ethmoid turbinate as they appear to be redder in appearance and feel bony to the tweezers.  
The maxilloturbinates and nasoturbinates were removed with the fine, smooth curved 
tweezers.  The tweezers were then placed posterior to the ethmoid turbinate and then 
scooped out of the head without disturbing the septum (K).  The other ethmoid turbinate 
was then removed in the same manner. 
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PRO200 electronic homogenizer (PRO Scientific Inc., Monroe, CT, USA).  Between 
samples, the homogenizer was cleaned by rinsing twice in 4 ml of water or HBSS, being 
wiped with a tissue wipe, rinsed with 10% bleach, 70% ethanol, and finally rinsed twice 
more in each of 4 ml sterile distilled water and 4 ml sterile HBSS.  Samples were 
homogenized until they appeared homogeneous.  The cNT were homogenized in a 1 ml 
glass homogenizer.  Between samples, the glass homogenizer was cleaned three times 
with 70% ethanol and rinsed twice with both sterile distilled water and sterile HBSS.  
Tissues were plated both 100 l neat and serially diluted on TSAII plates containing 5% 
sheep blood agar (Becton, Dickinson, and Co., Sparks, MD, USA).  Bacterial growth was 
observed after growth at 37C.  Total bacterial growth and -haemolytic S. pyogenes 
were assessed. 
 
2.11. Histology 
2.11.1. Organ isolation 
 Mice were fully anesthetized with isoflurane and the mouse was perfused through 
the heart with sterile PBS containing heparin to flush the blood from the mouse using a 
Gilson Minipuls 3 peristaltic pump (Middletown, WI, U.S.A) at a constant flow rate.  
Mice were then perfused with 10% neutral buffered formalin (BDH, VWR, West Chester, 
PA, USA) through the peristaltic pump at a constant flow rate until organs were fully 
perfused with formalin.  Organs were surgically removed without tool marks and were 
placed in 10-volumes of fresh formalin.  The head was prepared for histology by 
removing the lower jaw and tongue and the tip of the nose which was removed by cutting 
behind the front teeth and then placed 10-volumes of formalin. 
 
2.11.2. Histology tissue processing 
 Formalin-perfused soft tissues (spleen, kidneys, liver, lung and heart) were further 
fixed in formalin for 48 hours at 4C, changed daily.  Organs were rinsed in 1  PBS 
before being resuspended in 10-volumes of 1  PBS twice a day for three days, and 
washed in 10-volumes of 70% ethanol twice and stored in 70% ethanol until processed.  
To process bony tissues, such as the head, the formalin-perfused mouse tissues were 
soaked in 10 volumes of formalin for 24 hours and then the formalin was removed and 
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the tissue was re-suspended in Shandon TBD-2 Decalcifier (TBD; Thermo Scientific, 
Kalamazoo, MI, USA) for 96 hours.  The TBD-treated tissue was tested for 
decalcification by cutting the back of the skull with a scalpel to determine whether or not 
the bone could be sectioned smoothly after further processing.  TBD-decalcified heads 
were placed in formalin for 48 hours and washed with 1  PBS, and resuspended in 10-
volumes of 1  PBS twice daily for 4 days and washed in 70% ethanol twice and stored in 
10-volumes of 70% ethanol until cassetted and processed. 
 
2.11.3. Cassetting, embedding and sectioning fixed tissues 
 Fixed tissues were placed in 4 mm Fisherbrand TRU-Flow tissue cassettes.  The 
head was sectioned between the first and second molar and the front section of the head 
was placed in one cassette and the back portion in a second for processing.  Formalin-
fixed cassetted tissues in 70% ethanol were sent to The Robarts Research Institute 
Molecular Pathology Core Facility for processing in preparation for embedding in wax.  
Cassettes were processed in Leica ASP300 fully enclosed paraffin wax tissue processor 
overnight in the bone program.  Cassettes were transferred into a warm wax bath and 
embedded in paraffin wax.  Embedded tissues were stored at room temperature until 
sectioning. 
 Tissues were sectioned on a microtome HM335E Microtome Leica in the Robarts 
Research Institute Molecular Pathology Core Facility using MB35 Premier Microtome 
blades (Thermo Scientific) into 5 micron sections.  Serial sections were collected for head 
sections, and representative sections were cut for the spleen.  Sections were mounted on 
Fisherbrand Superfrost Plus microscope slides (Fisher Scientific, Fair Lawn, NJ, USA) 
and were dried at 45C for 48 hours prior to storage/staining. 
 
2.11.4. Haematoxylin and eosin staining of processed tissue 
Tissues were stained with haematoxylin and eosin in a Leica Autostainer XL.  
Slides were allowed to dry and Fisher Finest Premium Cover Glass (Fisher Scientific, 
Fair Lawn, NJ, USA) cover slips were affixed to the slides using Cytoseal 60 low 
viscosity mounting medium (Richard-Allen Scientific, Kalamazoo, MI, USA).  Cover 
slipped slides were dried for at least 24 hours horizontally before vertical storage.  
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2.11.5. Histology evaluation 
 Slides were blindly evaluated in collaboration with a pathologist.  After all slides 
were observed evaluation criteria were determined for each tissue type.  The relative 
amount of mucus present covering the epithelia, the presence of red blood cells, and the 
presence of nucleated cellular debris on the surface of the epithelia was assessed.  The 
presence and severity of these findings were used to assign a score of zero to two points 
to each of two sections per mouse.  The scores were averaged to determine differences in 
histological pathology in the mice.   
 
2.12. Flow cytometry 
2.12.1. Tissue isolation and processing 
 Mice were anesthetized as previously described.  The cervical lymph nodes were 
surgically removed and collected and suspended in RPMI 1640 (Gibco, Burlington, 
Ontario, Canada) and the mouse was decapitated.  The spleen was surgically removed and 
placed into 5 ml of complete RPMI (cRPMI). The remaining lymph nodes were collected 
into the lymph node collection tube.  The cNT were removed as described above and 
placed in a tube with 5 ml RPMI 1640.  Cells were isolated by passing the organs through 
40 m nylon cell strainers (BD Falcon, San Jose, CA, U.S.A) with the end of a syringe.  
Cells were spun at 1,200 RPM (Beckman Coulter Allegra 6) for 5 minutes and the pellet 
was resuspended into ACK lysis buffer (15 mM NH4CL, 10 mM KHCO3, 0.1 mM 
EDTA) for five minutes with inversions every 30 seconds.  ACK lysis buffer was 
neutralized with 10 ml cRPMI and the cells were pelleted as before.  Cells were loosened 
by racking and resuspended into filtered PBS with 5% fetal bovine serum (FBS).  Cells 
were enumerated and their viability was assessed by trypan blue (Gibco, Burlington, 
Ontario, Canada). 
 
2.12.2. Flow cytometry 
Isolated cells were aliquoted at 500,000 cells per 5 ml tube.  Cells were pelleted at 
1,200 RPM (Allegra 6 centrifuge, Beckman Coulter) for 5 minutes and the supernatant 
was carefully poured off.  The pellet was gently racked to resuspend the cells.  Cells were 
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pre-treated with Fc block from hybridoma clone 2.4G2 cell culture supernatant (produced 
by the Haeryfar lab) for 10 minutes prior to cell staining.  A master mix of the antibodies 
(Table 6) were used to stain the cells for each panel (Table 7) were added, the cells were 
mixed and incubated on ice in the dark for 30 minutes.  Cells were washed twice with 1  
PBS + 5% FBS, pelleting the cells at 1,200 RPM for 5 minutes between washes.  Cells 
were finally resuspended in 500 l of 1  PBS + 5% FBS.  Stained cells were run on a 
BD FACS Canto II flow cytometer, with capture of 100,000 events per sample.  Standard 
compensations were used for each tissue using FACSdiva software. 
 
2.13. Cytokine analysis 
2.13.1. Human peripheral blood mononuclear cell activation assay 
 Human blood was collected in heparinized vacuum tubes, diluted 1:1 with RPMI, 
layered over pre-warmed ficoll and spun at 2,500 RPM for one hour.  Peripheral blood 
mononuclear cells (PBMC) were removed by pipetting and washed in 40 ml of warm 
RPMI, pelleted for 5 minutes at 2,500 RPM, and resuspended in cRPMI.  Cells were 
assessed for viability by trypan blue and plated at 2  105 PBMCs per well in a 96-well 
plate.  Cells were stimulated with streptococcal culture supernatant so that the final 
volume per well was 200 l.  The potential mitogens were incubated at 37C with 5% 
CO2 for 18 hours.  Cell culture supernatant was removed and activation was assessed by 
measuring IL-2 by ELISA. 
 
2.13.2. Mouse splenocyte activation assay 
 The spleen was surgically removed from the mouse and was suspended in cRPMI.  
The spleen was passed through a 40 m nylon cell strainer, spun at 1,200 RPM (Beckman 
Coulter Allegra 6) for 5 minutes, and resuspended in ACK lysis buffer for five minutes 
with inversions every 30 seconds before being neutralized with 10 ml cRPMI.  Pelleted 
cells were loosened by racking and resuspended into cRPMI.  Cells were enumerated and 
their viability was assessed by trypan blue.  Cells were plated at 2  105 splenocytes per 
well in a 96-well plate and were stimulated with either recombinant SAg (rSAg) or 
streptococcal culture supernatant so that the final volume per well was 200 l.  The 
potential mitogens were incubated at 37C with 5% CO2 for 18 hours.  Cell culture 
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Table 6.  Antibodies for flow cytometry 
Target Fluorochrome Identifies Order Number Source  
Mouse CD3  APC Mature T cells 17-0031-82 eBioscience 
Mouse CD3  PE Cy7 Mature T cells 25-0051 eBioscience 
Mouse CD4  APC Cy7 CD4+ T cells  100414  Biolegend 
Mouse CD8  PE Cy7 CD8+ T cells  25-0081 
 
eBioscience 
Mouse CD25 PE Active and mature 
T cells and B cells 
and regulatory T 
cells 
12-0251-82 
 
eBioscience 
Mouse CD45  Alexafluor 700 Leukocytes 560510 BD Pharmigen 
Mouse CD19  FITC B cells 11-0191-81 eBioscience 
Mouse NK1.1  PE Natural killer and 
natural killer T cells 
12-5941-82 eBioscience 
Mouse CD1d 
tetramer, Unloaded  
APC Control for iNKT 
cell staining 
 NIH, Dr. M. 
Haeryfar 
Mouse CD1d 
tetramer, PBS-57 
Loaded  
APC iNKT cells  NIH, Dr. M. 
Haeryfar 
Mouse CD11c APC Cy7 Dendritic cells 17-0114-82 eBioscience 
Mouse F4/80 FITC Macrophages 11-4801 eBioscience 
Mouse GR1 FITC Neutrophils 53-5931 eBioscience 
Anti 7AAD  Dead cells 51-68981E BD Pharmigen 
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Table 7.  Flow cytometry staining panels 
Panel  Tissues stained Antibodies 
Panel 1 Lymph nodes 
Spleen 
Complete nasal turbinates 
7AAD 
CD45 Alexaflour700 (cNT only) 
CD19 FITC (cNT only) 
CD3 APC 
CD4 APC Cy7 
CD8 PE Cy7 
CD25 PE 
Panel 2 Lymph nodes 
Spleen 
7AAD 
CD1d APC (loaded and unloaded) 
CD3 PE Cy7 
CD19 FITC 
NK 1.1 PE 
Panel 3 Lymph nodes 
Spleen 
7AAD  
F4/80 FITC 
CD11c APC Cy7 
Panel 6 Lymph nodes 
Spleen 
Complete nasal turbinates 
7AAD  
CD45 Alexaflour700 (cNT only) 
CD11c APC 
F4/80 FITC 
NK 1.1 PE 
Panel 7 Lymph nodes 
Spleen 
Complete nasal turbinates  
7AAD  
CD45 Alexaflour700 (cNT only) 
GR1 FITC 
CD11b PE 
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supernatant was removed and activation was assessed by measuring mouse IL-2 by 
ELISA. 
 
2.13.3. Enzyme-linked immunosorbant assay 
 Human and mouse IL-2 ELISA kits were purchased from eBioscience, and were 
used to assess primary cell culture supernatants stimulated for 18 hours.  Kits were run as 
specified by the manufacturer in Costar ELISA plates.  Plates were read at OD450 and at 
the reference OD570. 
 
2.13.4. Multiplex cytokine analysis 
Cytokines were analyzed in cNT homogenates isolated from mice treated by 
either wild-type S. pyogenes MGAS8232 or S. pyogenes MGAS5005, isogenic SAg 
deletion strains or saline at either 24 or 48 hours in DR4/DQ8 and FVB mice respectively.  
The homogenates were analyzed in one of three way; by ELISA (eBioscience), Luminex 
was performed by the Screening Lab for Immune Disorders (Lawson Health Research 
Institute, London, Ontario, Canada) using the Bio-Rad BioPlex 200 to run a Millipore 12-
plex cytokine array, or with an eBioscience Flow Cytomix mouse Th1/Th2 10-plex 
ready-to-use cytokine analysis kit (San Diego, CA, U.S.A) as per manufacturer 
instructions. 
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Chapter 3:  Results 
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3.1. Establishment of a murine model of mild nasal infection by Streptococcus pyogenes 
3.1.1. Surgical removal of the complete nasal turbinates of mice 
Mice are obligate nose breathers, and hence all inspired air passes through the 
nasal passage, which is the first site of contact for inhaled infectious agents [143].  The 
lymphoid tissue that lines the basolateral surface of the nasopharyngeal meatus is known 
as the NALT, which is physiologically similar to the human tonsils [144].  The NALT has 
been established as a site of colonization of S. pyogenes in mouse nasal infection model at 
24 hours post-inoculation [149].   
Although there is a good description of one method of NALT extraction and 
processing in which the palate is excised around the perimeter with a small scalpel  and 
then carefully separated from the head to solely isolate the NALT which is attached to the 
posterior of the palate [144].  This process differs from the removal of the complete nasal 
turbinates (cNT) whose removal includes the NALT, the maxillary sinuses, and the 
ethmoid turbinates.  There was no previous existing detailed diagrammatic protocol of 
surgical removal of the complete nasal turbinates before this work (Figure 6).  The cNT 
isolation procedure differs in that the palate is removed without first incising the 
perimeter.  The premaxilla was shallowly cut all the way to the molars and the cheeks 
were separated away to reveal the cNT which is separated from the septum using fine 
tweezers. 
To illustrate the physiological location of the structures in the nasal passage 
relative to the rest of the head, histological sections were prepared from 10% formalin-
perfused TBD decalcified mouse heads embedded in wax. Sequential cross-sections of 
the mouse head were prepared between the T3 and T4 sections to demonstrate the 
differences in the nasoturbinates throughout the head (Figure 7).  Cross-sections of the 
mouse heads, stained with haematoxylin and eosin, were visualized by microscopy and 
have been used to indicate the location of the NALT in relation to the ethmoid nasal 
turbinates at the T4 cross-section (Figure 8).   
 The surgical technique used for the isolation of the cNT in this work was learned 
in the laboratory of Dr. P. P. Cleary (University of Minnesota), an established expert in 
this model [149, 151-152, 168].  Despite the fact that in previous literature the primary 
site of colonization has been established to be highly localized in the NALT [149], the  
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Figure 7.  Histological transition in the haematoxylin and eosin-stained murine head cross 
sections from T4 to T3.  The prepared sections of the fixed mouse head were scanned in 
their entirety.  The sections were taken at 200 m intervals from the T4 cross-section to 
the T3 cross-section, a total of 1,400 m (A-G).  At the T4 section the eye (E) and the 
optical lobes of the brain (B) are visible.  The nasal turbinates (NT) are distinct from the 
nasopharyngeal meatus (M) and are divided by the septum (S).  The oral cavity (OC) is 
located at the base of the section and the molar teeth (T) are visible.  Starting at 200 m 
towards the anterior of the head (B) the NALT (*) is visible bilaterally throughout the rest 
of the sections (B-G).  At 300 m towards the anterior of the head the maxillary sinuses 
(MS) are visible bilaterally through the rest of the sections (C-G).  At 800 m (D), the 
nasopharyngeal meatus connects to the nasal turbinates and the teeth are no longer 
apparent. 
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Figure 8.  Haematoxylin and eosin-stained section of transected murine head indicating 
the position of the NALT from a wild type S. pyogenes MGAS8232-infected mouse.  The 
40 magnification orients where the NALT (N) is located in relation to the rest of the 
tissue in the head.  The oral cavity (OC) and palate (HP) and optical lobe of the brain (B) 
serve to orient the diagram.  The septum (S) divides the two ethmoid turbinates (NT) of 
the sinuses.  The 200 magnification image shows the lymphoepithelium (LE) separating 
the NALT from the nasopharyngeal meatus.  The 600 magnification image highlights 
the LE and identifies the ciliated (C) cells, goblet cells (G) and overlying mucus (M) 
which is located on the basolateral surface of the nasopharyngeal meatus (NPM). 
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surgical technique learned from the Cleary lab varies slightly from the documented 
NALT surgical technique described in Asanuma et al. [144] in that it removes the cNT 
(Figure 6).  All surgeries in this work recovered the cNT which includes the ethmoid 
turbinates along with the NALT and maxillary sinuses.  This thesis has provided a 
detailed pictorial diagrammatic protocol of how to perform the removal of the cNT 
(Figure 6).  Importantly, this technique resulted in reproducible streptococcal counts 
within the expected range (described below). 
 
3.1.2. Bacterial dose determination for streptococcal colonization in mice 
 To examine streptococcal colonization potential, mice were sacrificed at 48 hours 
post-inoculation.  The 48 hour time point was chosen as the time point to assess 
streptococcal colonization based on previous work by Park et al. [149], which described 
that in a BALB/c mouse model of streptococcal nasal infection with an M1 strain of S. 
pyogenes (strain 90-226), after an initial decrease in the streptococcal burden at four 
hours post-infection, the population of streptococci in the cNT recovers and peaks at 48 
hours.  
To determine the optimal dose of bacteria to use in a mouse model of nasal 
colonization, 10
7
, 10
8
 and 10
9
 cfu of wild-type S. pyogenes MGAS8232 were prepared 
and tested in B6 mice, or B6 mice transgenic for HLA-DR4 (hereafter referred to as 
DR4).  Mice were sacrificed at 48 hours and their blood, organs and cNT were assessed 
for the presence of live S. pyogenes MGAS8232.  The streptococci colonized B6 mice 
very poorly at all dose concentrations tested; however, S. pyogenes MGAS8232 
consistently colonized DR4 mice 2-3 logs higher compared with the B6 mice (Figure 9).  
Ultimately, due to the viscosity and technical difficulty in the preparation of the 10
9
 cfu 
dose of S. pyogenes MGAS8232 (data not shown), it was decided to use a dose of 1  108 
cfu for both S. pyogenes MGAS8232 and S. pyogenes MGAS5005 for colonization 
experiments in the mice. 
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Figure 9.  Efficient nasal colonization in humanized mice by S. pyogenes is dependent on 
human MHC class II.  Mice expressing either mouse or transgenic human MHC class II 
molecules were nasally inoculated with (A) S. pyogenes MGAS8232 (N=4-7) and (B) S. 
pyogenes MGAS5005 (N=3-6).  At 48 hours post inoculation mice were sacrificed and 
the streptococcal burden in the cNT was assessed.  DR4/DQ8* mice are F1 generation 
mice of a cross of DR4/DQ8 and DR4 mice from the Western University colony. 
Statistical differences were assessed by unpaired t-test.  *, P <0.05; **, P <0.005; ***, P 
<0.0005. 
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3.1.3. Streptococcal nasal colonization varies depending on transgenic expression of 
human MHC class II 
 Different human MHC class II haplotypes have been previously established to 
alter susceptibility to streptococcal SAg-induced T cell proliferation and have been linked 
to clinical outcomes in patients with severe streptococcal infection [29, 59, 112-114].  
Human MHC class II was also found to contribute to the severity of streptococcal sepsis 
in a transgenic mouse model [113]. To assess the sensitivity of mouse strain variation on 
streptococcal colonization, S. pyogenes MGAS5005 or S. pyogenes MGAS8232 were 
used to nasally inoculate B6 background mice which do not express mouse H-2 and 
express different MHC class II molecules with a 1  108 cfu/dose of bacteria.  At 48 hours 
post-inoculation this resulted in strikingly different amounts of streptococci recovered.  In 
particular it was noted that DR4/DQ8 or DQ8 mice were colonized more effectively than 
DR4 mice, and DR4 mice were colonized more effectively than the parental B6 mice, 
with both streptococcal strains (Figure 9).  Specifically, mice expressing DQ8, with or 
without DR4, had counts that were ~ 4-5 orders of magnitude higher than B6 mice. 
DR4/DQ8-expressing mice are thought to be neutral in their susceptibility to severe 
streptococcal disease when compared to other human MHC class II and are responsive to 
some streptococcal SAgs [113].  These data indicate that human MHC class II molecules 
are critical host factors for the efficient colonization of cNT by S. pyogenes. 
 
3.1.4. Streptococcal colonization is not dependant on the source of mice 
The DR4/DQ8 mice are not available commercially and all transgenic mice were 
bred and genotyped on site by the researcher using MHC class II sequencing primers 
(Table 4) (data not shown).  Because the DR4 and DR4/DQ8 mouse populations used in 
this study were from two different sources, the two strains were crossed and the F1 
generation expressing both DR4 and DQ8 was used in colonization experiments.  The 
DR4  DR4/DQ8 mice had similar levels of streptococcal colonization at 48 hours post-
inoculation with S. pyogenes MGAS8232 (Figure 9A., Right column denotes 
DR4/DQ8*).  This data indicates that the source of the mouse is not likely a factor in the 
HLA-dependent colonization phenotype.  
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3.1.5. Nasal colonization by S. pyogenes in mice expressing different murine MHC class 
II is variable and S. pyogenes strain-dependant 
Mice expressing different mouse MHC class II alleles (Table 5) were also assessed for 
their ability to be colonized by different strains of S. pyogenes (Figure 10).  The Friend 
leukemia virus B-type (FVB) line of mice are albino inbred mice that were purchased 
from The Jackson Laboratory.  They express the mouse MHC class II H2 haplotype q 
[169-170].  FVB mice were initially derived in 1966 from an outbred population of Swiss 
mice at the National Institutes of Health in the United States of America to have 
sensitivity to post-pertussis vaccination histamine challenge.   These mice are reported to 
be susceptible to asthma-like airway responsiveness and have higher than average 
activity, anxiety and basal body temperature [169-170].  FVB mice infected with S. 
pyogenes MGAS5005 had the highest yield of streptococci of all mouse strains tested at 
48 hours. Inoculation with MGAS8232 did not result in a similarly high yield of S. 
pyogenes in isolated cNT.  Ultimately it was decided that HLA-DR4/DQ8 transgenic 
mice would be used to assess S. pyogenes MGAS8232 isogenic deletion strains, and FVB 
mice would be used to assess S. pyogenes MGAS5005 isogenic deletion strains.  
 
3.1.6. Streptococcal superantigenic sensitivity varies with murine expression of MHC 
class II 
 It has been well-established that streptococcal SAgs have different activities 
depending on their interactions with MHC class II [29, 112-114, 171] and V TCR [86, 
172], whose specificities can vary with concentration [87].  In general, streptococcal 
SAgs do not interact with mouse MHC class II as efficiently as they do with human MHC 
class II [59], which often results in poor murine response to streptococcal SAg 
stimulation. 
To assess the activation of murine lymphocytes by streptococcal SAgs, splenocyte 
activation was used as an ex vivo readout to predict in vivo sensitivity to SAgs (Figures 11 
and 12) in strains of mice with different murine and human MHC class II molecules 
(Table 5).  The activation of splenocytes was assessed by mIL-2 ELISA after 18 hours of 
stimulation by rSAg.  The activation potential of each SAg encoded in the genomes of S. 
pyogenes MGAS5005 and S. pyogenes MGAS8232 is summarized in Table 8.  None of   
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Figure 10.  Streptococcus pyogenes colonization variability in mice expressing murine 
MHC class II.  Strains of mice expressing different mouse MHC class II were assessed 
for their ability to be colonized nasally by (A) S. pyogenes MGAS5005 wild type and (B) 
S. pyogenes MGAS8232 wild type.  All mice were infected for 48 hours before the 
streptococcal burden was assessed in the cNT.  FVB mice colonized with S. pyogenes 
MGAS5005 were colonized more efficiently than any mouse strain tested.  Statistical 
differences were assessed by unpaired t-test. **, P <0.01 (N=2-4). 
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             Table 8.  Summary of mouse strain-specific superantigen sensitivity
A
 
Superantigen C57Bl/6 DR4 DR4/DQ8 BALB/c FVB 
SpeA Neg + + + + Neg Neg 
SpeC Neg Neg Neg
B
 Neg Neg 
SpeG Neg Neg Neg Neg Neg 
SpeJ Neg + Neg Neg + 
SpeL Neg Neg Neg Neg Neg 
SpeM Neg Neg Neg Neg Neg 
SmeZ Neg + + + + + + + +  + 
                   A 
Superantigen sensitivity was assessed by looking at the concentration of SAg in pg/ml  
             neccessary to result in the production of mIL-2 at 18 hours. 
                   B 
SpeC is considered a negative result because activation did not occur in concentrations  
             above 100 ng/ml. 
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Figure 11.  Splenocyte activation of B6 and transgenic HLA-mice by recombinant 
streptococcal superantigens.  Splenocytes isolated from female B6, DR4, and DR4/DQ8 
mice were treated with ten-fold serial dilutions of the pure recombinant streptococcal 
SAgs encoded in S. pyogenes MGAS5005 and S. pyogenes MGAS8232 for 18 hours.  
Activation of the splenocytes was assessed by determining the amount of mIL-2 produced 
in the cell culture supernatants by ELISA.  Results are representative of independent 
experiments in at least two mice. 
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Figure 12.  Splenocyte activation of BALB/c and FVB mice by recombinant streptococcal 
SAgs.  Splenocytes isolated from female (A) BALB/c and (B) FVB mice were treated 
with ten-fold serial dilutions of pure rSAg from S. pyogenes MGAS5005 and S. pyogenes 
MGAS8232.  Activation of the splenocytes was assessed by determining the 
concentration of mIL-2 in the cell culture supernatants after 18 hours of stimulation by 
ELISA. 
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the streptococcal rSAgs were found to efficiently stimulate B6 splenocytes at any 
concentration tested (Figure 11A) and streptococcal SAgs only activated DR4 splenocytes 
at the highest concentrations for SpeA, SmeZ, and SpeJ (Figure 11B).  Splenocytes from 
DR4/DQ8 mice were stimulated by recombinant SpeA, SpeL and SmeZ (Figure 11C).  
White mice were also tested and were selected for their expression of different murine 
MHC class II haplotypes.  BALB/c mice express H2 haplotype d and were stimulated by 
recombinant SmeZ and mildly stimulated by SpeA and SpeJ.   FVB mice express H2 
haplotype q and were stimulated by recombinant SmeZ and SpeJ (Figure 12). 
 
3.2. Streptococcus pyogenes MGAS8232 and MGAS5005 superantigen isogenic deletion 
strain creation and characterization 
3.2.1. Superantigen production by Streptococcus pyogenes 
 Streptococcal SAgs encoded in the genomes of S. pyogenes MGAS5005 and S. 
pyogenes MGAS8232 were predicted by data mining their sequenced genomes which are 
annotated in the NCBI genome database for superantigens [136, 138]  (Figures 3 and 4).  
The presence of four SAgs in S. pyogenes MGAS5005 and six SAgs in S. pyogenes 
MGAS8232 were initially confirmed by PCR analysis with primers for all eleven 
streptococcal SAgs (data not shown).  Between the two strains of streptococci there are 
seven unique SAgs encoded: speA, speC, speG, speJ, speL, speM, and smeZ. 
Anti-SAg antibodies were generated against six SAgs produced in MGAS5005 
and MGAS8232, noting that SpeC and SpeJ have cross-reactive epitopes [173]. 
Recombinant SAgs were expressed by induction of the proteins from pET expression 
vectors in E. coli BL21 (DE3) (Table 2) and purified to apparent homogeneity  
as previously described (data not shown) [102].  The chromatography-purified SAgs were 
used as immunogens to generate polyclonal rabbit anti-SAg antibodies.  The resulting 
rabbit polyclonal anti-SAg antibodies in sera were assessed for antibody titres by ELISA 
(data not shown) (Table 9), and tested for specificity against recombinant pure SAgs by 
Western blot (Figure 13). There was no cross-reactivity between any of rSAgs when 
probed with the polyclonal rabbit anti-SAg antibodies, which supports the notion that 
individual superantigens are immunologically distinct.  
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Table 9.  Antibodies used for Western blot analysis 
Antibody Target Dilution
B
 Source 
Rabbit anti-SpeA Polyclonal SpeA 1:32,000 Pro-Sci - This study 
Rabbit anti-SpeC
A
 Polyclonal SpeC 1:32,000 Pro-Sci - This study 
Rabbit anti-SpeG Polyclonal SpeG 1:8,000 Pro-Sci - This study 
Rabbit anti-SpeL Polyclonal SpeL 1:32,000 Pro-Sci - This study 
Rabbit anti-SpeM Polyclonal SpeM 1:8,000 Pro-Sci - This study 
Rabbit anti-SmeZ Polyclonal SmeZ 1:8,000 Pro-Sci - This study 
IRDye700 conjugated 
goat anti-human IgG 
Human IgG 1:10,000 
Rockland Inc. 
609-130-123 
IRDye800 conjugated 
donkey anti-rabbit IgG 
Rabbit IgG 1:10,000 
Rockland Inc. 
611-732-127 
goat anti-rabbit HRP Rabbit IgG 1:10,000 
Rockland Inc. 
611-1302 
A 
SpeC antibody cross-reacts with SpeJ [173] and was used for detection of SpeJ at 
1:8,000 
B
 The dilution was calculated by antibody titre ELISA and then tested by Western blot 
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Figure 13. Anti-streptococcal superantigen antibodies are specific for their target proteins.  
Polyclonal anti-streptococcal superantigen antibodies were tested by Western blot for 
specificity against streptococcal SAgs.  Rabbit anti-SpeC cross-reacts with SpeJ, which is 
the only superantigen that is found in S. pyogenes MGAS5005 and not in S. pyogenes 
MGAS8232 (data not shown). 
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3.2.2. Construction of Streptococcus pyogenes MGAS5005 and Streptococcus pyogenes 
MGAS8232 superantigen deletion mutants 
 To assess the potential contribution of SAgs to the establishment and persistence 
of colonization by S. pyogenes in mouse nasal colonization, isogenic deletion strains of S. 
pyogenes were created with individual and complete SAg deletion profiles (Figure 14).  
To construct the isogenic deletion strains pG+host5-based plasmids were constructed with 
a truncated version of the SAg flanked by 500 bp homologous regions upstream and 
downstream of the SAg.  The presence of the electroporated plasmid was confirmed by 
PCR before the clone was grown under antibiotic selection at a temperature that was not 
permissive for free-living plasmid replication (Figure 5).  After shifting the growth 
temperature to the non-permissive plasmid replication temperature under antibiotic 
selection, the integration of the plasmid was confirmed by PCR in clones that grew at 
40C and were erythromycin-resistant (data not shown).  Subculture without antibiotic 
selection at the permissive growth temperature encourages a second recombination event 
which excises the integrated plasmid from the genome.  The plasmid was subsequently 
cured by growth at 30C.  Erythromycin sensitivity and growth at 30C was an indicator 
that S. pyogenes transformants had lost the pG+host5 plasmid.  Erythromycin-sensitive 
clones were further tested with primers that were outside of the homologous 
recombination areas flanking the SAg (Figure 15).  The lack of SAg genes in the 
respective deletion strains was also confirmed using primers internal to the SAgs as listed 
in Table 4 (Figure 16). 
 
3.2.3. Complementation of speA into the S. pyogenes MGAS8232 complete superantigen 
deletion strain. 
S. pyogenes MGAS8232 SAg was complemented by speA with its native 
promoter.  The native promoter was determined from published data [174] and by 
scanning the upstream regions for putative (Lactococcal-like) SigmaA binding sites using 
PPP software (http://bioinformatics.biol.rug.nl/websoftware/ppp) [164].  This speA 
cassette was ‘knocked in’ to the non-coding transgenic region between genes encoding 
endopeptidase O (pepO) and EF-Ts (tsf; involved in translational protein elongation 
[175]).  The intergenic region between pepO and tsf has been used previously for the  
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Figure 14.  Streptococcal superantigen deletion strategy for individual and entire 
superantigen deletion strains.  (A)  S. pyogenes MGAS8232 encodes six SAgs.  Each 
superantigen was disrupted to generate single deletion strains in S. pyogenes MGAS8232.  
The speL and speM genes were deleted in tandem, as they are encoded adjacent to one 
another on a bacteriophage.  Each subsequent round deleted an additional superantigen 
until, after five rounds, a complete isogenic superantigen deletion strain was created.  (B)  
S. pyogenes MGAS5005 encodes four SAgs.  The SAgs are deleted in a manner similar to 
those in MGAS8232.  The one notable difference was that the final round of superantigen 
disruption resulted in an isogenic knockout with speA, speJ and smeZ deleted. 
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Figure 15.  Strategy to evaluate the superantigen deletion strains. Primers were designed 
to create and screen for all of the integration and subsequent clearing stages of the 
pG+host5 superantigen deletion plasmids within the streptococcal genomes.  Similarly 
located primers were designed for all of the superantigen deletion and complementation 
constructs.  The primer sequences are listed in Table 4.  All PCR templates were total 
DNA preparations isolated from S. pyogenes cultures.  PCR products from primers 2 & 4, 
and 3 & 5 were cut, ligated together and cloned into pG+host5 to create the superantigen 
deletion and complementation construct plasmids.   Primers 2 and 5 were used in PCR to 
confirm the presence of the superantigen deletion construct in electroporated clones of S. 
pyogenes by the presence of two different sized PCR products.  Integration of the 
pG+host5 constructs was confirmed by PCR using primers 1, 6, 7, and 8.  The final 
superantigen deletion was confirmed by PCR with primers 1 and 6 and by primers 
internal to the wild type SAgs.  Internal superantigen primers 9 and 10 were used to 
screen for the presence of wild type SAgs in the isogenic mutant deletion strains. 
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Figure 16. Confirmation of superantigen deletions in mutant strains of Streptococcus 
pyogenes.  Superantigen deletions were confirmed by PCR with primers internal to the 
superantigen genes for all (A) S. pyogenes MGAS5005 and (B) S. pyogenes MGAS8232 
strains. 
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successful insertion of genes into streptococcal strains in our laboratory. This location 
was initially chosen because the pepO and tsf genes are oriented in opposite directions 
facing each other, and there are two hairpin structures present between the two genes 
which implies that there is no transcriptional read through in that area (Brent Armstrong, 
personal communication).  The presence of the speA gene in the complemented clone was 
confirmed by PCR (Figure 16). 
 
3.2.4. Superantigen deletion did not induce significant growth defects 
Streptococcus pyogenes MGAS5005 and MGAS8232 SAg deletion mutants were 
assessed for growth both by manual (data not shown) and Bioscreen automated growth 
analysis (Figure 17).  There were no gross differences in the in vitro growth between the 
parental wild type MGAS5005 and MGAS8232 and the individual and complete isogenic 
SAg deletion mutant strains of MGAS5005 and MGAS8232.   
 
3.2.5. Superantigen protein production by in vitro cultured isogenic streptococcal deletion 
mutants confirms superantigen deletion 
The production of SAgs from wild type S. pyogenes MGAS5005 and S. pyogenes 
MGAS8232 and isogenic SAg deletion mutants grown in vitro was assessed.  The 
precipitated culture supernatants were concentrated 10-fold by TCA precipitation and 
analyzed by SDS PAGE and Western blot analysis.  Western blot using polyclonal rabbit 
anti-streptococcal SAg antibodies with rSAg used as a positive control (Figure 18).  Of 
the four SAgs encoded in S. pyogenes MGAS5005 only SpeA was detectable by Western 
blot (Figure 18A).  Of the six SAgs encoded within the genome of S. pyogenes 
MGAS8232, SpeC was produced in the greatest quantity, and SpeA and SpeL were also 
detectable by Western blot. SpeG, SpeM and SmeZ were not detectable (Figure 18B).  
Western blot analysis additionally confirmed that in the S. pyogenes deletion strains there 
was no production of the superantigens when the superantigens were otherwise produced 
and detected in the in vitro expression.  
 
3.3. Role of superantigens in nasal colonization of Streptococcus pyogenes MGAS5005 in 
FVB mice. 
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Figure 17. Assessment of the growth of isogenic streptococcal superantigen 
deletion strains.  (A) S. pyogenes MGAS5005 and (B) S. pyogenes MGAS8232 were 
assessed for growth defects potentially introduced by the superantigen deletion and 
complementation processes by growth in the Bioscreen assay. 
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Figure 18.  Expression analysis of streptococcal superantigens in the isogenic 
superantigen deletion strains.  TCA protein precipitation of all streptococcal supernatants 
from cultures grown to late exponential phase were assessed for superantigen production 
by Western blot.  (A) S. pyogenes MGAS5005 produced similar amounts of detectable 
SpeA in all strains with the exception of the deletion strains.  (B) S. pyogenes MGAS8232 
produced detectable SpeA, SpeC and SpeL that was of similar concentration in all 
isogenic strains unless the respective gene was deleted. 
  
102 
 
 
 
 
  
103 
 
 
3.3.1. Streptococcal superantigens influence the colonization of Streptococcus pyogenes 
MGAS5005 in the nasal passage of FVB mice 
Wild type S. pyogenes MGAS5005 efficiently colonized FVB mice with ~8 logs 
of streptococci recovered from the cNT of the mice at 48 hours post-inoculation.  FVB 
mice that were inoculated with the MGAS5005 speA and MGAS5005 speG isogenic 
deletion strains had no significant decrease in streptococcal burden recovered from the 
cNT of mice sacrificed 48 hours post-inoculation.  Inoculation of FVB mice with S. 
pyogenes MGAS5005 speJ, smeZ and speA/speJ/smeZ resulted in significantly fewer 
streptococci recovered from the cNT (Figure 19).  There was also a striking difference in 
the amount of piloerection, which is indicative of stress in mice, observed in wild type 
MGAS5005-treated mice at 48 hours, which was notably absent in the saline-treated, and 
MGAS5005 speA/speJ/smeZ-treated mice (Figure 20), and there were no significant 
differences in the amount of S. pyogenes recovered from the other organs (Figure 21).  
Mice inoculated with MGAS5005 speA and speG were piloerected similar to wild-
type-treated FVB mice, and MGAS5005 speJ-, and smeZ-treated mice were not 
piloerected (data not shown), which corresponds to the streptococcal load assessed in the 
mice at 48 hour post-inoculation. 
 
3.4. Role of superantigens in nasal colonization of Streptococcus pyogenes MGAS8232 in 
DR4/DQ8 mice 
3.4.1. Streptococcal superantigens produced by S. pyogenes MGAS8232 contributed to 
the colonization of the nasal passage at 48 hours post-inoculation 
Wild type MGAS8232 colonized the cNT of DR4/DQ8 mice at ~6 logs at 48 
hours.  Although most of the individual SAg deletions did not impact the colonization 
potential of MGAS8232, MGAS8232 speA and MGAS8232 SAg both had dramatic 
reductions in the ability to colonize nasal tissue.  Although there was some variation in 
the number of streptococci recovered from the other isogenic mutant streptococci, there 
were no statistically significant differences between those groups and the wild-type 
MGAS8232-treated mice (Figure 22). 
Streptococcus pyogenes MGAS8232 SAg was complemented with a copy of 
speA integrated into the streptococcal genome between the pepO and tsf genes to create S.  
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Figure 19.  Specific superantigens are critical for successful colonization of cNT by 
Streptococcus pyogenes MGAS5005 in FVB mice.  Nine week-old FVB mice were 
inoculated with wild type MGAS5005 and isogenic superantigen deletion mutants as 
indicated.  The cNT samples were homogenized and the bacterial burden of S. pyogenes 
strains was assessed at 48 hours.  Shown are the data points from individual mice, with 
the average ( SEM) log10 cfu/cNT.  (*, P < 0.05, and ***, P < 0.0005 as assessed by 
unpaired t-test) (N=4-8). 
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Figure 20.  Piloerection of FVB mice in Streptococcus pyogenes MGAS5005-treated 
mice.  Nine week old FVB mice were inoculated nasally with 1  108 S. pyogenes 
MGAS5005.  Mice were photographed under anesthesia at 48 hours post-infection, 
immediately prior to sacrifice.  Photographs are representative of three mice per group. 
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Figure 21.  Streptococcus pyogenes MGAS5005 recovered from the organs of nasally-
treated FVB mice.  There were no streptococci recovered from the S. pyogenes 
MGAS5005-deletion mutants the blood, the kidney or the spleen.  There were no 
significant difference in the number of streptococci recovered from the liver, and heart.  
There were significantly fewer streptococci recovered from the lungs of S. pyogenes 
MGAS5005 SpeJ and SpeA/SpeJ/SmeZ-treated mice.  Statistics were assessed by 
unpaired t test.  *, P <0.05, and **, P <0.005 (N=4-8). 
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Figure 22.  Nasal colonization by isogenic superantigen deletion strains of Streptococcus 
pyogenes MGAS8232.  DR4∕DQ8 transgenic mice were treated nasally with 1  108 cfu S. 
pyogenes MGAS8232 wild type and isogenic superantigen deletion mutant and were 
sacrificed at 48 hours post-infection.  Recovered cNT were homogenized and the 
concentration of S. pyogenes was assessed as the number of colonies that were -
haemolytic on TSAII sheep blood agar plates.  There was a statistically significant 
decrease in recoverable S. pyogenes in the speA and the complete superantigen deletion-
treated mice.  speA complementation in the genome resulted in a statistically significant 
increase in recoverable S. pyogenes.  Shown are the data points from individual mice, 
with the average ( SE) log10 cfu/cNT.  (**, P <0.005, and ***, P <0.0005 as assessed by 
unpaired t-test) (N=5-8). 
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pyogenes MGAS8232 SAg + SpeA. Nasal infection with the complementation strain of 
S. pyogenes MGAS8232 SAg + SpeA resulted in a significantly greater recovery of 
streptococci at 48 hours post-inoculation as compared to the S. pyogenes MGAS8232 
SAg, and it was not statistically significantly different in the recovery from the S. 
pyogenes MGAS8232 wild type. 
 
3.4.2. Streptococcal burden in the organs of Streptococcus pyogenes MGAS8232-infected 
transgenic DR4/DQ8 mice 
There were fewer streptococci recovered from the organs of S. pyogenes MGAS8232 
mutant-infected DR4/DQ8 mice as compared to S. pyogenes MGAS5005 mutant-infected 
FVB mice (Figure 23).  Streptococci were detected in the lungs and livers and hearts of 
some mice.  However, there were no statistically significant difference in the amounts of 
streptococci recovered from the organs of mice inoculated with the wild type and mutant 
S. pyogenes MGAS8232.  
 
3.4.3. Superantigen deletion impacts streptococcal burden at 48 hours, but not the 
persistence of S. pyogenes in DR4/DQ8 nasal passage 
 The kinetics of S. pyogenes MGAS8232 infections in transgenic DR4/DQ8 mice 
were addressed by nasally infecting mice and assessing the streptococcal burden in the 
cNT at one, two, three, four, and six day time points.  Both the wild type and complete 
SAg deletion strains of S. pyogenes MGAS8232, at 24 hours, were cleared to a level that 
was lower than the inoculating dose and there was no significant difference in the 
streptococcal burden recovered from the cNT at this time point.  At 48 hours, MGAS8232 
SAg colonization was dramatically decreased in comparison to wild type MGAS8232.  
However, despite the inability of the mutant to recover to wild-type levels at 48 hours it 
still persisted in the cNT of the transgenic DR4/DQ8 mice for the same length of time as 
the wild-type S. pyogenes MGAS8232, and was not recovered in statistically significantly 
different amounts between groups between days three and six (Figure 24).  This suggests 
that streptococcal SAgs play a role in the initial establishment of colonization in this 
model, but not in the kinetics of clearance. 
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Figure 23.  Streptococcus pyogenes MGAS8232 recovered from the organs of nasally-
treated DR4/DQ8 mice.  There were no detectable streptococci in the blood, spleen, 
kidney and heart of DR4/DQ8 mice nasally treated with S. pyogenes MGAS8232.  Some 
streptococci were detected in liver and lung homogenates.  Shown are the data points 
from individual mice, with the average ( SEM) log10 cfu/organ.  There was no statistical 
significance between groups as assessed by unpaired t test. 
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Figure 24.  Kinetics of nasal colonization by Streptococcus pyogenes MGAS8232 wild-
type and SAg strains in DR4/DQ8 mice.  DR4/DQ8 mice were inoculated with S. 
pyogenes MGAS8232 wild type and SAg and were sacrificed at day 1, 2, 3, 4, and 6 and 
the streptococcal burden in the cNT was assessed.  Statistically different amounts of S. 
pyogenes MGAS8232 wild type and S. pyogenes MGAS8232 SAg were recovered at 
day 2.  There were no statistically significant differences in the number of streptococci 
recovered at any other time point assessed.  Shown is the average of individual mouse 
data points, with the average ( SEM) log10 cfu/cNT.  (***, P < 0.0005 as assessed by 
unpaired t-test) (N=4-8). 
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3.4.4. Infection with a superantigen-competent strain of S. pyogenes MGAS8232 results 
in greater mucus production and cellular debris in the nasopharyngeal meatus 
Two representative haematoxylin and eosin-stained histological sections of the 
heads of three mice in each treatment group were examined along the entire length of the 
respiratory epithelial lining in the nasopharyngeal meatus, including the 
lymphoepithelium covering the NALT and over the entire length of the neuroepithelium 
in the ethmoid turbinates for the presence of mucus, cellular debris, tissue damage and 
other abnormalities by two independent researchers in a blinded fashion.  Scores between 
zero to two points were assigned to each sample depending on the presence and amount 
of mucus, red blood cells and nucleated cellular debris along the respiratory (including 
lymphoepithelium) and the neuroepithelium in the nasal turbinates.  Scores were averaged 
and assessed statistically by unpaired t test. There were no statistically significant 
differences between the treatment groups in the neuroepithelium (Figure 25B).  In the 
respiratory epithelial lining of the nasopharyngeal meatus there was a greater incidence of 
red blood cells and nucleated cells in the mucus covering the respiratory epithelium in the 
nasopharyngeal meatus in wild type S. pyogenes MGAS8232-treated mice as compared to 
the saline- or S. pyogenes MGAS8232 SAg-treated mice (Figure 25A).  There was no 
visible damage or break in the continuity of the either the neuroepithelium or the 
respiratory epithelium observed in any of the sections examined, hence we were unable to 
attribute the cellular debris to a specific epithelial damage. 
 
3.4.5. Immunophenotyping of spleen, lymph node, and nasal cells in S. pyogenes 
MGAS8232-treated mice 
 Transgenic mice expressing HLA DR4/DQ8 were inoculated with either saline, 
wild type S. pyogenes MGAS8232, or S. pyogenes MGAS8232 SAg were sacrificed at 
48 hours and the spleen, pooled lymph nodes and cNT were collected.  The cells were 
stained for differential markers for immune cells and analyzed by flow cytometry.  Gating 
strategies for flow cytometry are detailed in Figures 26, 28, and 30.   
One hundred thousand events were captured for each treatment.  Both the spleen 
and lymph nodes were gated on live cells based on 7AAD staining and were assessed for 
the presence of different cellular types based on staining.  Cellular concentrations were 
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assessed as the proportion of cells that were live.  Although there were subtle changes in 
the cell populations detected in the spleen, there were no statistically significant 
differences in the immune cell populations between treatment groups (Figure 27).  The 
pooled lymph nodes included the cervical, the axillary, iliac and the popliteal lymph 
nodes.  There was a statistically significant increase in the F4/80+ macrophage population 
between the S. pyogenes MGAS8232 wild type and isogenic deletion-treated mice (Figure 
29).   
One hundred thousand events were captured for each sample.  The samples were 
gated on the live cell populations based on 7AAD staining.  The live cells were further 
gated on the CD45+ cell population.  Live CD45+ cell populations in the cNT were 
assessed by flow cytometry for various immune cell populations.  There was a significant 
decrease in the CD11c+ DC cell populations in the cNT with S. pyogenes MGAS8232 
wild type-treated mice as compared with the S. pyogenes MGAS8232 SAg-treated mice, 
and lower than the saline-treated mice (Figure 31).  The S. pyogenes MGAS8232 SAg-
treated mouse cNT CD11c+ cell population was not significantly different from the 
saline-treated mice.  There were no other significant differences in any of the other cell 
populations assessed in the cNT. 
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Figure 25.  Histological assessment of nasal tissue sections. Difference in the pathological 
severity in mice inoculated with saline, S. pyogenes MGAS8232 wild type and SAg-
treated mice sacrificed at 48 hours post-infection were assessed by examination of 
haematoxylin and eosin stained sections.  Sections were assessed for the presence and 
severity of mucus, red blood cells, and nucleated cellular debris on the surface of the (A) 
respiratory epithelium and the (B) neuroepithelium.  There was a significantly greater 
amount of mucus and cellular debris observed in the S. pyogenes MGAS8232 wild type-
treated mice as compared to the saline- and SAg-treated mice.  Shown is the average of 
individual mouse data points, with the average ( SEM).  (*, P <0.005 as assessed by 
unpaired t-test). 
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Figure 26.  Splenocyte gating strategies to assess the proportions of immune cells in mice 
treated with S. pyogenes.  Splenocytes were isolated from mice treated with HBSS, S. 
pyogenes MGAS8232 wild type or S. pyogenes MGAS8232 SAg.  Representative 
gating strategies are shown for all panels used to determine proportions of immune cells 
in the spleen.  Splenocytes in all panels were first separated by forward and side scatter 
and gated on the lymphocyte population, and then further gated on the live cell 
populations based on 7AAD staining.  Immune cells were assessed based on 
immunoreceptor staining.  One hundred thousand events were captured for each sample. 
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Figure 27.  Nasal infection with wild type and superantigen deletion strains of 
Streptococcus pyogenes MGAS8232 does not result in changes in the lymphocyte 
population in the spleen.   Mice were inoculated with HBSS (empty bar), 1  108  cfu S. 
pyogenes MGAS8232 wild type (black bar) or S. pyogenes MGAS8232 SAg (grey bar).  
Mice were sacrificed at 48 hours post-infection.  The spleen was harvested and cells were 
stained to identify immune cell sub-populations by flow cytometry.  There were no 
statistically significant differences in (A) any of the immune cells assessed (N=6) 
including the (B) GR1+ and GR1+CD11b+ populations (N=2).   Shown is the average of 
individual mouse data points, with the average ( SE). 
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Figure 28.  Lymph node gating strategies to assess the proportions of immune cells in 
mice treated with S. pyogenes.  Total pooled lymph nodes were isolated from mice treated 
with HBSS, S. pyogenes MGAS8232 wild type or S. pyogenes MGAS8232 SAg.  
Representative gating strategies are shown for all panels used to determine proportions of 
immune cells in the lymph nodes.  Cells in all panels were first separated by forward and 
side scatter and gated on the lymphocyte population, and then further gated on the live 
cell populations based on 7AAD staining.  Immune cells were assessed based on 
immunoreceptor staining.  One hundred thousand total events were captured for each 
sample.  
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Figure 29. Nasal infection with wild type and superantigen deletion strains of 
Streptococcus pyogenes MGAS8232 results in significantly more macrophages in the 
pooled lymph nodes.   Mice were inoculated with HBSS (empty bars), 1  108 S. 
pyogenes MGAS8232 wild type (black bars) or S. pyogenes MGAS8232 SAg (grey 
bars).  The mice were sacrificed at 48 hours post-infection.  Cells were stained to identify 
immune cell sub-populations by flow cytometry.  A statistically significant difference was 
detected in the F4/80+ macrophage population between S. pyogenes MGAS8232 and 
isogenic knockout-treated mice (P=0.0357) as assessed by unpaired t-test (N=4).  Shown 
is the average of individual mouse data points, with the average ( SE).  (*, P = 0.05 as 
assessed by unpaired t-test). 
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Figure 30.  Gating strategies to assess the proportions of immune cells in mice treated 
with S. pyogenes in the complete nasal turbinates.  The complete nasal turbinates were 
isolated from mice treated with HBSS, S. pyogenes MGAS8232 wild type or S. pyogenes 
MGAS8232 SAg at 48 hours post-infection.  Representative gating strategies are shown 
for all panels used to determine proportions of immune cells in the complete nasal 
turbinates.  The complete nasal turbinates cells were first separated based on 7AAD 
staining and gated on live cells only.  The live cells were further gated on CD45 positive 
population before being assessed for the proportion of immune cells. One hundred 
thousand total events were captured for each sample. 
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Figure 31.  Nasal infection with wild type deletion strains of Streptococcus pyogenes 
MGAS8232 results in a decrease in CD11c+ cells in the cNT.   Mice were inoculated 
with HBSS (clear bars), 1  108 cfu S. pyogenes MGAS8232 wild type (black bars) or S. 
pyogenes MGAS8232 SAg (grey bars).  Mice were sacrificed at 48 hours post-infection 
and the cNT including NALT were harvested and stained to identify immune cell sub-
populations in the various tissues by flow cytometry.  All samples were gated to exclude 
7AAD positive cells (dead cells).  Additionally, cells from the cNT were gated on all 
CD45-positive cells to indicate the lymphocytic population.  Immune cell populations 
assessed in (A) had an N of ≥ 4.  (B) The CD11b+ cell marker marks myeloid progenitor 
cells (N=2).  A statistically significant difference in the CD11c+ DC cell populations in 
the cNT was observed between the wild-type and isogenic knockout-treated (P=0.0304).  
Shown is the average of individual mouse data points, with the average ( SEM).  (*, P < 
0.05 as assessed by unpaired t-test). 
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Chapter 4: Discussion 
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The bacterial SAg toxins have evolved to target two critical receptors of adaptive 
immunity, and although the role of these toxins in severe disease is well established, little 
is known about why so many different SAgs are encoded within the S. pyogenes genome, 
and why ultimately these genes are maintained in the genome as the bacteria evolve.  The 
natural lifecycle of S. pyogenes is a state of colonization in the pharynx, where most 
carriers do not develop symptomatic pharyngitis. In fact, ~20% of school children in the 
winter and spring may be asymptomatic chronic carriers of S. pyogenes [176]. Thus, we 
believe that SAgs have evolved in the context of “colonization”, rather than “virulence”, 
and therefore their true evolutionary role is likely important for the  state. 
There are eleven identified streptococcal SAgs [116, 123-125] and to date, every 
sequenced strain of S. pyogenes encodes multiple SAgs within its genome [35, 57-58, 
126, 136, 138, 177-184]. Despite the impressive body of work focused on streptococcal 
SAgs as potent virulence factors, there have been no efforts made to understand the 
physiological function of streptococcal SAgs in the transmission, establishment of 
colonization, and persistence of S. pyogenes within the human population. In addition, 
there are very few studies that have examined the role of streptococcal SAgs using 
defined genetic deletion strains [2, 59, 88, 112-113], and even fewer that are coupled with 
live in vivo infections in appropriate animal models [185], and none have examined the 
role of SAgs in colonization and mild infection in an appropriate mouse model.  
Superantigens have been shown, indirectly, to play a role in the early stages of mild 
pharyngeal infection as examined by transcriptome analysis of Streptococcus-infected 
macaques [82].  Although there is a lack of mechanistic studies to address these 
questions, a role for SAgs in the persistence of S. pyogenes in humans with mild infection 
or colonization is supported by the existence of many healthy adults who have not had 
severe or invasive streptococcal infections, and yet have antibodies against streptococcal 
SAgs [133-134].  
Group A streptococci are obligate human pathogens [3], and their primary site of 
colonization is the human tonsils and S. pyogenes is often found in surgically excised 
tonsils [147].  Human tonsils, or Waldeyer’s ring, are composed of the adenoid, bilateral 
tubular, palatine, and lingual tonsils [142].  Physiologically similar structures have been 
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identified in other mammals [145], and in mice the functionally analogous tissues are the 
NALT, which are located bilaterally along the base of the nasal passage in mice [143].   
The streptococcal colonization model of nasal infection has been previously 
established as a model to mimic human colonization or pharyngeal infection [149].  The 
surgical technique used in this work to isolate cNT was learned directly from the 
laboratory of Dr. P. Patrick Cleary at the University of Minnesota (Figure 6).  Use of this 
technique deviates from other NALT extraction techniques published in the literature 
[144].  This technique resulted in consistent and highly reproducible streptococcal and 
bacterial counts from S. pyogenes colonized mice (Figures 9 and 10), and when assessed 
for immune cells by flow cytometry, gave consistent proportions of subsets of live 
CD45+ immune cells (Figure 31).  Together, these results validate the surgical method as 
an alternate method for the removal of cNT which includes the NALT along with the 
ethmoid turbinates and maxillary sinuses.  The details of this model and the surgical 
method, as described in this thesis, which represents a significant contribution to this field 
of research. 
The genetic makeup, innate defenses, cytokine levels and the potential presence of 
underlying health conditions which may alter the immune responsiveness of the host may 
influence the course of a streptococcal infection [186].  Also, the ability of the MHC class 
II to determine the clinical outcome of severe or invasive streptococcal infection has been 
previously established [112-115, 135].  We found that murine lineages expressing 
different murine or human MHC class II molecules respond differently to nasal challenge 
by different S. pyogenes strains, as assessed at 48 hours post-infection (Figures 9 and 10).  
Mouse lineages that expressed human MHC class II colonized much more effectively 
than the parental B6 lineage (Figure 9); B6 mice did not colonize well with either strain 
of S. pyogenes tested.  Mice expressing MHC class II HLA-DR4 colonized better than B6 
mice but not as well as the mice expressing HLA-DQ8 or HLA-DR4/DQ8 (Figure 9).  
These experiments demonstrate clearly that host genetics can have an enormous influence 
on the ability of S. pyogenes to colonize the nasopharynx. 
To assess whether the colonization phenotypes were due to divergent evolutionary 
differences in the DR4 and the DR4/DQ8 lineages of mice, DR4/DQ8 mice were back-
crossed with the DR4 mice and infection of the F1 generation (DR4/DQ8*) resulted in 
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similar levels of colonization to the DR4/DQ8 mice when tested with the S. pyogenes 
MGAS8232 serotype (Figure 9).  This experiment supports our findings that the human 
MHC class II molecules are responsible for the colonization differences. 
Mice expressing different murine MHC class II (Table 5) were also assessed for 
their potential colonization with two strains of S. pyogenes (Figure 10).  In general, the 
mice were found to have low levels of S. pyogenes recovered after 48 hours of 
colonization, with the exception of FVB mice. Strikingly, FVB mice infected with S. 
pyogenes MGAS5005 had the highest recovery of S. pyogenes of any group of mice 
tested with any strain of S. pyogenes, yet these mice were only poorly colonized by S. 
pyogenes MGAS8232, the main difference between the superantigen complement 
encoded in these strains being the presence of speJ in S. pyogenes MGAS5005, which is a 
streptococcal superantigen that is immunostimulatory in FVB mice but not in transgenic 
DR4/DQ8 mice.  These experiments strongly suggest that the strain of S. pyogenes can 
also have a major influence on the ability to colonize, and that this is also linked with host 
genetics, specifically MHC class II.  
  To study infectious organisms, it is important to use a model system that is 
sensitive to the virulence factors produced by the pathogen being assessed. SAg research 
in mice has commonly utilized external sensitizing agents, such as D-galactosamine: 
However, this agent could mask or exaggerate significant pathogenic effects of the 
bacterial infection on the animal [140].  Theoretically, a naturally sensitive model is 
critical to the proper understanding of the course of pathogenesis and the interactions 
between pathogen and host.  Streptococcal SAgs interact with human MHC class II with 
higher affinity than to murine MHC class II molecules [139].  The demonstrable 
sensitivity of a mouse to streptococcal SAgs, either with transgenic human MHC class II 
expression or sensitive mouse H-2 for the SAgs in question is important in the study of 
any streptococcal infection. 
In order to understand the role of MHC class II in the nasal colonization model, 
recombinant SAgs were evaluated on the different mouse splenocyte cells ex vivo.  Mice 
that expressed different MHC class II molecules were found to have different sensitivities 
to rSAg as judged by the ability of their splenocytes to secrete IL-2 in response to various 
SAgs (Figures 11 and 12).  Mice expressing transgenic human MHC class II were more 
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sensitive to rSAg than B6 mouse splenocytes which demonstrated little to no activation 
by any of the toxins.  Splenocytes from mice expressing DR4/DQ8 were more sensitive 
than splenocytes from mice expressing only DR4 (Figure 11).  It is important to note that 
DR4/DQ8 mice were stimulated by SpeA and SmeZ, with SmeZ being 100-fold more 
potent than SpeA (Figure 11).  This supports previous findings that SpeA is more 
responsive in DQ-expressing mice [59, 113].  Overall the reactivity to SmeZ in all mice 
with the exception of B6 was not unexpected as SmeZ has been reported to be, in general, 
at least 10 times more potent in its T cell stimulating ability [187].  FVB mouse 
splenocytes were also stimulated by both SpeJ and SmeZ (Figure 12).  Given the 
universally poor superantigenic activity of streptococcal SAgs in B6 mice it may be 
concluded that B6 mice are not an appropriate murine model with which to study 
streptococcal SAgs.  Additionally, B6 mice may not be appropriate murine models with 
which to study streptococcal pathogenesis, despite the availability of many interesting 
deletion strains in mice, as they are not reactive to streptococcal SAgs, which are 
considered to be major streptococcal virulence factors.   
Streptococcus pyogenes MGAS5005 encodes four SAgs [79], and S. pyogenes 
MGAS8232 encodes six SAgs [136].  To evaluate the level of SAg expression from these 
strains, recombinant SAgs were used to generate SAg-specific polyclonal rabbit 
antibodies against the streptococcal SAgs encoded in both serotypes of S. pyogenes used 
in this study (Figure 13).  The amount of SAgs produced by S. pyogenes MGAS8232 and 
S. pyogenes MGAS5005 in vitro were assessed by Western blot using the rabbit anti-SAg 
antibodies (Figure 18).  S. pyogenes MGAS5005 produced detectable amounts of SpeA, 
and S. pyogenes MGAS8232 produced detectable amounts of SpeA, SpeC and SpeL.  
However, it is important to note that S. pyogenes may have distinctively different protein 
expression profiles in vitro depending on the medium or condition that they are grown in 
and the transcriptome also varies based on growth phase [188].  There is evidence that 
SAgs are produced in vivo at different points in the infection [82] and that the production 
of SAgs in vivo has been linked to the selective pressure exerted by the innate immune 
system [79, 189].  Previously, S. pyogenes MGAS5005 was grown in human blood and 
the transcriptome was analyzed at various time points.  It was found that the SAgs SpeA, 
SpeJ, SpeG, and SmeZ were all upregulated within the first thirty minutes of growth in 
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blood [186].  In a macaque model of pharyngitis that was used to evaluate changes in the 
streptococcal transcriptome it was determined that the temporal upregulation of SAgs 
coincided with a successful infection and inflammatory reaction and that SpeA, SpeJ and 
SmeZ were expressed during distinct disease phases and in general were associated with 
the colonization phase [82].  This suggests that there may be changes in SAg protein 
expression profiles during nasal infection of the mouse which could affect virulence and 
colonization potential of the streptococci.  Thus, the SAgs produced in vitro may not 
necessarily reflect the production of SAgs in vivo, but even if the SAg is produced, if the 
mouse is not sensitive to SAg stimulation then the SAg may not necessarily have an 
impact.  Based on that premise it was surmised that the streptococci that will successfully 
infect a mouse nasally will express SAgs that are immunostimulatory to that mouse, and 
that it will not be able to effectively infect mice that are not stimulated by the SAgs 
expressed in that strain.  As a result of both the initial nasal colonization experiments and 
the splenocyte sensitivity experiments it was ultimately decided to use the DR4/DQ8 
transgenic mice to assess the colonization of the S. pyogenes MGAS8232 isogenic SAg 
deletion strains and FVB mice to assess the nasal colonization potential of S. pyogenes 
MGAS5005 isogenic SAg deletion strains. 
Isogenic SAg deletions were created for S. pyogenes MGAS5005 and S. pyogenes 
MGAS8232 (Figure 14) to address the role that streptococcal SAgs play in colonization 
in a mouse model of nasal infection.  The isogenic SAg deletion mutants were made as 
in-frame markerless deletions using Gram-positive temperature-sensitive plasmids 
(Figure 6).  In-frame, markerless deletions have the advantage that they are stable and 
likely non-polar, and result in the deletion of the central portion of the gene, which 
maintains the genetic reading frame [163] (Figure 5).  The resulting isogenic SAg 
deletion mutants were confirmed by PCR using primers that were located internally to the 
SAg gene (Figure 16), Western blot for deletion of protein production (Figure 18), and by 
growth curve to ensure that there were no serious growth defects introduced from the 
genetic manipulations (Figure 17).  A similar scheme was used to complement wild type 
speA into the genome of the complete SAg deletion strain of S. pyogenes MGAS8232 
between the pepO and tsf genes. 
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Streptococcus pyogenes MGAS5005 encodes 4 SAgs that were disrupted to make 
four single SAg isogenic deletion strains and one strain with deletions of three of four 
SAgs, speA/speJ/smeZ (Figure 14A).  Nasal inoculation of FVB mice with wild-type S. 
pyogenes MGAS5005 resulted in approximately log10 7 recovery of S. pyogenes at 48 
hours post-infection.  The S. pyogenes MGAS5005 speA and speG strains resulted in 
S. pyogenes recovery that was not significantly different from that of wild type S. 
pyogenes MGAS5005.  There was a significantly lower recovery from the single isogenic 
S. pyogenes MGAS5005 speJ and smeZ deletions (Figure 19), which corresponds to 
the superantigens that are immunostimulatory in the FVB mice (Figure 12B).  Similarly, 
FVB splenocytes stimulated with in vitro S. pyogenes MGAS5005 isogenic SAg deletion 
culture supernatants and assessed for splenocyte activation showed a profile that indicated 
that the disruption of speA/speJ/smeZ resulted in an absence of splenocyte activation 
(Appendix 4B).  FVB mice inoculated with S. pyogenes MGAS5005 wild type became 
piloerected by 48 hours, the S. pyogenes MGAS5005 speA/speJ/smeZ deletion-treated 
mice did not show any piloerection at 48 hours, similar to the saline-treated mice (Figure 
20), as did the speJ and smeZ deletion-treated mice (data not shown).  Taken together 
this data indicates that in S. pyogenes MGAS5005 SpeJ and SmeZ play a significant role 
in the establishment of colonization at 48 hours post-inoculation in FVB mice. 
 There were no significant differences in the number of streptococci recovered 
from the blood, spleen, kidneys, liver or heart in any of the S. pyogenes MGAS5005 SAg 
deletion mutants in FVB mice sacrificed at 48 hours post-inoculation (Figure 21).  There 
were statistically fewer streptococci recovered from the lungs of mice infected nasally 
with S. pyogenes MGAS5005 speJ and speA/speJ/smeZ-infected mice as compared to 
the wild type-infected mice, which may reflect the fact that there were fewer streptococci 
present in the nasal cavity of those mice, which resulted in fewer streptococci being 
inspired into the lungs of the mice at this time point.  
Transgenic DR4/DQ8 mice infected nasally with wild type S. pyogenes 
MGAS8232 resulted in approximately log10 6 recovery of S. pyogenes at 48 hours (Figure 
22).  There were significantly fewer S. pyogenes MGAS8232 speA and S. pyogenes 
MGAS8232 SAg isogenic deletion mutants recovered from the cNT.  When speA was 
complemented into the genome of the S. pyogenes MGAS8232 SAg strain there was a 
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significant recovery in the colonization potential (Figure 22).  DR4/DQ8 splenocytes 
stimulated with in vitro S. pyogenes MGAS5005 isogenic SAg deletion culture 
supernatants assessed for splenocyte activation showed that the deletion of speL/M, and 
speA resulted in a decrease of mIL-2 produced, and that the complete deletion of all of the 
SAgs in S. pyogenes MGAS8232 resulted in an absence of splenocyte activation 
(Appendix 4C), which is in accordance with the superantigens produced by this bacterium 
in vitro (Figure 18B) and the superantigens that are immunostimulatory in the DR4/DQ8 
mice (Figure 11C).  This was a critical experiment, as it established that the phenotypes 
observed for both the MGAS8232 speA and SAg strains are not due to secondary 
mutations introduced through the mutagenesis process.  There were no statistically 
significant differences in the numbers of streptococci recovered from the organs of 
infected mice (Figure 23).  This indicates that the superantigen deletions in S. pyogenes 
MGAS8232 did not affect the invasiveness of S. pyogenes in the nasal infection of 
DR4/DQ8 mice. 
A time-course study was performed in which wild type and the isogenic SAg 
deletion strains of S. pyogenes MGAS8232 were inoculated at the same initial 
concentration of 10
8
 cfu per animal, and streptococcal burden was assessed over the 
course of a week (Figure 24).  There was an initial drop in streptococcal recovery 24 
hours after inoculation. Although there was a significant difference in the recovery of 
wild type and SAg S. pyogenes MGAS8232 at 48 hours, both strains ultimately took the 
same time to clear from the nasal passages of the mice.  Both the S. pyogenes MGAS8232 
wild type and S. pyogenes MGAS8232 SAg were not recovered at significantly different 
concentrations after the 48 hour time point up to when the streptococci were cleared from 
the cNT after day six.  The results of colonization kinetics with wild type S. pyogenes in 
DR4/DQ8 mice were similar to what was previously documented in streptococcal nasal 
infections in BALB/c mice inoculated with five-times the streptococcal burden with S. 
pyogenes 90-226 [149].   In the S. pyogenes 90-226-infected BALB/c mice, the infection 
initially appeared to clear but then recovered to reach peak colonization at 48 hours post-
infection and was detected in the nasal cavity of the mice for greater than 72 hours and up 
to seven days [149].  
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 Haematoxylin and eosin stained histological sections of nasal turbinates from 
mice nasally treated with saline, S. pyogenes MGAS8232 wild type, and S. pyogenes 
MGAS8232 SAg were assessed along the respiratory epithelium and neuroepithelium 
for production of mucus, nucleated cellular debris, and red blood cells along the 
epithelium.  There was a significant increase in the pathological severity in the S. 
pyogenes MGAS8232 wild type-treated mice as compared to the saline and the S. 
pyogenes MGAS8232 SAg-treated mice (Figure 25A).  There were no significant 
differences in the pathophysiology along the neuroepithelium between groups (Figure 
25B).  This indicates that the histological severity of the infection at the level of the T4 
cross-section (Figure 2) was significantly different along the respiratory epithelium in the 
nasopharyngeal meatus.  This may be due to the fact that mice are quadrupedal and that 
inspired antigens, mucus, and bacteria gravitationally settle in the nasopharyngeal meatus 
where they are subsequently cleared by cilia [143]. This may be the practical 
physiological reason for the location of the NALT being located on the basolateral 
surface of the nasopharyngeal meatus in mice.  
Investigation into how SAgs alter host immunity during the establishment of 
colonization revealed that there were no significant differences in the number of T cell or 
B cell populations amongst various treatment groups in the splenocyte, pooled lymph 
nodes and cNT cell populations (Figures 27, 29, and 31).  Flow cytometric analysis 
revealed that there was an increase in the number of F4/80+ cells in the lymph nodes of 
mice treated with wild type S. pyogenes MGAS8232 (Appendix 2), which indicated that 
there was an increase in the macrophage population in mice infected with wild type S. 
pyogenes MGAS8232 compared to the S. pyogenes MGAS8232 SAg treated mice.  
Macrophages are able to rapidly recognize and internalize pathogens and can further 
recruit immune cells by producing chemokines and can also serve as APCs. Macrophages 
can play a critical role in streptococcal infections as previous work found that the 
depletion of macrophages within the first 24 hours post-infection rendered resistant mice 
susceptible to streptococcal intraperitoneal infection with higher bacterial loads and 
mortality [190].  The presence of increased numbers of macrophages in the lymph nodes 
of wild-type infected mice may indicate an active immune response to S. pyogenes. As 
there were significantly fewer macrophages in the lymph nodes of mice infected with S. 
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pyogenes MGAS8232 SAg at 48 hours, this may indicate the SAg activity has altered 
this response.  Further study on the kinetics of the macrophage response to Streptococcus 
pyogenes infection with and without superantigens focusing mainly on the cervical lymph 
nodes will allow us to draw further conclusions about the role of superantigens in 
macrophage response. 
Conventional DCs circulate within the peripheral tissues, take up antigens, and 
become activated upon contact with pathogens after which they become potent 
stimulators of T cell responses in the peripheral lymphoid organs [191].  As such, DCs 
play a major role in the identification and immune response to pathogens, and can be 
detected with the use of anti-CD11c antibodies.  There was a significant decrease in the 
proportion of CD11c+ cells in the CD45+ live population in the cNT of wild type S. 
pyogenes MGAS8232-treated mice (Appendix 3) indicating fewer dendritic cells present 
in the cNT of these mice.   In addition to antigen presentation and T cell activation DC 
cells can also produce IL-6 and TGF-, which in the abscence of IL-12, IL-4 and IFN- 
stimulate the differentiation of Th17 cells [191].  It has previously been reported in the 
literature that there were fewer CD45+ live cells that stained with anti-CD11c antibody in 
mice infected with S. pyogenes, than mice inoculated with Lactobacillus murinus, a 
commensal bacterium in mice [153]. Although it was suggested that the presence of S. 
pyogenes induced a migration of DC cells from the NALT to the lymph nodes or blood 
[153], we did not observe such an increase in the DC cell population in the lymph nodes.  
It is important  to note that in S. pyogenes MGAS8232 wild type-treated mice, there was a 
statistically insignificant, but potential trend, for an increase in the GR1+CD11b+ cell 
population in the CD45+ live cells in the cNT of two mice (Appendix 3).  GR1 and 
CD11b together are markers of myeloid progenitor cells, and potentially myeloid-derived 
suppressor cells (MDSC) in mice [192].  MDSCs are a heterogeneous cell population of 
myeloid origin, are in an immature state and have the potential to suppress T lymphocyte 
and adaptive immune responses [192].  The expansion of MDSCs is triggered by 
prostaglandin, macrophage colony stimulating factor, IL-6, granulocyte-macrophage 
colony stimulating factor and capsular endothelial growth factor [192].  It has been 
suggested that some diseases can block or partially block the differentiation of immature 
myeloid cells into granulocytes, macrophages or dendritic cells [192].  MDSCs are 
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considered part of the regulatory arm of the immune system, and may induce the 
expansion of the T regulatory cells [192].  Further study is needed to better characterize 
the cellular immune response to S. pyogenes, and the SAg deletion strain, to better 
understand the contribution of SAgs to the cellular immune response. 
Cytokines can be classified as regulatory, anti-inflammatory or pro-inflammatory 
and are often produced in a balance that is important for a controlled functional immune 
response [108].  Streptococcal superantigens have been shown to elicit different cytokine 
expressions depending on the concentration of superantigens used [87].  In vitro SAgs 
have been reported to induce a Th1 proinflammatory response that results in the release of 
IFN- and TNF [83].  Similarly, mice with severe streptococcal infections had high serum 
levels of inflammatory cytokines including IFN- , IL-12 and IL-1, which strongly 
indicates a Th1 response [193-194].  Cytokine profiles were assessed by Luminex and 
Multiplex on homogenized cNT supernatants from FVB mice inoculated with either 
saline, S. pyogenes MGAS5005 or S. pyogenes MGAS5005 speA/speJ/smeZ at 48 hours 
(Appendix 1) and by Luminex on cNT homogenates from transgenic DR4/DQ8 mice 
infected with saline, S. pyogenes MGAS8232 or S. pyogenes MGAS8232 SAg at 24 and 
48 hours (Appendices 5 and 6).  At 24 hours there were no statistically significant 
differences in the cytokines between the saline-, S. pyogenes MGAS8232 wild type-, and 
S. pyogenes MGAS8232 SAg-treated samples in the DR4/DQ8 mice.  At 48 hours post-
infection in both FVB mice treated with S. pyogenes MGAS5005 and DR4/DQ8 mice 
treated with S. pyogenes MGAS8232 there were notable differences in the amount of IL-
1, IL-6, IL-17, MCP-1, MIP-1 in the samples from both mice.  Additionally, FVB mice 
also had significantly more IL-10, IFN-, and TNF- produced in the S. pyogenes 
MGAS5005 wild type-treated mice.  The luminex cytokine analysis of the cNT tissue 
homogenate supernatant, and particularly the FVB experiments which produced more 
inflammatory cytokines, suggests that the mice could have potentially been mounting a 
Th17 response [191] in the FVB mice treated with S. pyogenes MGAS5005 wild type.  
The mice treated with the wild type streptococci had a stronger cytokine response than the 
saline-, S. pyogenes MGAS5005 speA/speJ/smeZ-, and S. pyogenes MGAS8232 SAg-
treated mice indicating that this response is likely SAg driven and likely contributes to the 
enhance survival of S. pyogenes.  
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One potential immunomodulatory route that has been suggested to be induced in 
streptococcal nasal infection is the development of Th17 T cells by TGF-1 assisted 
generation [195].  IL-17-producing T cells have been reported to enhance the infiltration 
of neutrophils and macrophages in infected tissue which aids in pathogen clearance [196].  
In the literature, the frequency of NALT cells with a Th17 phenotype is similar to the 
number of CD4+IL-17+ cells that have been characterized in human tonsils [197].  The 
Th17 population of T cells (CD4+IL-17+) was not directly examined in the cNT of S. 
pyogenes-infected mice by flow cytometry in this study; however, we did detect a low but 
statistically significant increase in IL-17 in DR4/DQ8 mice that were inoculated with 
wild-type S. pyogenes MGAS8232 as compared to saline-treated mice.  There was a 
lower trend, but not statistically significant decrease in the amount of IL-17 between the 
wild-type- and SAg deletion-treated mice.  In the S. pyogenes MGAS5005-treated FVB 
mice there was a significantly higher amount of IL-17 produced in the wild-type-treated 
mice as compared to the saline- and speA/speJ/smeZ-treated mice (Appendix 1).  Future 
experiments to examine cells producing IL-17, by flow cytometry doing ICS staining for 
IL-17 or RORT at different time points, are needed to better characterize the significance 
of S. pyogenes SAgs to the Th17 response in the mouse model of cNT colonization.   
In all instances we observed a striking increase in the amount of IL-6 in all wild-
type streptococci-treated mice compared to the other two treatment groups.  IL-6 is 
necessary, along with TGF-1, which was not assessed in this study, TNF- and IL-1 to 
contribute to Th17 cellular expansion in mice [198].  In the S. pyogenes MGAS5005-
treated FVB mice there was an increase in both IL-1 and TNF- that was not observed 
in either the saline or SAg deletion-treated mice.  This indirectly suggests that there is an 
up regulation of the Th17 population of cells in the mice that are infected with SAg-
competent S. pyogenes that is absent in mice treated with SAg-disrupted S. pyogenes. 
It is tempting to draw broad sweeping conclusions about the contributory role of 
streptococcal SAgs in the immune response by comparing the immunological results of S. 
pyogenes MGAS8232-treated DR4/DQ8 mice (Figures 27, 29, 31, and Appendix 2 and 3) 
and S. pyogenes MGAS5005-treated FVB mouse data (Appendix 1).  Both data sets 
assess the contributory role of SAgs in nasal colonization of mice at the 48 hour time 
point, in different strains of S. pyogenes that produce different virulence factors which 
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may play a contributory role in the overall colonization potential in their different, and 
respective, mouse models, and despite this both models yielded similar results indicating 
that superantigens played a contributory role in the establishment of murine nasal 
colonization.  Further studies examining the cell populations and cytokines within the 
cNT at various time points in one strain of mouse infected with one serotype of S. 
pyogenes is necessary to elucidate a clear mechanism by which SAgs contribute to 
mediating the establishment of colonization in the murine nasal passage. 
There are multiple strains of S. pyogenes circulating globally at any given time, 
and these strains vary in prevalence region-to-region [11], and different strains are 
associated with the different incidences of S. pyogenes-related diseases in a regional 
manner [11].  Different subsets of SAgs are produced by different strains of S. pyogenes, 
which may affect the persistence of the strain within a population of people who encode 
MHC class II that optimally binds the superantigens in the particular strain of S. 
pyogenes.  Future studies examining the immune response to S. pyogenes with different 
SAg complements naturally within the human population, will help us better understand 
the differences in sensitivity to superantigens within the human population.  Specific 
immune cell responses may be examined by cellular depletion, and cytokine 
neutralization in a murine model of colonization to help further elucidate the mechanism 
by which superantigens subvert the immune system to allow S. pyogenes to establish 
colonization. 
To apply Koch’s postulates to microbial pathogenesis, Stanley Falkow’s 
“molecular Koch’s postulates’ suggests that the (1) phenotype or factor under 
investigation should be associated with pathogenic organisms, (2) the virulence genes 
should be identified, and isolated (3) an inactivation of the virulence factor should result 
in a decrease in pathogenicity and (4) the re-introduction of the wild type gene should 
restore pathogenicity [199].  Based on this bacterial pathogenesis application of Koch’s 
postulates, the role of streptococcal SAgs in severe and invasive disease has been well-
documented [18].  Secondly, SAg genes have been identified in the genomes of all S. 
pyogenes strains sequenced [57, 116, 123-125], and these streptococcal SAgs have been 
isolated and recombinantly produced and mutagenized to characterize their 
immunoreceptor interfaces [160-161].  Thirdly, in this work streptococcal SAgs were 
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completely inactivated by markerless in-frame deletions of all of the streptococcal SAgs 
in S. pyogenes MGAS8232, and three of four SAgs in S. pyogenes MGAS5005, the 
resulting SAg deletion strains revealed decreased ability to establish colonization in a 
nasopharyngeal-associated lymphoid tissue murine model of infection in strains with the 
SAgs that were immunostimulatory to the mouse model employed in the colonization.  
Finally, the re-introduction of the wild type speA into an alternate location within the 
genome of S. pyogenes MGAS8232 SAg restored the pathogenicity of the strain by 
recovering its ability to establish colonization in a similar manner to wild type S. 
pyogenes MGAS8232.  Therefore having satisfied Koch’s postulates, as they can be 
applied to microbial pathogenesis, it can be said that in regards to the hypothesis that the 
results indicate that streptococcal SAgs play a role in the establishment in the 
colonization of a nasopharyngeal-associated lymphoid tissue model of murine 
streptococcal infection.   
 In summary, this work has provided important evidence that the true evolutionary 
function of the bacterial SAgs, at least those produced by streptococci, is to aid in the 
establishment of nasopharyngeal infection in SAg-sensitive mice, and potentially the 
persistence of S. pyogenes within human populations. The role of SAgs in the life-cycle 
of bacterial pathogens has remained an enigma, and this work will contribute to a more 
complete understanding of this interesting and important family bacterial toxins. 
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Appendix 1.  Cytokine analysis of complete nasal turbinate tissue homogenate 
supernatants from FVB mice inoculated with Streptococcus pyogenes MGAS5005 at 48 
hours.  The cNT homogenates were assessed for cytokine production by luminex and 
multiplex analysis (N=3).  Shown is the average of individual mouse data points, with the 
average ( SE).  (*, P <0.05, and ***, P <0.0005 as assessed by unpaired t-test). 
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Appendix 2.  Cytokine analysis of complete nasal turbinate tissue homogenate 
supernatants from DR4/DQ8 mice infected with Streptococcus pyogenes MGAS8232 at 
24 hours.  The homogenates were assessed for cytokine production by luminex.  There 
were no statistically significant differences between groups (N=4).  Shown is the average 
of individual mouse data points, with the average ( SE).  Assessed by unpaired t-test. 
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Appendix 3.  Cytokine analysis of complete nasal turbinate tissue homogenate 
supernatants from DR4/DQ8 mice inoculated with Streptococcus pyogenes MGAS8232 
taken at 48 hours.  The cNT homogenates were assessed for cytokine production by 
luminex analysis (N=3). Shown is the average of individual data points, with the average 
( SEM). (*, P <0.05, and **, P <0.005 as assessed by unpaired t-test). 
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Appendix 4.  Activation of human PBMCs and murine splenocytes by 
Streptococcus pyogenes wild-type and isogenic mutant bacterial culture 
supernatants.  (A) Human PBMCs were treated with S. pyogenes MGAS5005 and 
MGAS8232 bacterial supernatants.  Mouse splenocytes were treated with (B) S. 
pyogenes MGAS5005 and (C) MGAS8232 bacterial supernatants.  Cells were 
treated with serial dilutions of bacterial culture supernatants for 18 hours.  The 
amount of IL-2 detected in human PBMC cultures stimulated with wild type S. 
pyogenes serotype supernatants was in general higher than mIL-2 produced by 
murine splenocytes stimulated with the same wild type streptococcal supernatants.  
The superantigen complete knockout strain in S. pyogenes MGAS8232 and the 
triple deletion mutant in S. pyogenes MGAS5005 supernatant-treated splenocytes 
did not produce mIL-2.  Mouse and human IL-2 cytokines was assessed by 
ELISA. 
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Appendix 5.  Human PBMC stimulated with isogenic Streptococcus pyogenes mutant 
supernatants. Human PBMCs were treated with (A) S. pyogenes MGAS5005 and (B) S. 
pyogenes MGAS8232 bacterial culture supernatants for 18 hours.  Human IL-2 was 
assessed by ELISA.  There was a significantly lower amount of IL-2 produced between 
the wild-type S. pyogenes MGAS5005 and the speJ, smeZ and the speA/speJ/smeZ 
isogenic knockout supernatant-treated PBMCs.  There was statistically significant lower 
amount of IL-2 produced between the S. pyogenes MGAS8232 wild-type and the speC, 
SAg and the SAg + speA-treated PBMCs.  Shown is the average of individual data 
points, with the average ( SE).  (*, P <0.05, and **, P <0.005, and ***, P <0.0005 as 
assessed by unpaired t-test). 
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Appendix 6.  Animal protocol ethics approval.  
171 
 
 
 
 
  
172 
 
 
 
 
 
 
Appendix 7.  Human ethics approval. 
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May 2011-Apr. 2012 Ontario Graduate Scholarship ($15,000) 
 
May 2011  Drs Charles & Madge Macklin Award for Teaching and Research ($3000) 
Schulich School of Medicine and Dentistry 
 
May 2008-Apr. 2011 Doctoral Research Award ($63,000) 
Canadian Institute for Health Research. 
 
May 2005-Apr. 2011 Western Graduate Research Scholarship ($28,000) 
The University of Western Ontario, London, Ontario. 
 
May 2009  Drs Charles & Madge Macklin Award for Teaching and Research ($3000) 
Schulich School of Medicine and Dentistry 
 
Sept. 2007-May 2008 Schulich Graduate Enrichment Scholarship Research Award ($12,000) 
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Schulich School of Medicine and Dentistry 
 
Oct. 2008  Travel Award ($500) 
Gram-positive Pathogens Conference in Omaha, Nebraska, U.S.A. 
 
Oct. 2006  Travel Award ($1,000) 
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
Oct. 2006  Travel Award ($500) 
Gram-positive Pathogens Conference in Omaha, Nebraska, U.S.A. 
 
Summer 2002  Summer Studentship ($5,000) 
The Samuel Lunenfeld Institute, Mount Sinai Hospital, Toronto, Ontario 
 
Publications: 
 
1. Rahman, A. K. M. N., D. A. Bonsor, C. A. Herfst, F. Pollard, M. Peirce, A. W. Wyatt, D. M. 
Mazzuca, K. J. Kasper, J. Madrenas, E. J. Sundberg, and J. K. McCormick. 2011.  The T 
cell receptor -chain second complimentarity determining region loop (CDR2β) governs T 
cell activation and Vβ-specificity by bacterial SAgs.  Journal of Biological Chemistry  
286(6):4871-81. 
 
2. Hayworth J. L.*, Kasper, K. J.*, Leon-Ponte, M., Herfst, C. A., Yue, D., Brintnell, W. C., 
Mazzuca, D. M., Heinrichs, D. E., Madrenas, J., Hoskin, D. W., McCormick, J. K., and S. M. 
Haeryfar.  2009.  Attenuation of massive cytokine response to the staphylococcal enterotoxin 
B superantigen by the innate immunomodulatory protein lactoferrin.  Clinical Experimental 
Immunology.  157(1):60-70. *Equal contribution. 
 
3. Chau, T. A., McCully, M. L., Brintnell, W., An, G., Kasper, K. J., Vines, E. D., Kubes, P., 
Haeryfar, S. M., McCormick, J. K., Cairns, E., Heinrichs, D. E., and J. Madrenas.  2009.  
Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-
induced T cell activation and prevent toxic shock syndrome.  Nature Medicine.  15(6):641-8. 
 
4. Kasper, K. J., W. Xi, A. K. M. N. Rahman, M. Kotb, J. Madrenas, E. J. Sundberg, and J. K. 
McCormick.  2008.  Molecular Requirements for MHC Class II α-Chain Engagement by the 
Group IV Bacterial Superantigen SpeC. Journal of Immunology. 181(5):3384-92. 
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5. Günther, S., Varma, A. K., Moza. B., Kasper, K. J., Wyatt, A. W., Zhu, P., Rahman, A. K. 
M. N., Li, Y., Mariuzza, R.A., McCormick, J.K. and E.J. Sundberg. 2007.  A novel loop 
domain in SAgs extends their T cell receptor recognition site.  Journal of Molecular Biology. 
371(1):210-21. 
 
6. K.J. Kasper. 2007. Functional Characterization of Streptococcal Superantigen Low-Affinity 
MHC Class II Binding Interfaces. The University of Western Ontario. (Master’s thesis) 
 
Oral Presentations At Professional Meetings: 
 
January 2013 “Superantigens dictate host-specific nasopharyngeal infection by Streptococcus 
pyogenes”.  PhD public lecture.  Western University, London, Ontario. 
 
November 2007 “Functional Mapping of the Low-Affinity MHC Class II Site of the 
Streptococcal Superantigen SpeC”.  Infection and Immunity Research Forum.  The University of 
Western Ontario, London, Ontario. 
 
Poster Presentations At Professional Meetings:  
 
1. Kasper, K. J.,  Xu, S. X., Mazzuca, D. M. Baroja, Land McCormick, J. K.  Development of a 
model to assess the role of streptococcal virulence factors in nasal-associated lymphoid tissue 
colonization in mice.  London Health Research Day.  London, Ontario.  March, 2012. 
 
2. Kasper, K. J.,  Xu, S. X., Mazzuca, D.M. and McCormick, J. K.  Development of a model to 
assess the role of streptococcal virulence factors in nasal-associated lymphoid tissue 
colonization in mice.  Canadian Society of Microbiology Conference. St. Johns, 
Newfoundland. June 2011 
 
3. Kasper, K. J., Mazzuca, D. M., and J. K. McCormick.  Development of a model to assess the 
role of streptococcal SAgs in nasal-associated lymphoid tissue colonization in mice.  Margaret 
Moffat Research Day, London, Ontario.  March, 2011. 
 
4. Kasper, K. J., Mazzuca, D. M., and J. K. McCormick.  Development of a model to assess the 
role of streptococcal SAgs in nasal-associated lymphoid tissue colonization in mice.  Banff 
Conference on Infectious Diseases, Banff, Alberta.  May, 2010 
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5. Patterson K. G., Dixon, J. L., Bastedo, P. S., Gupta, S. S., Kasper K. J., and J. K. McCormick. 
Development of superantigen-derived anti-cancer immunotherapeutics. Infection and 
Immunity Research Forum. London, Ontario.  November 2009. 
 
6. Kwon, T., Kasper, K. J., Pollard, F., and J. K. McCormick.  Allium sativum as a potential 
antimicrobial against group A streptococcal infections.  The Infection and Immunity Research 
Forum.  London, Ontario, Canada.  November 2009. 
 
7. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick.  Inhibition of streptococcal 
SAgs by IVIG.  The Third Annual Infection and Immunity Research Forum.  London, Ontario, 
November 2008. 
 
8. Patterson K.G., Dixon, J.L., Bastedo, P.S., Gupta, S.S., Kasper K.J., and J.K. McCormick. 
Development of superantigen-derived anti-cancer immunotherapeutics. Infection 
and Immunity Research Forum. London, Ontario. November 2008. 
 
9. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick.  Inhibition of streptococcal 
SAgs by IVIG.  The Third Annual Canadian Society for Life Sciences Research Conference.  
Toronto, Ontario, November 2008. 
 
10. Gupta, S., Herfst, C. A., Kasper, K. J., and J. K. McCormick.  Inhibition of streptococcal 
SAgs by IVIG.  The National Conference for Gram-positive Pathogens.  Omaha, Nebraska, 
U.S.A. October 2008. 
 
11. Patterson K. G., Dixon, J. L., Bastedo, P. S., Gupta, S. S., Kasper K. J., and J. K. McCormick. 
Development of superantigen-derived anti-cancer immunotherapeutics. Canadian Society of 
Microbiology Conference. Calgary, Alberta. June 2008. 
 
12. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick.  Low-affinity MHC class II 
binding of streptococcal SAgs.  The National Conference for Gram-positive pathogens.  
Omaha, Nebraska, USA.  October 2006. 
 
13. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick.  Low-affinity MHC class II 
binding of streptococcal SAgs.  Canadian Society of Microbiologists Annual Meeting Student 
Poster Competition.  London, Ontario.  June 2006. 
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14. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick.  Low-affinity MHC class II 
binding of streptococcal SAgs.  Margaret P. Moffatt Graduate Research Day.  University of 
Western Ontario, London, Ontario.  May 2006. 
 
15. Kasper, K. J., A. K. M. N. Rahman, and J. K. McCormick.  Low-affinity MHC class II 
binding of streptococcal SAgs.  Lawson Health Research Day.  London, Ontario.  March 2006. 
 
16. McCormick, J. K., C. A. Herfst, J. M. Laughton, J. L. Dixon, J. N. W. Herbert, A. K. M. N. 
Rahman, C. M. Kerr, K. J. Kasper, I. Gryski, N. Brouillard, and S. A. Cuozzo. Molecular 
biology of Gram-positive bacteria: toxins, islands, communication, and in vivo expression 
technology. The Canadian Institutes of Health Institute for Infection and Immunity New 
Investigator Forum. Toronto, Ontario. April 2005. 
 
17. Kasper, K., and J. K. McCormick.  Evolution of pathogenicity islands in Streptococcus 
pyogenes.  University of Toronto Microbiology and Infectious Diseases Research Day.  
Toronto, Ontario.  July 2004. 
 
18. Kasper, K., and J. K. McCormick.  Evolution of pathogenicity islands in Streptococcus 
pyogenes.  15
th
 Annual Sister Mary Doyle Research Day.  London, Ontario.  March 2004. 
 
19. Kasper, K., Detmar, J., and R. Casper.  The role of Bax in apoptosis in mouse placenta and 
the creation of an inducible mouse model for preeclampsia. Samuel Lunenfeld Institute 
Summer Studentship Poster Competition.  August 2002. 
 
Scholarly and Professional Activities: 
 
Student Mentorship and Supervision 
Feb. 2008 –Jan. 2013  Actua Student Mentor 
Actua Science Mentorship Program, CIHR. 
 
Sept. 2010-May 2011 Direct Supervisor and Mentor to 4
th
 year Honors Thesis Student 
Supervised and mentored a 4
th
 year honors thesis student in day-to-day 
lab work.   
 
Nov. 2007-Aug. 2010 Supervisor and Mentor High School Student 
Mentored a high school student (Tony Kwon) who worked on science fair 
projects.  He placed first in the local science fair for three years, which 
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allowed him to participate in Canada-Wide Science Fair.  In 2009 he 
placed first at The National Science Fair and was invited to present his 
work at an international science fair in Tunisia in the summer of 2009. In 
2010 was named one of the top 20 under 20. 
 
Roles in Conferences 
Nov. 2012  Volunteer 
 Infection and Immunity Research Forum Organizing Committee. 
The Department of Microbiology and Immunology, Western University 
London, Ontario. 
 
Nov. 2009-Jan 2011 VP of Donor/Sponsor Relations 
Infection and Immunity Research Forum Organizing Committee. 
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
Nov. 2009-Jan. 2010 Past Chair  
Infection and Immunity Research Forum Organizing Committee.   
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
Nov. 2008-Jan. 2009 Chair 
Infection and Immunity Research Forum Organizing Committee.   
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
May 2007–2008  VP Advertising and Event Promotion 
Infection and Immunity Research Forum Organizing Committee 
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
June 2006  Student Volunteer 
The Canadian Society of Microbiologists Annual Meeting 
 
Memberships in Professional Societies 
2009-Present  Society for Industrial Microbiology and Biotechnology 
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2007-Present  American Society for Microbiology 
 
2006-Present  Canadian Society of Microbiologists 
 
University Committees 
May 2007-Sept. 2010  Student Representative 
Infection and Immunity Seminar Series Committee Student 
Representative.  The Department of Microbiology and Immunology, The 
University of Western Ontario, London, Ontario. 
 
Sept. 2009-Sept. 2010 Graduate Student Representative 
Student Liaison to the Faculty Committee 
The Department of Microbiology and Immunology, The University of 
Western Ontario, London, Ontario. 
 
Sept. 2004-Sept. 2008  Social Committee Member 
Department of Microbiology and Immunology Social Committee 
The University of Western Ontario, London, Ontario. 
 
Outreach and Volunteer Work 
March 2012  Science Fair Judge 
   Orchard Park Public School 
 
Oct. 2010  Representative of Schulich School of Medicine and Dentistry  
Represented The Schulich School of Medicine and Dentistry at a graduate 
training recruitment event at The University of Toronto at Mississauga 
Campus. 
 
March 2010  Science Fair Judge 
London District Science and Technology Fair, London, Ontario. 
 
March 2010  Representative at Faculty of Science March Break Open House 
The University of Western Ontario, London, Ontario. 
 
March 2009  Science Fair Judge and Assistant Division Chair 
London District Science and Technology Fair, London, Ontario. 
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March 2009  Representative at Faculty of Science March Break Open House 
The University of Western Ontario, London, Ontario. 
 
April 2008   Science Fair Judge 
London District Science and Technology Fair, London, Ontario. 
 
March 2007  Representative at Faculty of Science March Break Open House 
The University of Western Ontario, London, Ontario. 
 
 
Professional Development 
2012  Alternative Curriculum Delivery (Schulich School of Medicine and Dentistry) 
2012  Rethinking Multiple Choice (Schulich School of Medicine and Dentistry) 
2011  Microsoft Access 2010 Level 1 (Schulich School of Medicine and Dentistry) 
2011  Microsoft Excel 2010 Level 2 (Schulich School of Medicine and Dentistry) 
2011  Microsoft Powerpoint Level 2 (Schulich School of Medicine and Dentistry) 
2011  Teamboard Instruction (Schulich School of Medicine and Dentistry) 
2010  WHMIS (The University of Western Ontario 
2010  Radiation Safety (The University of Western Ontario) 
2009  Gas anesthesia training (UWO ACVS) 
2009  Rodent Handling (UWO ACVS) 
2009  Basic animal care and use (UWO ACVS) 
 
 
